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INTRODUCTION
Biliary Tract Cancer
Biliary tract cancers (BTC) are a group of malignancies developing in the intra- 
and extrahepatic biliary tracts, as well as in the gallbladder. Four separate groups of 
biliary cancers are recognized, intrahepatic cholangiocarcinoma (ICC), perihilar 
cholangiocarcinoma (PHC), gallbladder carcinoma (GBC) and distal cholangio-
carcinoma.1 ICC is an adenocarcinoma developing in the peripheral bile ducts 
within the liver.1 With an incidence of 1-2 per 100,000 in the Western world, it 
is the second most common primary malignancy forming in the liver.2,3 Perihilar 
cholangiocarcinoma originates from the left and right hepatic ducts as well as 
the common bile duct in the hilum of the liver. Its incidence is slightly higher 
than that of intrahepatic cholangiocarcinoma with an average of 2 per 100,000.2,4 
Gallbladder is a malignancy often accidentally diagnosed in the gallbladder after 
cholecystectomy.  It has an incidence of 2.5 per 100,000, mostly in women, and 
is perhaps the most aggressive biliary tract tumor.5-7 Distal cholangiocarcinoma, 
finally, forms in the distal common bile duct, close to the pancreas.1 Because of 
the differences in operation techniques resulting in different disease course and 
because of the different anatomical location, this thesis will not focus on patients 
with distal cholangiocarcinoma. 
Etiologically, BTC share many risk factors. A correlation with diseases causing 
biliary inflammation and fibrosis, such as primary sclerosing cholangitis and 
primary biliary cirrhosis, has been noted.8,9 Risk factors primarily associated with 
ICC are congenital malformations of the bile duct, hepatolithiasis, hepatitis B and 
C virus, and alcoholic liver cirrhosis8 In East-Asia hepatic parasite infections, in 
particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk fac-
tors for both ICC and PHC.10,11 PHC risk factors are mostly similar to those for 
ICC, although this may be a consequence of population databases insufficiently 
differentiating between the two diseases.12 Risk factors more associated with 
PHC include Caroli’s disease and congenital choledochal cysts.13 GBC specific 
risk factors include gallbladder polyps, porcelain gallbladder, as well as H. pylori 
infection,  and S. paratyphi or S. typhi infections.14,15
BTC pathologically classify as adenocarcinomas, carcinomas of epithelial origin 
with glandular features.16-18 Formation of cholangiocarcinomas is frequently 
caused by mutations of the KRAS oncogene, a protein normally involved in the 
cell proliferation, in combination with the deletion of the p53 tumor suppressor 
gene.19,20 A critical signaling protein downstream of KRAS and p53 mutations is 
9Introduction
interleukin 6 (IL-6), which is a serum biomarker for ICC and PHC.21-23 Further 
downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been 
associated with an aggressive phenotype and metastatic disease at diagnosis.24,25 
Existing candidate gene studies in GBC susceptibility have so far been insufficient 
to confirm any association.26
Surgical Treatment
Surgical resection remains the only curative treatment approach in hepatobiliary 
malignancies, even though only a minority of patients are eligible for surgery at 
the time of diagnosis.1 Resection rates vary from 10%-40% in recent reports. 1,27 
Hepatobiliary tumors often necessitate large resections, accompanied by a high 
rate of complications and severe complications.1 Major postoperative morbidity 
and mortality of 5 to 15% are reported in Western centers.28 The incidence of 
postoperative liver failure, a complication associated with 30% mortality, is cur-
rently reported to be between 0.7% and 34%.29-33
Resection strategies for BTC often include radical en-bloc extirpation of the af-
fected part of the biliary tree and its neighboring anatomical structures in order 
to achieve negative resection margins.34 For peripheral ICC, a left or right hemi-
hepatectomy is often required, while for central ICC an extended hepatectomy 
is performed.34 PHC usually requires extirpation of the common bile duct and, 
conditional on the Bismuth-Corlette stage, an (extended) hepatectomy in the di-
rection of growth.35 When lymph node metastases are found, lymphadenectomy 
up to the hepatoduodenal ligament is often performed, and sometimes extended 
to the celiac or aorto-caval lymph nodes.34 GBC is sometimes found during rou-
tine laparoscopic cholecystectomy. In these cases, resection of the cystic duct and 
Couinaud segment IVb and V of the liver is performed.36,37 The role of common 
bile duct resection is more controversial.38,39 Lymphadenectomy is performed 
dependent on the presence of suspicious lymph nodes.36,37 When the diagnosis 
of GBC is known in advance, these procedures are performed during the same 
operation, usually after laparotomy.36,37
There is disagreement about the place of palliative surgery. Non-operative man-
agement is recommended among patients with a life expectancy of less than 6 
months, and the best course of treatment among patients found to have unresect-
able disease at the time of surgery is debated.40-43 Data evaluating the utilization 
patterns and outcomes of palliative surgery are scarce.  Studies into palliative 
surgery are often conducted in small cohorts. As a result, these reports are limited 
and may not be generalizable. 40-43
Introduction
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Non-Surgical Treatment
When surgical treatment is not an option, several non-surgical treatments are 
available to patients with BTC. Some of these treatments may, in time, replace 
surgery as a means of curation. In most cases, non-surgical procedures are pallia-
tive in nature and aim to extent the patient’s life and improve the quality thereof. 
The main symptom of BTC, which also causes most BTC to be diagnosed, is 
biliary obstruction.1 The foundation of palliative treatment therefore is the al-
leviation of this condition by means of biliary drainage.44-46 However, procedures 
for biliary drainage including percutaneous transhepatic cholangiography and 
endoscopic retrograde cholangiography are invasive and complications following 
their use may compromise further management and quality of life.44-46 Best sup-
portive care is recommended for patients with a poor performance status or a life 
expectancy of less than 6 months.40-43 
Preoperative and adjuvant chemotherapy are not routinely prescribed for BTC 
due to a lack of evidence.47 Preoperative therapy is aimed at occult metastatic 
disease or used to facilitate resection, while adjuvant chemotherapy is aimed at 
decreasing the chance of tumor recurrence.48 Chemotherapy consists of mainly 
nucleoside analogues, most commonly gemcitabine, sometimes in combination 
with cisplatin.48 While a significant portion of US patients receive chemotherapy, 
no randomized trials have been completed.48,49 Following the outcomes of the 
ABC-02 trial for palliative chemotherapy, a combination of gemcitabine and 
cisplatin is offered most often.47 The efficacy of chemotherapy regimens is usually 
poor, and only a small subgroup benefits significantly in terms of quality of life 
and survival length.11,48
For palliative chemotherapy, the aforementioned ABC-02 trial, randomized 410 
patients with BTC and found an improvement in overall survival of nearly four 
months with gemcitabine plus cisplatin compared to gemcitabine alone.47,50 
Gemcitabine plus cisplatin has been the standard palliative regimen for locally 
advanced or metastatic BTC since. 
Other non-surgical treatments for locally advanced BTC include transarterial 
chemoembolization (TACE) and radio-embolization with Yttrium-90.51 TACE 
affects the blood flow to the tumor in addition to locally releasing cytotoxic agents 
and thereby reducing tumor burden.51,52 Y-90 radio-embolization is based on 
administration of beads filled with the radioactive isotope yttrium-90 into the 
hepatic artery branch supplying the tumor.53,54
11
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Prognostication and Prediction
In order to truly personalize treatment, individual patient prognosis has to be de-
termined and response to specific treatments needs to be predicted. For prognos-
tication, several prognostic models have been developed in addition to the classic 
American Joint Committee on Cancer Tumor-Node-Metastases (TNM) staging 
system.55 More accurate prediction of individual patient outcome may provide 
better individual survival estimates, as well as improve identification of high-risk 
groups who may benefit from adjuvant therapy.56 While the AJCC staging and 
e.g. the Mayo Staging system for PHC concern all diagnosed patients, other 
models pertain only to patients who have undergone a complete resection.55,57-59 
Few prognostic models for GBC are available. Predictive models are available for 
the efficacy of adjuvant therapy for GBC, the chance of detection of metastases 
during laparoscopy for PHC, and finally, postoperative mortality after PHC.60-62
Because of the comparatively low incidence of BTC, derivation studies for prog-
nostic models have often lacked statistical power.63 Underpowered studies are at a 
risk of over-fitting the model to the data, causing decreased reproducibility.63 This 
results in poor results in validation studies.59,64,65  Although multiple well-known 
prognostic factors are used in the prognostic models, accurate estimation of their 
impact on survival remains elusive.
Personalized Treatment
Personalized treatments for BTC patients could improve the overall outcomes, 
mainly by withholding treatments from patients who are unlikely to benefit from 
surgery or chemotherapy. In order to determine the best treatment, at the optimal 
time in the disease course, in the center with the best outcomes, for each individual 
patient, large databases have to be utilized to construct appropriate validated 
models. The works included in this thesis aim to contribute to the development 
of personalized medicine using accurate prognostication and prediction rules.
Introduction
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THESIS OVERVIEW
Part I aims to determine which patients are best selected for the different treat-
ment modalities. More specifically, which patients should be considered eligible 
for surgery and which patients should rather be treated non-surgically. In Chapter 
1, the importance of hospital and surgery volume for individual patient outcomes 
is assessed in a United States (U.S.) national registry. Chapter 2 is a review of the 
definitions of post-hepatectomy liver failure, detailing predictive patient-specific 
factors. Chapter 3 is a retrospective analysis of perihilar cholangiocarcinoma 
patients, and tries to determine whether it is prudent to attempt a resection when 
lymph node metastases are present. In Chapter 4 and Chapter 5 the prognostic 
and predictive value of frailty, determined by low skeletal muscle mass, is discussed 
for general and elderly patients undergoing liver surgery.
In Part II, prognosis after surgery is discussed. Prognostic and predictive tools 
are explored, which can be used for both patient information and treatment 
allocation. The purpose of Chapter 6 is to review current literature in hepato-
pancreato-biliary model building, discussing current practices and shortcomings 
in validated models. In Chapter 7 models for intrahepatic cholangiocarcinoma 
are validated in a large international cohort.  Chapter 8 introduces the concept of 
conditional survival, the notion that accrued survival time is the most important 
prognostic factor for further survival, to a large cohort of patients with perihilar 
cholangiocarcinoma. Chapter 9 gives conditional survival estimates for patients 
with gallbladder cancer. Finally, Chapter 10 questions the prognostic impact of 
routine resection of the common bile duct in patients with gallbladder carcinoma.
In Part III, non-surgical techniques and their efficacy in battling biliary tract 
cancers is discussed. Chapter 11 gives an overview of novel surgical and non-
surgical techniques in patients with intrahepatic cholangiocarcinoma. Chapter 12 
discusses the effect of preoperative chemotherapy in the same population. Chap-
ter 13 assesses the outcomes and effects of palliative surgery in gallbladder and 
perihilar cholangiocarcinoma in a large U.S. cohort. Finally, Chapter 14 gives an 
overview of utilization of Yttrium-90 for radioembolization of the liver in patients 
with intrahepatic cholangiocarcinoma in the largest cohort to date, discussing its 
safety and efficacy.
13
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Abstract
Background: Although previous reports have focused on factors at the hospital-
level to explain variations in postoperative outcomes, less is known regarding the 
effect of provider-specific factors on postoperative outcomes such as failure-to-
rescue (FTR) and postoperative mortality. The current study aimed to quantify the 
relative contributions of surgeon and hospital volume on the volume-outcomes 
relationship among a cohort of patients undergoing liver resection. 
Methods: Patients undergoing liver surgery for cancer were identified using the 
Nationwide Inpatient Sample (NIS) from 2001 and 2009. Multivariable hierar-
chical logistic regression analysis was performed to identify factors with mortality 
and FTR. Point estimates were used to calculate the relative effects of hospital and 
surgeon volume on mortality and FTR.
Results: A total of 5,075 patients underwent liver surgery and met inclusion 
criteria. Median patient age was 62 years (IQR 52-70) and 55.2% of patients 
were male. Mortality was lowest among patients treated at high volume hospitals 
and among patients treated by high volume surgeons (both p<0.001). Similar 
patterns in FTR were noted relative to hospital and surgeon volume (hospital 
volume; low vs. intermediate vs. high; 10.3% vs. 9.0% vs. 5.2%, surgeon vol-
ume; low vs. intermediate vs. high; 11.1% vs. 9.1% vs. 4.1%, both p<0.05). 
On multivariable analysis, compared with high volume surgeons, lower volume 
surgeons demonstrated greater odds for mortality (intermediate; OR 2.27, 95% 
CI 1.27-4.06, p=0.006, low; OR 2.83, 95% CI 1.52-5.27, p=0.001) and FTR 
(intermediate; OR 2.86, 95% CI 1.53-5.34, p=0.001; low; OR 3.40, 95% CI 
1.75-6.63, p<0.001). While hospital volume accounted for 0.5% of the surgeon 
volume effect on increased FTR for low volume surgeons, surgeon volume ac-
counted for nearly all of the hospital volume effect on increased FTR in low 
volume hospitals.
Conclusion:  The risk of complications, mortality and FTR were lower among 
both high volume hospitals and high volume surgeons, but the beneficial effect of 
volume on outcomes was largely attributable to surgeon volume.
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Introduction
Treatment at high volume hospitals has been associated with improved peri-
operative and postoperative outcomes.1-7 Consistent with reports of improved 
mortality at high volume hospitals following esophageal, cardiac, lung and pan-
creatic surgery, the volume-outcomes relationship has also been defined for pa-
tients undergoing complex liver surgery.2,8 As such, policy makers and healthcare 
organizations such as the Leapfrog Group and the Agency for Healthcare Research 
and Quality (AHRQ) have promoted the regionalization of care to high volume 
centers noting that high volume hospitals likely have implemented standardized 
processes and systems of care that facilitate a better transition between the peri- 
and post-operative periods.9,10 
Traditionally, most studies have focused on operative mortality when reporting 
on the volume-outcomes relationship following major surgery, however more 
recent reports suggest that differences in mortality may not solely be a function 
of volume.11 In particular, failure-to-rescue (FTR: mortality after a major com-
plication) has emerged as a potential quality parameter to explain variations in 
post-operative outcomes including mortality. For example, Ghaferi and colleagues 
demonstrated that differences in postoperative mortality following gastric, pancre-
atic and esophageal surgery could be explained by variations in the development 
of major complications and therefore FTR rates among hospitals.11-13 Similarly, 
in their report of patients undergoing liver surgery, Spolverato et al. demonstrated 
that while postoperative mortality was lower at high volume centers these dif-
ferences were attributed to the ability of a high volume center to better identify 
and subsequently “rescue” patients from postoperative complications.14 Despite 
a significant decrease in operative mortality among patients undergoing liver 
resection in recent years, the incidence of morbidity following liver surgery still re-
mains high at about 20-40%.15-17 Quality improvements can only be achieved by 
identifying and subsequently improving factors related to structures and processes 
of care. Although previous reports have focused on factors at the hospital-level to 
explain variations in postoperative outcomes, less is known regarding the effect of 
provider-specific factors on postoperative outcomes such as FTR and postopera-
tive mortality. Furthermore, recent studies assessing the volume-outcomes rela-
tionship following cardiothoracic, pancreatic and esophageal surgery suggest that 
a significant proportion of this relationship may be accounted for by differences 
in provider characteristics.3,4 For example, Birkmeyer et al. demonstrated that 
as much as 54% of the hospital volume-outcomes relationship among patients 
undergoing complex cancer surgery was attributed to differences in provider 
volume.3 Given this, using a nationally representative dataset, the current study 
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aimed to explore the effect of hospital and surgeon volume on FTR as well as 
operative mortality. In particular, we sought to quantify the relative contributions 
of surgeon and hospital volume on the volume-outcomes relationship among a 
cohort of patients undergoing liver resection for a malignant indication. 
Methods 
Data Sources and Patient Population
Patient-level discharge data from the Healthcare Cost and Utilization Project 
(HCUP) - Nationwide Inpatient Sample (NIS) between January 1, 2000 and 
December 31, 2009 was utilized to identify the study cohort. Maintained by the 
AHRQ, the NIS represents the single largest all-payer in-patient dataset. Per year, 
the database contains information from over 30 million in-patients admissions 
collected from over 1,000 hospitals in more than 40 states. Using a stratified sam-
pling technique based on hospital level characteristics (geographic region, teaching 
status, hospital bed size and urban vs. rural location), the NIS is a representation 
of 20% of all in-patient hospital visits in the U.S.  The study was approved by the 
Johns Hopkins Hospital Institutional Review Board.
Patients undergoing major liver surgery were identified using International 
Classification of Disease, Ninth Revision, Clinical Manifestation (ICD-9-CM) 
procedure codes “5022”, and “5033.” To enhance the homogeneity of the patient 
cohort, only patients undergoing a liver resection for a primary diagnosis of cancer 
(primary neoplasm of the liver and metastatic disease) were selected using ICD-
9-CM diagnosis codes “1550” and “1997.” Patient comorbidity was categorized 
according to the Charlson Comorbidity Index (CCI).18 Further, as previously 
described, patients with a CCI score >6 were categorized as “high comorbidity.”14 
Using unique hospital and surgeon identifiers, an annual surgical volume was cal-
culated for each hospital and for each surgeon. In particular, the total numbers of 
surgeries performed at a hospital or by a surgeon were divided by the total number 
of years the hospital / surgeon appeared in the dataset. In the instance where a 
surgeon was practicing at multiple hospitals, surgical volumes for each individual 
surgeon was calculated at each hospital. For ease of interpretation, surgeon and 
hospital volumes were described as terciles with volume cut-offs chosen such that 
each volume group was represented by an equal number of patients. Surgeons 
were classified as low, intermediate or high based on their annual surgical caseload: 
≤4 cases per year, >4 and ≤15 cases per year, and ≥16 cases per year, respectively. 
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Similarly, hospitals were classified as low, intermediate or high based on their 
annual surgical caseload: ≤11 cases per year, >11 and ≤45 cases per year, and ≥46 
cases per year, respectively. Patient records missing information for hospital and 
surgeon identifier were excluded from further analysis.
Postoperative complications were described using previously validated ICD-9-CM 
diagnosis codes.11 Specifically, postoperative complications included pulmonary 
edema, respiratory insufficiency, pneumonia, myocardial infarction, surgical site 
infection, venous thromboembolism, acute renal failure and gastrointestinal 
bleeding. Using these diagnosis codes, FTR was defined as an inpatient death in 
a patient who had developed at least one these pre-defined post-operative com-
plications. As previous described, the failure-to-rescue rate for each hospital and 
provider tercile was evaluated by calculating the proportion of deaths in patients 
who developed a postoperative complication (numerator) to the total number of 
patients who developed a postoperative complication (denominator).11,14,19 
Statistical Analysis
Continuous variables were described as medians with interquartile range (IQR) 
or means with standard deviation (SD) as appropriate; categorical variables were 
displayed as whole numbers and percentages. Categorical data were compared 
using the Pearson χ2 test. To assess the association between hospital and surgeon 
volume on postoperative mortality and FTR, multivariable logistic regression 
analyses were performed adjusting for patient- and hospital-level characteristics. 
Specifically, patient, surgeon and the hospital characteristics found to be statisti-
cally significant on univariable analysis (p<0.05) were included in the multivariable 
model. As we failed to reject the null hypothesis testing for the interdependence 
of variance between clusters of patients within hospital (p=0.173), hierarchical 
modeling techniques were not employed in subsequent analyses. Of note, further 
analysis comparing results using hierarchical modeling techniques demonstrated 
comparable findings and similar conclusions regardless of the modeling approach 
used (Supplemental Material 1). To quantitate the relative effects of surgeon and 
hospital volume on postoperative mortality and FTR, three separate models were 
built for each postoperative outcome. Model 1 quantified the independent effect 
of surgeon volume, model 2 the independent effect of hospital volume and model 
3 included both surgeon and hospital volume effects. As previously described, 
results from these analyses were subsequently used to calculate the relative effects 
of surgeon and hospital volume on postoperative mortality and FTR using the 
formulas [1- ( ln ORSH / ln ORS )] and [1- ( ln ORHS / ln ORH)], respectively.20 
ORH represented the risk-adjusted odds ratio for hospital volume and ORS the 
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risk-adjusted odds ratio for surgeon volume.3,20 Similarly, ORHS represented the 
odds ratio for effects of hospital volume and ORSH the surgeon volume odds ratio 
obtained from model 3 including both surgeon and hospital volume effects.3,20 
Statistical analyses were performed using SPSS version 22 (IBM, Armonk, NY). 
Statistical significance was defined as p<0.05.  
Results
Patient and hospital characteristics
A total 5,075 patients underwent liver surgery and met inclusion criteria. The 
median age of patients was 62 years (IQR 52-70) while a majority of patients 
were male (n=2,802, 55.2%) and white (n=3,267, 75.0%). Comorbidity was 
frequently noted among patients as 20.5% of patients had a “high” preoperative 
morbidity with a CCI>6. Roughly one-half of the cohort was insured by private 
payers (n=2,583, 50.9%) and 29.3% were categorized among the highest income 
quartile (n=1,271). Of note, 91.8% (n=4,309) of surgeries were performed on an 
elective basis with a greater proportion of patients undergoing a partial hepatec-
tomy (3,097, 61.0%) versus hepatic lobectomy (1,978, 39.0%, Table 1).  A total 
of 408 hospitals were identified within the study cohort; 360 (88.2%) hospitals 
were categorized as low volume hospitals while 38 (9.3%) as intermediate volume 
hospitals and 10 (2.5%) as high volume hospitals performing >45 liver resec-
tions per year. Similarly, a total of 1,099 unique surgeons were identified in the 
study cohort with only 35 (3.2%) surgeons categorized as high volume surgeon 
performing more than 15 liver resections per year (Table 2). Of note, 75.1% 
(n=1,264) of liver resections performed at high volume hospitals were performed 
by high volume surgeons while a majority of resections performed at low volume 
centers were performed by low volume surgeons (n=1,275, 69.9%); no surgeon at 
a low volume center was categorized as a high volume surgeon (Table 2).
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Table 1: Patient characteristics and perioperative parameters
Characteristic Total Cohort (n=5,075)
No. of Hospitals 408
No. of Surgeons 1099
Age 
   < 50 921 (18.2)
   50-59 1362 (26.8)
   60-69 1509 (29.7)
   ≥ 70 1282 (25.3)
Male Gender 2802 (55.2)
Race
   White 3267 (75.0)
   Black 381 (8.7)
   Hispanic 352 (8.1)
   Other/Unknown 358 (8.2)
Year of Treatment
   2001-2003 1374 (27.1)
   2004-2006 1539 (30.3)
   2007-2009 2162 (42.6)
Household Income
   Low 932 (22.2)
   Medium 1064 (25.6)
   High 956 (23.0)
   Highest 1217 (29.3)
Household Payer
   Government 2267 (44.7)
   Private 2583 (50.9)
   Self/Other 224 (4.4)
Admission Type
   Emergency 384 (8.2)
   Elective 4309 (91.8)
High Comorbidity 1042 (20.5)
Operation
   Lobectomy 1978 (39.0)
   Partial Hepatectomy 3097 (61.0)
Hospital Size
   Small 228 (4.5)
   Medium 544 (10.8)
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Effect of hospital and surgeon volume on in-hospital mortality
The in-hospital mortality for all patients undergoing a liver resection was noted 
to be 3.2% with marked differences noted among hospitals and providers. In par-
ticular, when stratified by hospital volume, mortality among patients treated at a 
low volume hospital was proportionally higher that that noted for patients treated 
at high volume hospitals (low vs. intermediate vs. high; 4.5% vs. 3.2% vs. 1.8%, 
p<0.001, Figure 1a). A similar pattern in mortality was also noted by annual 
surgeon volume (low vs. intermediate vs. high; 4.7% vs. 3.4% vs. 1.4 %, p<0.001, 
Figure 1b). After adjusting for sociodemographic and hospital characteristics on 
multivariable analysis, both increasing surgeon and hospital volume were associ-
ated with decreased odds of mortality (Table 3). In particular, compared with 
patients treated by high volume surgeons, patients treated by intermediate and low 
volume surgeons demonstrated over 2.0 times greater odds of mortality following 
Table 1: Patient characteristics and perioperative parameters (continued)
Characteristic Total Cohort (n=5,075)
   Large 4285 (84.7)
Metropolitan Location 4933 (97.5)
Teaching Hospital 4400 (87.0)
Hospital Region
   North-East 1810 (35.7)
   Mid-West 636 (12.5)
   South 1910 (37.6)
   West 719 (14.2)
Table 2: Hospitals, Surgeon and Patients by Hospital and Surgeon Volume Tertile
Low Volume 
Hospital
Intermediate  
Volume Hospital
High Volume 
Hospital
*Total Number of Hospitals, n (%) 360 (88.2%) 38 (9.3%) 10 (2.5%)
*Total Number of Surgeons, n (%) 775 (70.5%) 206 (18.7%) 118 (10.7%)
Low Volume Surgeon† 720 (92.9%) 128 (62.1%) 73 (61.9%)
Intermediate Volume Surgeon† 55 (7.1%) 66 (32.0%) 22 (18.6%)
High Volume Surgeon† 0 (0.0%) 12 (5.8%) 23 (19.5%)
*Total Number of Patients, n (%) 1,824 (35.9%) 1,568 (30.9%) 1,683 (33.2%)
Low Volume Surgeon† 1,275 (69.9%) 311 (19.8%) 136 (8.1%)
Intermediate Volume Surgeon† 549 (30.1%) 888 (56.63%) 283 (16.8%)
High Volume Surgeon† 0 (0.0%) 369 (23.53%) 1,264 (75.1%)
*Represents row percentage, †Represents column percentage
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surgery (intermediate volume; OR 2.56, 95% CI 1.54-4.26, p<0.001; low vol-
ume; OR 3.01, 95% CI 1.80-5.04, p<0.001). Similarly, an inverse relationship 
was observed between hospital volume and mortality among patients undergoing 
liver surgery. In comparison to patients treated at high volume hospitals, patients 
treated at low volume hospitals demonstrated 2.1 times greater odds of mortality 
(low volume; OR 2.13, 95% CI 1.31-3.47, p=0.002) while patients treated at 
intermediate volume hospitals demonstrated a 2 times greater odds of mortality 
(OR 2.00, 95% CI 1.24-3.21, p=0.004). Interestingly, when adjusting for both 
surgeon and hospital volume, only surgeon volume was found to be associated 
with a greater odds of mortality (Table 3). Specifically, increasing surgeon volume 
was associated with a step-wise decrease in the odds of mortality with patients 
treated by an intermediate volume surgeon demonstrating 2.2 times greater odds 
of mortality (OR 2.27, 95% CI 1.27-4.06, p=0.006) while those treated by low 
volume surgeons demonstrated a 2.8 times greater odds of mortality (OR 2.83 
Figure 1: Unadjusted incidence of postoperative complications, postoperative mortality and fail-
ure-to-rescue by (a) hospital volume terciles (b) surgeon volume terciles 
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Table 3: Multivariable Logistic Regression Analyses of Factors Associated with Postoperative Mor-
tality
Characteristic Odds Ratio 95% CI P value
Hospital volume (Without Surgeon Volume)
   High Ref. - -
   Medium 2.00 1.24-3.21 0.004
   Low 2.13 1.31-3.47 0.002
Surgeon volume (Without Hospital Volume)
   High Ref. - -
   Medium 2.56 1.54-4.26 <0.001
   Low 3.01 1.80-5.04 <0.001
Hospital volume
   High Ref. - -
   Medium 1.33 0.78-2.27 0.293
   Low 1.12 0.62-2.03 0.701
Surgeon volume
   High Ref. - -
   Medium 2.27 1.27-4.06 0.006
   Low
Age (years)
2.83 1.52-5.27 0.001
   <50 Ref. - -
   50-59 1.26 0.67-2.38 0.474
   60-69 1.77 0.96-3.27 0.068
   ≥ 70 2.35 1.23-4.48 0.009
Male sex 1.63 1.14-2.31 0.007
Year of Treatment
   2001-2003 Ref - -
   2004-2006 0.80 0.53-1.21 0.294
   2007-2009 0.64 0.42-0.97 0.037
Household Payer
   Government Ref - -
   Private 0.72 0.47-1.11 0.142
   Self/Other 1.68 0.85-3.31 0.136
Emergency Admission 2.03 1.28-3.22 0.003
Operation
   Partial Hepatectomy Ref. - -
   Lobectomy 1.94 1.39-2.71 <0.001
Non-teaching Hospital 1.13 0.71-1.81 0.607
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95% CI 1.52-5.27, p=0.001) when compared with patients treated by high a 
volume surgeon. 
Effect of Hospital and surgeon volume on failure to rescue
Overall, postoperative complications were noted in 31.6% of patients undergoing 
a liver resection with differences noted by both surgeon and hospital volume. Of 
note, postoperative complications were lowest among patients treated by high 
volume surgeons (low vs. intermediate vs. high; 35.3% vs. 32.4% vs. 26.8%, 
p<0.001) and highest at low volume hospitals (low vs. intermediate vs. high; 
36.0% vs. 30.8% vs. 28.6, p=0.004, Figure 1). The overall rate of FTR was 8.1% 
and noted most commonly among patients who developed postoperative renal 
failure (n=85, 54.8%). Further, FTR was noted to vary by surgeon and hospital 
volume; FTR was lowest among high volume surgeons (low vs. intermediate vs. 
high; 11.1% vs. 9.1% vs. 4.1%, p<0.001) and at high volume hospitals (low vs. 
intermediate vs. high; 10.3% vs. 9.0% vs. 5.2%, p<0.001).  
To further explore factors associated with FTR, multivariable analysis was per-
formed adjusting for patient, surgeon and hospital level characteristics. On multi-
variable analyses, an inverse relationship between volume and FTR was observed. 
Specifically, compared with patients treated by high volume surgeons, patients 
treated by lower volume surgeons were associated with a 3 times greater odds of 
FTR (intermediate volume; OR 3.08, 95% CI 1.77-5.34, p<0.001; low volume; 
OR 3.42, 95% CI 1.98-5.93, p<0.001). Similarly, patients treated at high volume 
hospitals demonstrated a decreased odds for FTR (intermediate volume; OR 
2.04, 95% CI 1.25-3.33, p=0.004; low volume; OR 2.15, 95% CI 1.33-3.48, 
p=0.002). Interestingly, when adjusting for both surgeon and hospital volumes 
within the same model, only surgeon volume and not hospital volume was noted 
to be associated with FTR (intermediate volume; OR 2.86, 95% CI 1.53-5.34, 
p=0.001; low volume; OR 3.40, 95% CI 1.75-6.63, p<0.001, Table 4). Other fac-
tors associated with a greater odds of FTR included increasing patient age, hepatic 
lobectomy, and surgeries performed on an emergent basis (all p<0.05, Table 4). 
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Table 4: Multivariable Logistic Regression Analyses of Factors Associated with Failure-to-Rescue
Characteristic OR 95% CI P
Hospital volume (Without Surgeon Volume)
   High Ref. - -
   Medium 2.04 1.25-3.33 0.004
   Low 2.15 1.33-3.48 0.002
Surgeon volume (Without Hospital Volume)
   High Ref. - -
   Medium 3.08 1.77-5.34 <0.001
   Low 3.42 1.98-5.93 <0.001
Hospital volume
   High Ref. - -
   Medium 1.24 0.72-2.14 0.446
   Low 1.03 0.57-1.85 0.928
Surgeon volume
   High Ref. - -
   Medium 2.86 1.53-5.34 0.001
   Low
Age (years)
3.40 1.75-6.63 <0.001
   <50 Ref. - -
   50-59 1.37 0.70-2.69 0.360
   60-69 1.92 1.00-3.68 0.051
   ≥ 70 2.58 1.30-5.12 0.007
Male sex 1.57 1.09-2.27 0.016
Year of Treatment
   2000-2003 Ref - -
   2004-2006 0.80 0.52-1.25 0.327
   2007-2009 0.66 0.43-1.03 0.067
Household Payer
   Government Ref - -
   Private 0.76 0.48-1.19 0.227
   Self/Other 1.91 0.96-3.80 0.064
Emergency Admission 1.74 1.06-2.86 0.028
Operation
   Partial Hepatectomy Ref. - -
   Lobectomy 1.86 1.31-2.65 <0.001
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Relative effects of hospital and surgeon volume on postoperative outcomes
Results of the multivariable analysis were used to obtain risk-adjusted mortal-
ity and FTR by surgeon and hospital volume terciles (Tables 5 and 6). While 
mortality and FTR were noted to decrease with increasing volume, a stronger 
relationship was observed relative to surgeon volume in comparison to hospital 
volume. For example, among surgeons practicing at a high volume hospital, the 
risk-adjusted mortality was noted to decrease with increasing surgeon volume 
(low vs. intermediate vs. high; 3.5% vs. 3.2% vs. 1.3%, p<0.05). In contrast, risk-
adjusted mortality was comparable among intermediate volume surgeons, regard-
less of the hospital volume (p>0.05, Table 5). Interestingly, within each hospital 
volume strata, FTR was noted to decrease with increasing surgeon volume. Of 
note, among surgeons practicing at a high volume hospital, FTR was lower among 
high volume surgeons compared with intermediate and low volume surgeons (low 
vs. intermediate vs. high; 9.4% vs. 9.0% vs. 3.9%, both p<0.05). A similar pattern 
in FTR was also observed at intermediate volume hospitals, with FTR noted to be 
the lowest among high volume surgeons (low vs. intermediate vs. high; 11.8% vs. 
9.5% vs. 5.1%, both p<0.05, Table 6).  
Point estimates for surgeon and hospital volume obtained from multivariable 
analyses were used to calculate the relative effects of hospital and surgeon vol-
umes on in-hospital mortality and FTR (Table 7). In particular, hospital volume 
accounted for 12.8% and 5.6% of the effect of surgeon volume on mortality 
among patients treated by intermediate and low volume surgeons, respectively. 
Conversely, surgeon volume accounted for a much larger proportion of the ef-
fect of hospital volume on mortality, accounting for 58.9% and 85.0% of the 
volume-mortality effect observed between intermediate and low volume hospitals, 
respectively. Similarly, hospital volume accounted for only 6.6% and 0.5% of the 
effect of surgeon volume on FTR among intermediate and low volume surgeons, 
whereas surgeon volume was the main contributor to the relationship between 
volume and FTR accounting for 69.8% of the increased effect of FTR observed 
among patients treated at intermediate volume hospitals and 96.1% of the effect 
at low volume hospitals (Table 7).
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Discussion
Over recent years, multiple studies have highlighted the inverse-relationship 
between hospital volume and operative mortality following complex surgery.1-3,5 
Based on these findings, policymakers and healthcare organizations have promoted 
the selective regionalization of surgical procedures including liver resections to 
high volume centers.21 However, more recent reports have identified FTR as a 
potential quality parameter to explain variations in surgical outcomes including 
mortality.11-13,22 While these reports have identified hospital-level characteristics 
associated with variability in surgical outcomes, less is known regarding the ef-
fects of provider-level characteristics on similar peri-operative outcomes. Using 
a large nationally representative dataset, the current study explored the effects 
of surgeon and hospital volume on operative mortality as well as FTR among 
a cohort of patients undergoing liver surgery for cancer. In particular, operative 
mortality was noted to be twice as high among patients treated by lower volume 
centers and among patients treated by lower volume surgeons. Similarly, while 
over 36% of all patients developed a post-operative complication, patients treated 
at higher volume centers and by higher volume surgeons were not only less likely 
to develop a post-operative complication but also were less likely to die follow-
ing the postoperative complication. Interestingly, while over 80% of the effect of 
hospital volume was accounted for by surgeon volume, less than 7% of the effect 
of surgeon volume was attributable to differences in hospital volume. 
Consistent with previous reports, this study noted that among patients undergo-
ing liver resection, 36% developed a post-operative complication.15-17 Although 
some reports have noted no association between hospital volume and the devel-
opment of post-operative complications, results from this study support other 
studies that have demonstrated a correlation between low volume hospitals and 
high postoperative complications.11,13,23-25 Specifically, we noted that 36.0% of 
patients treated at low volume hospitals developed a post-operative complication 
versus 28.6% of patients treated at high volume centers. These results are likely 
explained by the fact that low volume centers do not achieve appropriate thresh-
olds for complex surgery and therefore lack certain institutional processes and 
systems for these procedures.26 Perhaps more strikingly, the proportion of patients 
who developed a post-operative complication varied not only by hospital volume 
but also by surgeon volume. Among patients treated by high volume surgeons, 
26.8% developed a post-operative complication compared with 35.3% of patients 
treated by low volume surgeons.  These data suggest that quality improvement 
should not only target system-level factors, but also include interventions at the 
provider-level. 
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Mortality following a post-operative complication (FTR) is an emerging quality 
indicator and represents an additional system-level factor associated with varia-
tions in post-operative outcomes.11-13,22 Similar to previous reports, the current 
study of patients undergoing liver resections noted FTR to be 8.1%.  FTR varied 
by hospital with FTR at high volume hospitals almost 2 times lower than FTR 
observed at low and intermediate hospitals.11 While there is a growing body 
of evidence to suggest that the timely recognition and effective management 
of complications are essential to reducing variations in surgical mortality, it is 
almost intuitive that a lower rate of complications may translate to a lower FTR 
and postoperative mortality. Interestingly, we noted that while patients treated 
by high volume surgeons and hospitals were less likely to develop to a major 
postoperative complication these patients were also twice as likely to survive fol-
lowing a postoperative complication. These data support calls for regionalization 
of high-risk procedures such as liver resection.  High volume hospitals likely 
represent a setting where advanced clinical pathways and standardized systems 
are better able to detect and thereby “rescue” patients following a post-operative 
complication. In addition, larger hospital bed size, higher nurse-to-patient ratios 
and the availability of intensive care services may also contribute to decreasing 
in-hospital deaths following a major postoperative complication noted at high 
volume centers.11,13,27,28 
Perhaps more interestingly, we also noted that rates of FTR varied not only by 
hospital volume but also by the volumes of the individual surgeon. Of note, while 
hospital volume attributed less than 7% of the effect of surgeon volume on FTR, 
approximately all of the effect of hospital volume on FTR was accounted for by 
surgeon volume. Given the technical skill and use of specialized intraoperative 
processes when performing complex liver surgery; the relative importance of sur-
geon volume is not surprising. Further, the large variability in intraoperative and 
postoperative care pathways between and within hospitals likely also contributes 
the overwhelming effect of surgeon volume. For example, certain providers and 
institutions may routinely perform low CVP surgery to limit the extent of intra-
operatively bleeding. In contrast, other providers may not employ this approach 
and may allow for more liberal fluid practices, transfusion and postoperative care 
/ recovery that may increase risk for complications and subsequently mortality / 
FTR. Further, while FTR is undoubtedly influenced by a multitude of surgeon-
level factors such as skill and experience, it is likely that a portion of this relative 
effect of surgeon volume represents a difference in patient mix between providers. 
To this end, Ghaferi et al. noted that despite appropriate risk-adjustment, large 
proportions of variation in FTR remain unexplained.11 Similarly, although the 
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current study employed a modeling approach that accounted for the interdepen-
dence of outcomes between clusters of hospital and surgeons, it is likely that some 
variability in FTR and mortality was unexplained at the patient level.  In aggregate, 
data such as those presented in the current study lend credence to the movement 
by some academic medical centers to impose minimum caseload requirements 
for surgeons to perform certain complex operations within their institutions. 
Future work, however, is warranted to determine root causes for the variations 
in postoperative outcomes, as well as understand barriers to implementation and 
adherence to evidence-based processes of care.
The current study had several limitations. Using administrative claims data, the 
study lacked specific details pertaining to the extent of disease as well as additional 
intra-operative details. Moreover, due to the cross-sectional nature of the data, 
long-term outcomes such as readmission and subsequent prognosis which may 
have allowed for an assessment of other potential benefits of regionalized care 
could not be evaluated. However, despite the inherent limitations of administra-
tive data, the use of a nationally representative sample allowed for generalizable 
results across a large cohort of patients undergoing liver surgery.
In conclusion, this study demonstrated significant variability in post-operative 
mortality and FTR relative to hospital and surgeon volume. In particular, lower 
complications, lower FTR and consequently lower post-operative mortality was 
noted at high volume hospitals and among patients treated by high volume 
surgeons. Interestingly, even within high volume centers, high volume surgeons 
reported lower complications, lower FTR and improved operative mortality. 
Rather than factors related to the hospital, nearly 80% of the inverse relationship 
observed between volume and FTR / operative mortality was accounted for by 
differences between individual providers. Further research should explore these 
microsystems within hospitals that potentially drive variations in post-operative 
outcomes such as mortality. 
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Supplementary Table 1 – Multivariable analysis of factors associated with in-hospital mortality
Multivariable Logistic (In Paper) Hierarchical Multivariable
OR 95% CI P OR 95% CI P
Hospital volume (Without Surgeon Volume)
   High Ref. - - Ref. - -
   Medium 2.00 1.24-3.21 0.004 1.49 0.81-2.74 0.196
   Low 2.13 1.31-3.47 0.002 1.82 1.00-3.30 0.049
Surgeon volume (Without Hospital Volume)
   High Ref. - - Ref. - -
   Medium 2.56 1.54-4.26 <0.001 2.34 1.26-4.32 0.007
   Low 3.01 1.80-5.04 <0.001 3.04 1.63-5.59 <0.001
Hospital volume
   High Ref. - - Ref. - -
   Medium 1.33 0.78-2.27 0.293 1.09 0.59-2.00 0.782
   Low 1.12 0.62-2.03 0.701 1.08 0.57-2.08 0.807
Surgeon volume
   High Ref. - - Ref. - -
   Medium 2.27 1.27-4.06 0.006 2.23 1.12-4.48 0.023
   Low
Age (years)
2.83 1.52-5.27 0.001 2.89 1.38-6.06 0.005
   <50 Ref. - - Ref. - -
   50-59 1.26 0.67-2.38 0.474 1.26 0.67-2.40 0.474
   60-69 1.77 0.96-3.27 0.068 1.77 0.95-3.30 0.070
   ≥ 70 2.35 1.23-4.48 0.009 2.42 1.26-4.65 0.008
Male sex 1.63 1.14-2.31 0.007 1.61 1.13-2.31 0.009
Year of Treatment
   2001-2003 Ref - - Ref. - -
   2004-2006 0.80 0.53-1.21 0.294 0.78 0.50-1.21 0.261
   2007-2009 0.64 0.42-0.97 0.037 0.63 0.41-0.98 0.042
Household Payer
   Government Ref - - Ref. - -
   Private 0.72 0.47-1.11 0.142 0.73 0.47-1.13 0.156
   Self/Other 1.68 0.85-3.31 0.136 1.69 0.84-3.40 0.140
Emergency Admission 2.03 1.28-3.22 0.003 2.00 1.24-3.23 0.005
Operation
   Partial Hepatectomy Ref. - - Ref. - -
   Lobectomy 1.94 1.39-2.71 <0.001 1.92 1.37-2.71 <0.001
Non-teaching Hospital 1.13 0.71-1.81 0.607 1.05 0.64-1.71 0.854
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Supplementary Table 2 – Multivariable analysis of factors associated with failure-to-rescue
Multivariable Logistic (In Paper) Hierarchical Multivariable
OR 95% CI P OR 95% CI P
Hospital volume (Without Surgeon Volume)
   High Ref. - - Ref. - -
   Medium 2.04 1.25-3.33 0.004 1.49 0.79-2.84 0.222
   Low 2.15 1.33-3.48 0.002 1.73 0.94-3.21 0.079
Surgeon volume (Without Hospital Volume)
   High Ref. - - Ref. - -
   Medium 3.08 1.77-5.34 <0.001 2.71 1.46-5.01 0.002
   Low 3.42 1.98-5.93 <0.001 3.49 1.91-6.39 <0.001
Hospital volume
   High Ref. - - Ref. - -
   Medium 1.24 0.72-2.14 0.446 1.00 0.54-1.90 0.980
   Low 1.03 0.57-1.85 0.928 0.93 0.48-1.81 0.836
Surgeon volume
   High Ref. - - Ref. - -
   Medium 2.86 1.53-5.34 0.001 2.76 1.39-5.47 0.004
   Low
Age (years)
3.40 1.75-6.63 <0.001 3.67 1.78-7.57 <0.001
   <50 Ref. - - Ref. - -
   50-59 1.37 0.70-2.69 0.360 1.38 0.70-2.72 0.348
   60-69 1.92 1.00-3.68 0.051 1.91 0.99-3.68 0.052
   ≥ 70 2.58 1.30-5.12 0.007 2.66 1.33-5.31 0.005
Male sex 1.57 1.09-2.27 0.016 1.56 1.08-2.26 0.019
Year of Treatment
   2000-2003 Ref - - Ref. - -
   2004-2006 0.80 0.52-1.25 0.327 0.77 0.49-1.22 0.273
   2007-2009 0.66 0.43-1.03 0.067 0.66 0.42-1.04 0.073
Household Payer
   Government Ref - - Ref. - -
   Private 0.76 0.48-1.19 0.227 0.76 0.48-1.20 0.236
   Self/Other 1.91 0.96-3.80 0.064 1.93 0.96-3.88 0.064
Emergency 
Admission
1.74 1.06-2.86 0.028 1.72 1.03-2.86 0.038
Operation
   Partial 
Hepatectomy
Ref. - - Ref. - -
   Lobectomy 1.86 1.31-2.65 <0.001 1.84 1.29-2.63 0.001
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ABSTRACT
Background
Post-hepatectomy liver failure (PHLF) is a major source of morbidity and mortal-
ity in patients undergoing liver resection. The aim of this review is to summarize 
the recent literature available on PHLF including its definition, predictive fac-
tors, preoperative risk assessment, severity grading, preventative measures, and 
management strategies.
Methods 
A systematic literature search was carried out with the search engines PubMed, 
Medline, and Cochrane Database using the keywords related to “liver failure”, 
“posthepatectomy”, and “hepatic resection”.
Results 
Liver resection is a curative treatment of liver tumors. However, it leads to con-
current death and regeneration of the remaining hepatocytes. Factors related to 
the patient, liver parenchyma and the extent of surgery can inhibit regeneration 
leading to PHLF.
Conclusion
Given its resistance to treatment and the high postoperative mortality associated 
with PHLF, great effort has been put in to both accurately identify patients at high 
risk and to develop strategies that can help prevent its occurrence.
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Introduction 
Liver resection remains the mainstay of treatment for both primary and secondary 
liver tumors. Advances in operative techniques, perioperative care, and patients 
selection have resulted in an increase in the number of patients who are amenable 
to surgical resection, as well as decreased the morbidity and mortality associated 
with liver surgery.1-3 However, one of the most serious complications following 
liver resection is the development of post-hepatectomy liver insufficiency/ failure 
(PHLF), which can be a major cause of morbidity and mortality.4-6 The reported 
incidence of PHLF varies between 0.7 and 34 % in the literature.4,7-10 This wide 
range of incidence may be explained, in part, by the different definitions of PHLF, 
variability of the extent of hepatic resection (wedge resection vs. minor vs. major 
hepatectomy), as well as the diverse characteristics of the patients analysed.4,11 We 
herein review the risk factors associated with PHLF, as well as the different defini-
tions and predication models reported in the literature. In addition, we highlight 
several proposed prevention and treatment strategies for PHLF. 
Methods
A systematic literature search was carried out with the search engines PubMed, 
Medline, and Cochrane Database using the keywords related to “liver failure”, 
“liver insufficiency”, “post-hepatectomy”, “morbidity”, “mortality”, and “hepatic 
resection”. The resulting relevant English language studies were identified and 
reviewed.
Incidence
The incidence of PHLF varies between 0.7 and 34 % in the literature with most 
recent reports noting an incidence around 5–10 %.4,7-10 The wide range of inci-
dence may partially be explained by the lack of a uniform definition of PHLF.4,11 
There has been a decrease in incidence of PHLF over the past two decades likely 
due to improvements in surgical technique and perioperative care that have led to 
decreased mortality following hepatic resection. Mortality following partial hepa-
tectomy in the past two decades still ranges from 0 to 6 %, however, and PHLF 
has been implicated as contributing to mortality in the majority of cases.4,12,13
Risk Factors for Post Hepatectomy Liver Failure
Identification of the risk factors for PHLF is critical to help identify patients 
most at risk, as well as to inform strategies aimed at decreasing the incidence 
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and mortality associated with PHLF. Independent predictors of PHLF can be 
categorized into three main categories: patient- related, liver- related, and surgery/
postop-related factors (Table 1).
78 
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Patient-Related Factors
Patient-related factors associated with PHLF include age, male gender, malnutri-
tion, diabetes, and American Society of Anesthesiology (ASA) score. Some studies 
had implicated older age as a risk factor for PHLF; however, other studies have 
documented the safety of liver resection in the elderly. Animal models have sug-
gested a loss of the liver’s regenerative capacity, as well as impaired liver function 
with increased age.14-17 In a study of 775 patients, Balzan et al. reported age over 
65 years as an independent predictor of death in multivariate analysis.18 In a 
subsequent study, Mullen et al. evaluated 1509 non-cirrhotic patients undergoing 
hepatectomy and found older age to be an independent predictor of morbidity 
as well as death from liver failure.19 However, clinical data from several major 
centers have documented that hepatectomy can be performed with low morbid-
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ity in older patients. For example, in a study of 129 patients, Aldrighetti et al. 
reported that age >70 years did not correlated with an increased morbidity or 
mortality following partial liver resection.20 In a separate study, while an increase 
in the incidence of systemic complications was noted among elderly patients fol-
lowing hepatectomy for hepatocellular carcinoma (HCC), Nanashima et al. failed 
to detect a difference in the incidence of hepatic failure.21 Similarly, Kim et al. in 
a study of 279 patients undergoing both minor and major liver resections did not 
find any age-related differences in postoperative PHLF.22 
Diabetes, either alone or in combination with metabolic syndrome, has also been 
associated with a greater risk of PHLF. Little et al. reported on 727 patients who 
underwent liver resection and demonstrated an increase in 30-day mortality 
among diabetic versus non-diabetic patients (p <0.02); in fact, 80 % of the deaths 
in this study were attributable to PHLF.23 The association of diabetes with the 
risk of PHLF may be due to the important role insulin plays in the regulation of 
hepatocyte function and regeneration. Specifically, a lack of insulin has been noted 
to cause hepatic atrophy in animal models.24 In one clinical study, Zarzavadjian 
Le Bian et al. reported that in the 30 (19.8 %) of the 151 patients undergoing 
right hepatectomy who had two or more metabolic disorders (diabetes mellitus, 
hypertension, dyslipidemia, or obesity) perioperative mortality was 30 %.25 In 
a different study of 245 patients with well-preserved liver function undergoing 
liver resection for HCC, Huo et al. reported that diabetes was an independent 
prognostic factor associated with over a twofold increased risk of PHLF (RR=2.3, 
95 % CI=1.4–3.7, p=0.001).26 
Similar to diabetes, obesity—another factor related to metabolic syndrome—has 
been associated with an increased risk of PHLF.25 Schlindl et al. in a study of 
104 patients who underwent major liver resection reported that the body mass 
index (BMI) was higher among patients who experienced postoperative PHLF 
(median=29.9, SD=6.1) versus patient who did not (median=24.6, SD=4.2, p 
<0.001).27
Interestingly, malnutrition has also been associated with PHLF. The reasons for 
this are unclear, but may be due to an altered immune response in malnourished 
patients, as well as a decrease in hepatocyte regenerative capacity.28,29 In a pro-
spective study of 124 patients undergoing hepatectomy in Hong Kong, Fan et 
al. demonstrated that patients who were given perioperative nutritional therapy 
had a reduction in overall postoperative morbidity (34 vs. 55 %; RR=0.66; 95% 
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CI=0.34 to 0.96), as well as less deterioration of liver function measured by rate of 
clearance of indocyanine green (−2.8 vs. −4.8 % at 20 min, p=0.05).28
Liver-Related Factors
Patients undergoing hepatectomy present with a wide range of underlying 
hepatic parenchymal disease including cirrhosis, steatosis, steatohepatitis, and 
chemotherapy induced liver injury that can affect the ability of the liver to regen-
erate after liver resection. 
Cirrhosis is one of the most important and well-studied factors limiting the 
regenerative ability of the liver. Animal models have demonstrated that after resec-
tion, cirrhosis is associated with decreased levels of hepatocyte growth factor,30 
impaired transcription factors,31 and a reduction of DNA synthesis, leading to 
lower volumes of regenerated liver.32 Largely due to the risk of PHLF, mortality 
following liver resection has traditionally been associated with a high mortality, 
reaching 30 % in some series.33,34 While mortality among cirrhotic patients has 
decreased over the past several decades, 90-day mortality following liver resection 
still remains higher than among patients without underlying cirrhosis. Not sur-
prisingly, mortality is also associated with the degree of cirrhosis, as Capussotti et 
al. demonstrated that Child Pugh class A patients had a lower in-hospital mortality 
versus Child-Pugh class B or C patients (4.7 vs 21.3 %, respectively; p<0.001).35 
In addition to cirrhosis, steatosis and steatohepatitis can affect liver function and 
regeneration post resection. For example, an increased integrated stress response 
impairs regeneration of the liver in animal models in the setting of hepatic ste-
atosis.36 de Meijer et al. published a meta- analysis in which hepatic steatosis was 
noted to be a risk factor for increased perioperative morbidity and mortality in 
patients undergoing major hepatic resection.37 Specifically, patients with at least 
30 % steatosis had an increased risk both of postoperative death (RR= 2.79, 95 
% CI= 1.19– 6.51) and of developing postoperative complications (RR=2.01, 95 
% CI = 1.66–2.44) versus patients without steatosis.37 In a recent different study 
that compared 174 patients with steatohepatitis or >33 % simple steatosis versus 
patients with a normal liver, 90-day postoperative overall morbidity (56.9 vs. 37.3 
%; p = 0.008), any hepatic-related morbidity (28.4 vs. 15.7 %; p = 0.043), surgical 
hepatic complications (19.6 vs. 8.8 %; p = 0.046), and hepatic decompensation 
(16.7 vs. 6.9 %; p = 0.049) were all greater among patients with steatohepatitis 
versus those with normal liver parenchyma.38
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With the increasing utilization of neoadjuvant chemotherapy, possible che-
motherapy-related hepatotoxicity presents another factor that may impact the 
regenerative ability of the liver. Several studies have suggested that chemother-
apy-associated liver injury is regimen specific. In a study of 248 patients who 
underwent neoadjuvant chemotherapy for colorectal liver metastasis (CRLM) 
followed by hepatic resection, Vauthey et al. reported that an oxaliplatin-based 
regimen was associated with sinusoidal dilation on pathologic analysis compared 
with chemotherapy-naïve livers (18.9 vs. 1.9 %, respectively; p<0.001 ; OR=8.3, 
95 % CI=2.9–23.6).39 In addition, irinotecan-based therapy was associated with 
steatohepatitis versus no chemotherapy (20.2 vs. 4.4 %, respectively; p<0.001; 
OR=5.4, 95 % CI=2.2–13.5) (Fig. 1). Of note, patients with steatohepatitis on 
pathologic review had an increased 90-day mortality compared with patients 
without steatohepatitis (14.7 vs. 1.6 %, respectively; p=0.001; OR=10.5; 95 % 
CI=2.0–36.4).39 Robinson et al. corroborated these findings in a meta-analysis 
of 28 studies as neoadjuvant chemotherapy was associated with an increased risk 
of regimen-specific hepatic parenchymal injury.40 Patients receiving oxaliplatin-
based regimens had over a fourfold increased risk of sinusoidal injury compared 
with chemotherapy-naïve patients (95 % CI=1.36–13.97; p=0.01).40 Several 
studies have associated sinusoidal injury and steatohepatitis with compromised 
liver regeneration as well as increased morbidity following hepatic resection.41-44
Fig. 1  MRI images of normal liver parenchyma and severe steatohepatitis. a In phase axial im-
age of the liver showing normal liver signal. b Opposed phase axial image of the liver showing 
significant signal drop, indicating severe steatohepatitis in a patient following neoadjuvant che-
motherapy
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Surgery-Related Factors
In addition to patient- and liver-specific factors, the surgical procedure itself may 
influence the risk of PHLF in both the immediate postoperative period and in a 
delayed manner. Intraoperative blood loss and requirement of blood transfusion 
have been associated with an increase in postoperative complications following 
hepatectomy.45,46 In a study of 1056 hepatectomies, intraoperative blood loss 
>1000 mL was strongly associated with the occurrence of major complications 
(OR=4.17; 95% CI=1.04–17.5).47 Excessive blood loss can lead to fluid shifts, 
which may induce bacterial translocation leading to systemic inflammation 
and coagulopathy, which predisposes for intra-abdominal hematoma and infec-
tion.48,49 Moreover, postoperative blood transfusions required due to intraop-
erative blood loss, results an immunosuppressive effect that may contribute to 
PHLF.50
An important surgery-related factor is the extent of resection and avoidance of 
“small-for-size” liver remnant following hepatectomy. Much of the data regarding 
“small-for-size” liver remnant and resultant PHLF stems from the living donor 
liver transplant literature. First documented in 1996 by Emond et al., small 
for size graft syndrome initially was defined as graft-to-recipient weight ratio 
(GRWR) of less than 0.8 to 1.0 % or less than 30 to 50 % of standard/estimated 
liver volumes; small-for-size livers are associated with an increase in severe graft 
dysfunction with increased hepatocyte injury, hyperbilirubinemia, prolonged PT, 
portal hypertension, and ascites.51-53 A similar “small-for-size” syndrome can be 
seen following extended hepatic resections, and therefore, one should take efforts 
to preoperatively predict adequate FRL in an effort to decrease the risk of PHLF.
While most surgery-related factors may result in an increased risk of PHLF in 
the immediate postoperative period, PHLF can also occur in a delayed fashion. 
Specifically, PHLF may be due to a combination of initial patient, liver, and 
surgery-related factors combined with a postoperative “second hit” such as in-
fection or sepsis, which has been shown to decrease Kuppfer cell function and 
increase toxic cytokines both of which can inhibit hepatocyte proliferation in 
animal models.54,55 
Physiology and Molecular Mechanisms of PHLF
Following hepatecomy, sheer stress on the vascular endothelium can be elevated 
due to an increase in portal pressure.56,57 In turn, liver sinusoidal endothelial cells 
release nitric oxide in response to this increase in sheer stress with resulting sen-
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sitization of hepatocytes to hepatocyte growth factor (HGF).58 HGF stimulates 
hepatocyte proliferation through activation of multiple signaling pathways as well 
as an increase in transforming growth factor alpha (TGF α). In addition, several 
portal hepatotrophic factors, including lipopolysaccharide, are initiated to assist 
in regeneration.59 These portal hepatotrophic factors stimulate release of interleu-
kin-6 (IL-6) from Kupffer cells that induces transcription of several cell division 
and survival genes.60 In animal models of 70 % partial hepatectomy, 95 % of 
normally quiescent hepatocytes reenter the cell cycle and undergo mitosis peaking 
24 h post- hepatectomy.61 The resulting hepatocyte proliferation forms clusters 
of 10–14 unorganized “hepatic islands” that are not functional until connections 
are reestablished among hepatocytes and endothelial cells via extracellular matrix 
production by stellate cells.62 While in animal models, restoration of liver volume 
occurs quickly (by 72 h post-hepatectomy), the original studies of healthy human 
hepatic regeneration showed volume restoration at 2 to 6 months with biologic 
function restored significantly earlier—in less than 3 weeks post major hepa-
tectomy.63 To facilitate normal hepatic metabolism and regeneration, constant 
interaction between hepatocytes and biliary endothelial cells is necessary. In the 
setting of PHLF, there is Kupffer cell dysregulation and a decrease in secretion 
of prostaglandin E2. This leads to hypersecretion of tumor necrosis factor result-
ing in necrosis, microvesicular steatosis, and irreversible hepatocyte injury that 
ultimately decreases the available exchange surface necessary for normal hepatic 
metabolism to occur.64
Preoperative Evaluation of Liver Function
Given the irreversible cellular injury and high mortality associated with PHLF, 
there has been great effort to preoperatively identify patients at high risk for 
hepatic dysfunction or failure. The preoperative assessment of a patient’s risk of 
developing PHLF is performed using multiple different techniques to evaluate the 
quality and the quantity of the future liver remnant (FLR).
Quality Assessment of the Liver
Traditional Liver Function Markers and Clinical Scoring Systems
The correlation between PHLF and conventional laboratory parameters repre-
senting different synthetic and excretory functions of the liver such as alanine 
aminotransferase (ALT), aspartate aminotransferase (ALT), alkaline phosphatase 
(ALP), gamma-glutamyl transpeptidase (GGT), bilirubin, lactate dehydrogenase 
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(LDH), albumin and prothrombin time (PT) has been extensively reported in 
the literature.65-72 None of these laboratory factors taken alone have been shown 
to provide an adequate evaluation of liver function; however, a combination of 
biochemical parameters has been included in different scoring systems to evaluate 
preoperative hepatic function.
In clinical practice, one widely used tool for assessment of liver function is the 
Child-Pugh classification that is based on five biochemical (bilirubin, albumin, 
and international normalized ration (INR)) and clinical (ascites and hepatic 
encephalopathy) variables.73 The other clinical tool is the Model for End-Stage 
Liver Disease (MELD), which incorporates only three biochemical parameters 
(creatinine, bilirubin, and INR).74 Both scoring systems were originally developed 
to grade chronic liver disease and cirrhosis in liver transplant candidates; however, 
both are currently also used to screen patients preoperatively for the risk of PHLF 
as well as to evaluate the perioperative liver function.73,75,76
Patients at the extreme of the Child-Pugh classification, such as those classified 
as advanced B or C (i.e., bilirubin> 50 μmol/L, serum albumin<2.8 g/dL, PT 
INR>2.3, moderate to severe ascites, and absence of hepatic encephalopathy), are 
not candidates for hepatectomy due to their risk of PHLF.4 The use of the Child-
Pugh classification to risk stratify patients with more modest or mild cirrhosis has 
demonstrated a relatively poor ability to predict specific PHLF-related mortal-
ity.77 The role of MELD model as a preoperative predictor of PHLF has similarly 
been extensively evaluated with mixed results.74,77-79 Several studies have sug-
gested that MELD can be used in the preoperative setting to risk-stratify patients 
with regard to postoperative PHLF and death. In one study of 2056 patients, 
the laboratory values that comprise the MELD score were used to create a risk 
model in which a biological MELD higher than 10 was associated with a higher 
risk of PHLF and death.80 A separate study from the Mayo Clinic reported on 
772 patients with cirrhosis who underwent major surgery and noted that MELD 
was an independent predictor of 30- and 90-day postoperative mortality.81 While 
Rahbari et al. noted that MELD score was correlated with morbidity and mortal-
ity following hepatectomy, the sensitivity for morbidity and mortality was only 55 
and 71 %, respectively.79 Cucchetti et al. reported that increasing MELD scores 
between postoperative days (POD) 3 and 5 was correlated with impending PHLF 
and should be a strong indication for intensive treatment.78
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Indocyanine Green Retention Rate at 15 min
Preoperative evaluation for the risk of PHLF has included the use of the indocya-
nine green retention rate at 15 min (ICG- R15) test in some centers.82,83 ICG 
is a water-soluble, nontoxic fluorescent dye that is injected intravenously and is 
eliminated almost exclusively by the liver. The absorption and emission spectrum 
of ICG are both in the near infrared range allowing for measurements to be 
performed by non-invasive monitoring.10,65,84-90 The ICGR-R15 test has been 
shown to predict more accurately PHLF compared with both the Child-Pugh 
classification91 and MELD model.92
There is no clear consensus on the cut-off value for ICG- R15 allowing for safe 
hepatic surgery. Fan et al. reported on 101 patients with cirrhosis who underwent 
major hepatic resection and suggested an ICG-R15 value of 14 % was the cut- off 
point that could maximally separate patients with and with- out high postoperative 
mortality (p=0.01).93 In a separate study, Lam et al. reported that the cut-off value 
for a safe major hepatectomy could be increased to 17 % in relatively younger 
patients with an adequate remnant liver volume (RLV).94 While the ICG-R15 
test is used in the east, its adoption has not been widespread in western centers.
Other Liver Function Tests for the Quality Assessment of the Liver
Several quantitative estimations of liver function based on the principle of clear-
ance of substrate by the liver have been developed. These substances include 
lidocaine,73 galactose,95 aminopyrine,96 amino acid,97 and methacetin.98 None of 
these various tests have been proven to be superior than ICG-R15 for the predic-
tion of PHLF- or PHLF-related mortality.91 There are also several tests available 
that are based on the synthetic functions of the liver including serum levels of 
hyaluronate99 and type IV collagen,100 energy production of the liver (arterial 
ketone body ratio),101 and the number of receptors for asialoglycoprotein (tech-
netium-99 m-galactosyl-human serum albumin; 99 m Tc-GSA scan).68,102-106 
While these tests may provide important information regarding the quality of 
the remaining liver remnant, their high cost and complexity are barriers to their 
clinical implementation.91
Liver-Specific Agents for Contrast-Enhanced MRI
There is an increasing interest in the possibility of integrating both quantitative and 
qualitative assessments of the functional liver remnant. In particular, the role of 
magnetic resonance imaging (MRI) for assessment of the liver is well established. 
Recently, liver-specific contrast agents have been developed which both improve 
morphological assessment as well as provide functional information.107 The most 
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promising liver- specific contrast agent for predicting PHLF after major liver 
resection is gadoxatic acid.108 After intravenous injection, this gadolinium-based 
paramagnetic contrast agent is taken up by functional hepatocytes and excreted 
into bile ducts via membrane transporters. The temporary accumulation of this 
contrast agent in the liver and subsequent enhancement of the normal liver paren-
chyma permits the measurement of relative liver enhancement (RLE).109 Wibmer 
et al. reported that the preoperative RLE was strongly related to the probability 
of developing PHLF compared with both the “50-50 criteria”(OR=0.935, 95% 
CI=0.884–0.990; p=0.020) and the International Study Group of Liver Surgery 
(ISGLS) grading system (OR=0.967, 95 % CI=0.951–0.982; p<0.001).62
Quantity Assessment of the Liver
Future Remnant Liver Volume
Preoperative determination of the FLR size after hepatectomy is fundamental 
for effective and safe hepatic resection. Currently, there is no uniform consensus 
regarding the limit of the FRL volume necessary to achieve a “safe” liver resection 
or the modality most effective for evaluating FLR size preoperatively.110 Several 
studies have tried to validate different imaging techniques for liver volumetry 
including conventional ultrasound111 and three-dimensional ultrasound112; how-
ever, the techniques most frequently utilized to assess FLR include computed 
tomography (CT) and MRI.113 Both imaging techniques permit the calculation 
of the FRL volume, as well as the ratio of FRL volume to the total functioning 
liver volume (TLV) (Table 2).39,44,110,114-118
79 
 
   
In a consensus conference on the surgical management of liver metastasis, an 
expert panel conclude the “acceptable” FLR to be >20 % of TLV for patients with 
a normal liver, >30 % of TLV in patients with evidence of steatosis/ steatohepa-
titis, and >40 % of TLV in patients with hepatic fibrosis or cirrhosis.119 Ribero 
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et al. confirmed validated these cut-offs in a study of 112 patients with differing 
status of underlying liver disease (normal, steatosis, fibrosis, or cirrhosis) who 
underwent major hepatectomy.120 Specifically, in the group of patients with a 
FLR<20 % of TLV, the rate of post- operative liver-related complications and 
hepatic insufficiency was 90 and 30 % compared with 23 and 2 %, respectively, in 
the group of patients with a FLR>20 % of TLV (p<0.001 and 0.009). Moreover, 
in a recent study of 301 patients who underwent extended right hepatectomy, 
Kishi et al. reported that a FLR<20 % of TLV was the strongest predictor of 
PHLF (OR=3.18; CI 95 %=1.34–7.54) on multivariate analysis.121
Criteria for Defining and Predicting the Post Hepatectomy Liver Failure
Prior to this decade, there has been no uniform definition of PHLF. In 2011, 
the International Study Group of Liver Surgery (ISGLS) reviewed more than 50 
studies on hepatic resection between 2003 and 2009, using multiple criteria to 
define PHLF.5 In turn, the definition of PHLF involves acquired deterioration 
of one or more synthetic, excretory, or detoxifying functions of the liver includ-
ing hyperbilirubinemia, hypoalbuminemia, prolonged prothrombin time (PT) 
or international normalized ration (INR), elevated serum lactate, and hepatic 
encephalopathy during the postoperative period.5
80 
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In clinical practice, the most commonly used criteria for defining, predicting, and 
grading the severity of PHLF are the “50–50 criteria”18, peak bilirubin >7 mg/dL,19 the 
ISGLS criteria,5 and the more recent risk score proposed by Hyder et al. (Table 3).80
50–50 Criteria
In an effort to refine the definition of PHLF and its grades of severity, Balzan et 
al. proposed the “50-50 criteria”.18 The criteria for PHLF consisted of a combina-
tion of PT <50 % (INR>1.7) and serum bilirubin level >50 μmol/L (>2.9 mg/ 
dL) recorded on POD 5.18 In this study, patients who met these criteria had a 
59 % risk of early postoperative mortality versus only a 1.2 % risk of mortality 
in patients for whom both these conditions were not fulfilled (p<0.001). In the 
original study, the accuracy of the “50-50” criteria to predict in-hospital mortality 
was 97.7 % (95 % CI= 96.6–98.7 %; sensitivity=69.6 %; specificity=98.5 %).18
The role of the “50-50 criteria” as a predictor of postoperative mortality due to 
PHLF is still, however, unclear. While several studies have confirmed the ability of 
the “50-50” criteria to predict post-hepatectomy PHLF-related mortality,79,122,123 
other studies have noted a much more modest performance of the “50-50” cri-
teria.19,80 For example, in one large series of 1286 patients undergoing hepatic 
resection, only 14 of 28 patients who died fulfilled the “50-50 criteria”.19 In a 
second study of 2056 patients who underwent liver resection, on postoperative 
Fig. 2  Receiver operating characteristic (ROC) curves demonstrating that the cut-off peak postop-
erative bilirubin (PeakBil) value to predict liver failure-related death is 7.0 mg/dL (area under the 
curve [AUC] 0.982; sensitivity 93.3 %; specificity 94.3 %). Reprinted with permission.19
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day 5, only 60 (4.7 %) patients had a bilirubin ≥2.9 mg/dL, 3 (0.2 %) patients 
had an INR ≥1.7, and only 1 (0.07 %) patient had the requisite combination of 
both bilirubin ≥2.9 mg/dL and INR≥1.7.80
Peak Bilirubin >7 mg/dL
Mullen and colleagues have suggested that, rather than the “50-50” criteria, only 
peak bilirubin be utilized to define PHLF.19 In a large retrospective study of 1059 
patients who underwent major hepatectomy at three high volume centers in the 
USA and Italy from 1995 to 2005, a peak postoperative bilirubin greater than 7 
mg/dL was the most powerful independent predictor of any complication (OR= 
83.3), major complication (OR=10.0), 90-day mortality (OR=10.8), and 90-day 
PHLF-related mortality (OR= 250, all p <0.001).19 The authors reported an area 
under the curve (AUC) of 0.982, with a sensitivity and specificity of 93.3 and 
94.3 %, respectively (Fig. 2).19
While some studies have subsequently validated a peak bilirubin of 7 mg/dL,121 
others reports have questioned the overall accuracy and clinical applicability of 
this parameter as the sole means to predict post-hepatectomy PHLF-associated 
death.80,124 In one study, of the 2056 patients who underwent either minor or 
major hepatectomy, only 20 patients demonstrated a peak bilirubin concentration 
>7 mg/dL.80 Of the 20 patients, five (25 %) died within 90 days for a sensitivity 
and specificity of the >7 mg/dL rule of 25 and 99.3 %, respectively, with a poor 
overall accuracy (AUC=0.574).80
ISGLS Definition
More recently, in 2011, the ISGLS defined PHLF as an increase in INR and con-
comitant hyperbilirubinemia on or after POD 5.5 Grades of PHLF severity were 
also defined depending on the patient’s clinical management: mild disruption 
of liver function (normal trend after hepatectomy) not requiring management 
(Grade A); moderate liver dysfunction not requiring invasive therapy (Grade B); 
and severe dysfunction, requiring invasive therapy (Grade C) (Table 4).5
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This clinical risk score was validated in a study of 807 patients who underwent 
hepatic resection that showed the ISGLS criteria for PHLF to be an independent 
predictor of mortality.79 However, despite efforts by the ISGLS to define PHLF 
more accurately to predict prognosis early after hepatectomy, several studies have 
questioned the accuracy of the ISGLS criteria. Specifically, Skrzypczyk et al. com-
pared the ISGLS definition with the “50-50 criteria” and peak bilirubin >7 md/
dL criteria among 680 patients who underwent either minor or major hepatec-
tomy.122 In this study, the ISGLS definition was found to be the least predictive 
of both the occurrence of major complications (positive predictive value of 49.2 
% for ISGLS vs. 78.9 % for “50–50 criteria” and 65 % for peak bilirubin >7 md/
dL), as well as the risk of postoperative death (OR=6.9 for ISLGS vs. OR=21.1 
for “50-50” and OR=21.7 for peak bilirubin >7 md/dL).122
Hyder et al. Risk Score
In light of prior shortcomings, Hyder et al. proposed the use of an integer-based 
risk score that combines Clavien-Dindo complication grade, INR, bilirubin, and 
creatinine level on POD 3.80 In this study, the proposed model had the ability 
to estimate a numerical risk of developing PHLF, as well as to predict post-hepa-
tectomy 90-day mortality with high accuracy.80 Specifically, when patients were 
stratified accord- ing to the number of points derived from the aforementioned 
risk score, there was an incremental increased risk of death (<5.9 points, 0.2 % 
vs. 6.0 to 8.9 points, 1.2 % vs. 9.0 to 10.9 points, 34.3 % vs. ≥11 points, 83.3 
%; p<0.001). Among patients who had ≥11 points, the prediction score had a 
sensitivity of 83.3 % and specificity of 98.9 % (Fig. 3).80 Future studies will need 
to validate this integer-calculator-based risk score of PHLF and death proposed 
by Hyder et al.
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Fig. 3 Receiver-operating characteristic (ROC) of the Hyder et al. composite prediction rule. The 
composite score consists of weighted values for grade of postoperative complication, as well as 
INR, bilirubin, and creatinine on POD 5. ROC curve analysis resulted in an area under the curve 
[AUC] 0.927. Reprinted with permission75
Strategies to Prevent Post-Hepatectomy Liver Failure
Given the association of the FLR remnant volume and risk of post-hepatectomy 
liver function, increasing the remnant volume has been the rationale behind 
several preoperative procedures.125,126 Portal vein embolization (PVE) was first 
described in the 1980s as a technique to increase the remnant liver volume by 
Kinoshita127 and later by Makuuchi et al.128 PVE is typically an ultrasound-guided 
percutaneous procedure that induces liver hypertrophy following embolization of 
the portal vein ipsilateral to the side of disease. The blockade of the portal vein 
results in hypertrophy of the contralateral side and thus an increase in the size 
of the FLR. PVE also results in an increase in the production of hepatic growth 
factor (HGF) and TGF, along with redistributing the portal blood flow to the 
FRL. PVE allows for hypertrophy of the FLR by 30–40 % within 4–6 weeks in 
more than 80 % of patients.57 A meta-analysis of 1088 patients who underwent 
preoperative PVE for major liver resection demonstrated that 4 weeks after PVE, 
85 % of patients were able to undergo the planned hepatectomy with an 8 to 27 
% increase in FLR.129
In some circumstances, a surgeon may prefer portal vein ligation (PVL) rather 
than PVE. Specifically, PVL has been proposed in those cases in which resection 
of bilobar malignant liver lesions requires a two-stage approach due to inadequate 
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FLR volume.130,131 With this approach, clearance of the FLR is performed using 
a parenchymal sparing resection approach. At the time of the first surgery, the 
contralateral portal vein is ligated. Three to six weeks following the first stage after 
allowing time for hypertrophy of the FLR, the second stage is performed which 
consists usually of an extended/ major hepatectomy. A meta-analysis reported 
that there was no statistically significant difference comparing PVE and PVL in 
terms of increasing FLR volume (+39 % after PVE vs. +27 % after PVL; p=0.06), 
morbidity (RR=1.08, 95 % CI= 0.55–2.09; p=0.83), and perioperative mortality 
(RR=0.87, 95 % CI=0.19–3.92; p=0.85).132
In 2011, a third strategy combining in situ liver partition, PVL followed by hepa-
tectomy (ALPPS) in a two-stage surgical approach was developed to decrease the 
time between PVL and resection for patients with borderline FRL volume.133 This 
approach allows for clearance of one side of the liver while maintaining the main 
liver mass in place to assist with liver function while the FLR hypertrophies in 
order to avoid PHLF. ALPPS may also facilitate superior hypertro- phy of the FLR 
compared with PVE, with a reported 74 % volume increase of the remnant liver 
in a mean of 9 days.133 Schadde et al. reported on 202 patients who underwent 
ALPS S and noted that a median starting standardized FLR of 21 % increased 
by 80 % within a median of 7 days, in contrast to approximately 8–27 % within 
2–60 days by PVL/PVE.134 In a recent meta-analysis, reviewing the increase in 
FLR after dif- ferent procedures, Pandanaboyana et al. reported that ALPPS pro-
vided an additional 17 % increment of the FLR compared with PVE (p=0.03).132 
Although these results are promising, the ALPPS procedure has been reported to 
have high operative morbidity (16–64 % of patients) and perioperative mortality 
(12–23 % of patients), which has prevented it from becoming widely utilized.134
Treatment of Post-Hepatectomy Liver Failure
While patients are ideally screened preoperatively and any comorbid conditions 
optimized in an attempt to avoid PHLF, patients should also be monitored closely 
postoperatively with treatment initiated at any early indication of PHLF. Particu-
lar attention should be paid to early clinical and laboratory signs of liver failure 
including chang- es in coagulation factors (including PT and INR), bilirubin, 
as well as signs of encephalopathy. Patients should also be monitored for early 
signs of infection, hemodynamic failure, renal failure, malnutrition, or metabolic 
disorders so that these may be addressed at an early stage.135,136 Patients who 
develop any of these complications should be monitored in an ICU setting, and 
the use of hepatotoxic as well as nephrotoxic medications should be avoided.
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Generally, the management principles for PHLF resemble those suggested by the 
American Association for the Study of Liver Diseases (AASLD) for the manage-
ment of acute liver failure (ALF).137 The severity of the PHLF should be followed 
using laboratory values such as INR, platelets, ammonia, bilirubin, and creatinine. 
Resuscitative measures and organ support provide the optimal environment for 
liver regeneration. In early stages of encephalopathy, ammonia levels should be 
followed and lactulose, polyethylene glycol, or rifaximin used for treatment.138,139 
Volume depletion should be monitored and addressed by fluid replacement. 
Fluid- refractory hypotension may warrant the use of vasopressor agents. Acute 
renal failure is common in ALF and associated with increased mortality. Causes 
may be multifactorial, including direct drug toxicity, acute tubular necrosis, or 
the presence of the systemic inflammatory response syndrome.140 The administra-
tion of antibiotics in patients suffering from ALF is associated with a significant 
decrease in infectious complications and therefore early use of antibiotics may 
also be advantageous in patients suffering from PHLF.141 Hypoglycemia is seen 
in up to 45 % of patients with acute liver failure, and thus, glucose levels must be 
monitored and dextrose infusion used as necessary.142 There is still no widely ef-
fective treatment of PHLF once it has befallen the patient. Albumin, fresh frozen 
plasma, and antithrombin III may be used to support clotting factors depleted 
during liver failure.143
The introduction of the molecular absorbent recirculating system (MARS®), an 
extracorporeal albumin dialysis machine, was shown to be effective in bridging 
patients with fulminant liver failure to orthotopic liver transplant (OLT).144 Its 
use in PHLF, however, has been sparsely studied; while improvement in biochemi-
cal parameters has been reported with use of MARS for PHLF, there has been no 
demonstrable survival benefit.137,145,146
While rescue OLT remains the most definitive treatment for PHLF, such treat-
ment is not universally available for many patients who develop PHLF. In fact, less 
than 10 % of liver transplantations are performed in patients with ALF and OLT 
for PHLF has only been sparsely reported.147,148 Given that the initial indication 
for hepatic resection frequently involves a malignancy outside of transplantation 
criteria, salvage OLT for PHLF is often not feasible.
Conclusion
PHLF is a major cause of postoperative morbidity and mortality in patients 
following major hepatectomy. Physiologically, with the onset of PHLF, there 
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is induction of irreversible structural damage and hepatocyte injury in the re-
generating liver. Adequate preoperative risk assessment and maximal in- crease 
of FLR using PVE, PVL, or ALPPS are essential for PHLF prevention. Early 
diagnosis and treatment of postoperative complications following hepatic resec-
tion are essential to mitigate the risk of PHLF. Once PHLF occurs, treatment 
largely revolves around supporting organ function, use of colloid and crystalloid 
products, as well as maximal treatment of associated complications. Short of OLT, 
no definitive “curative” treatment of PHLF exists. Future studies should be aimed 
at understanding the mechanisms and risk factors of PHLF, as well as targeting 
means to better avoid and treat this challenging post-hepatectomy complication.
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Abstract
Introduction: The aim of this study was to compare patients with PHC with 
lymph node metastases (LN+) who underwent a resection with patients who did 
not undergo resection because of locally advanced disease at exploratory lapa-
rotomy.
Methods: Consecutive LN+ patients who underwent a resection for PHC in 12 
centers were compared with patients who did not undergo resection because of 
locally advanced disease at exploratory laparotomy in 2 centers. 
Results: In the resected cohort of 119 patients, the median overall survival (OS) 
was 19 months and the estimated 1-, 3- and 5-year OS was 69%, 27% and 13%, 
respectively. In the non-resected cohort of 113 patients, median OS was 12 months 
and the estimated 1-, 3- and 5-year OS was 49%, 7%, and 3%, respectively. 
OS was better in the resected LN+ cohort (p<0.001). Positive resection margin 
(hazard ratio [HR]:1.54; 95%CI:0.97-2.45) and lymphovascular invasion (LVI) 
(HR:1.71; 95%CI:1.09-2.69) were independent poor prognostic factors in the 
resected cohort. 
Conclusion: Patients with PHC who underwent a resection for LN+ disease 
had better OS than patients who did not undergo resection because of locally 
advanced disease at exploratory laparotomy. LN+ PHC does not preclude 5-year 
survival after resection.
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Introduction
Perihilar cholangiocarcinoma (PHC) is the most common bile duct cancer, with 
an annual incidence in Western countries of around 2 per 100,000.1,2 Patients 
usually present with obstructive jaundice, abdominal pain, and weight loss 2,3. 
Surgical resection is the only potentially curative option for patients with PHC, 
resulting in a median overall survival (OS) of about 35-40 months.4-7 At diagno-
sis, however, most patients are ineligible for resection because of locally advanced 
or metastatic disease.8-10 Resection typically involves a right or left (extended) 
hemihepatectomy with an extrahepatic bile duct resection.2 These extensive op-
erations have considerable major postoperative morbidity and mortality of 5 to 
15% in Western centers.11,12 Patient selection is paramount to make a trade-off 
between the potential improved OS and quality of life (QoL) after surgery versus 
the substantial postoperative morbidity and mortality.
Lymph node metastases (LN+) have been reported to be the major determinant 
of OS.2,13,14 In a recent study conducted in a large international cohort, patients 
with lymph node metastases had an estimated 100% chance of recurrence.15 
However,  resection of LN+ PHC may still improve life expectancy. The aim of 
this multi-institutional study was to compare survival of patients with PHC with 
LN+ who underwent a resection with patients who did not undergo resection 
because of locally advanced disease at exploratory laparotomy.
Methods
In this retrospective analysis, the resected cohort consisted of patients with PHC 
and LN+ who underwent curative-intent surgical resection between January 1, 
2000, and December 31, 2014 at one of twelve academic institutions in the Unit-
ed States and Western Europe (Johns Hopkins University, Baltimore, Maryland; 
Emory University, Atlanta, Georgia; Stanford University, Stanford, California; 
University of Wisconsin, Milwaukee, Wisconsin; Ohio State University, Colum-
bus, Ohio; Washington University, St. Louis, Missouri; Vanderbilt University, 
Nashville, Tennessee; New York University, New York, New York; University of 
Louisville, Louisville, Kentucky; Wake Forest University, Winston-Salem, North 
Carolina; Erasmus MC University Medical Center Rotterdam, Rotterdam, the 
Netherlands; Academic Medical Center, Amsterdam, the Netherlands). The non-
resected cohort consisted of patients who did not undergo resection because of 
locally advanced disease at exploratory laparotomy from two centers (Academic 
Medical Center, Amsterdam, the Netherlands, and Erasmus MC University Medi-
cal Center, Rotterdam, the Netherlands). Patients with locally advanced disease 
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at exploratory laparotomy were found to have vascular or biliary involvement 
precluding a complete resection with adequate liver remnant or had lymph node 
metastases (N1 or N2). When the reason for discontinuation of the resection 
was suspicion of extensive lymph node metastases, frozen analysis was conducted 
to confirm the suspicion. In both cohorts, patients were excluded if they had 
an Eastern Cooperative Oncology Group performance status 3 or 4 at presenta-
tion, distant metastases (M1) on preoperative imaging, at staging laparoscopy, or 
laparotomy.
Sociodemographic and clinicopathologic data were collected, including age and 
sex, as well as tumor size, tumor stage, presence of nodal disease, final resection 
margin, and the presence of lymphovascular invasion (LVI). A major hepatectomy 
was defined as a hepatic resection of more than 3 Couinaud segments. According 
to the American Joint Committee on Cancer (AJCC) 7th edition staging, involve-
ment of lymph nodes within the hepatoduodenal ligament was classified as N1, 
and lymph node involvement beyond the hepatoduodenal ligament (i.e. along the 
common hepatic artery and celiac trunc) as N2.16,17 Margin status was categorized 
as R0 for a negative transection margin, R1 when the margin was microscopically 
positive, and R2 when the margin was macroscopically positive. For the patients 
who underwent surgical resection, postoperative complications occurring within 
30 days after surgery, during index admission, or during readmission within 30 
days after discharge were recorded. 90-day postoperative mortality was registered. 
The severity of postoperative complications was scored according to the Clavien-
Dindo classification.18 Severe postoperative complications were defined as those 
with a Clavien-Dindo Grade IIIa or higher (i.e. requiring re-intervention). The 
respective institutional review boards of each participating institution approved 
this study.
Statistical analysis
Categorical variables were described as whole numbers and percentages, while 
continuous variables were reported as medians with interquartile range (IQR). 
Percentages for each variable were calculated based on available data, excluding 
missing values. Univariable comparison of categorical variables was performed 
using the Pearson chi-square test. Univariable comparison of continuous variables 
was performed using the Mann-Whitney U-test. The primary outcome of the 
study was OS. OS was calculated from the date of operation to the date of death 
or last follow-up and estimated using the Kaplan-Meier method. Last follow-up 
was defined as the last contact with the treating institution. Univariate and multi-
variable hazard ratios were calculated using the Cox proportional hazards method. 
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Risk factors were included in the multivariable model if the p-value was below 
0.10 in univariate analysis. All tests were 2-sided and p < 0.05 defined statistical 
significance. All analyses were performed using SPSS 22.0 (IBM, New York). 
Results
Demographic and Clinicopathologic Characteristics
The resected cohort included 119 LN+ PHC patients who underwent a curative 
intent resection. The non-resected cohort included 113 patients who did not un-
dergo resection because of locally advanced disease at exploratory laparotomy. The 
reason for aborting the procedure was the extent of LN+ in 49 patients (43%). In 
64 patients, the extent of vascular and or biliary involvement precluded surgery. 
The two cohorts are compared in Table 1. Table 2 presents resection characteristics 
of the resection cohort only. A notable difference between the resected cohort and 
the non-resected patients was observed in the administration of chemotherapy. In 
the resected cohort, 56 patients (49%) went on to have adjuvant chemotherapy, 
whereas in the non-resected cohort only 8 patients (7%) received chemotherapy.
Table 1. Characteristics of the Treatment Groups
Variable
Lymph-Node Positive 
Resection (n = 119)
Non-Resected 
Patients (n = 113)
P-value
Female Gender 42 (35) 38 (34) 0.790
Age, years 65 (55-72) 65 (55-70) 0.593
BMI, kg/m2 25 (22-28) 24 (22-27) 0.054
Clinical Jaundice at Presentation 99 (85) 89 (81) 0.373
Bismuth Classification on imaging
  I 5 (5) 12 (11) 0.318
  II 14 (13) 10 (9)
  IIIA 35 (32) 28 (25)
  IIIB 26 (24) 30 (27)
  IV 30 (27) 33 (29)
Vascular Involvement (hepatic artery or 
portal vein, on imaging) 57 (56) 76 (69) 0.057
N2 Lymph Node Metastases, 
pathologically confirmed 9 (8) 7 (12) 0.364
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Table 2. Resection Details and Postoperative Course After Lymph-Node Positive Resection
Variable Lymph-Node Positive Resection (n = 119)
ASA
I 10 (8)
II 41 (43)
III 42 (44)
IV 3 (3)
Drainage Preoperative
None 23 (19)
Percutaneous 45 (38)
Endoscopic 22 (19)
Both 29 (24)
AJCC pT-stage
  pT1-pT2 61 (60)
  pT3-pT4 40 (40)
Type of Resection
Minor hepatectomy (< 3 Couinaud Segments) 18 (15)
Major hepatectomy (≥ 3 Couinaud Segments) 100 (85)
Margin Status
R0 76 (64)
R1 42 (36)
Tumor Size
≤ 2.5 cm 65 (69)
> 2.5 cm 29 (31)
Any complication 87 (75)
Clavien Dindo Grade
I-II 32 (37)
III-V 55 (63)
Length of Stay (days) 12 (8-19)
Readmission within 30 days 16 (27)
Postoperative 90-day mortality 8 (7)
Adjuvant Therapy
Adjuvant Chemotherapy 56 (49)
Adjuvant Radiotherapy 37 (34)
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Factors Associated with Overall Survival
Ninety-day postoperative mortality in the resected cohort was 7% (n = 8), which 
did not differ significantly from the ninety-day mortality in the non-resected 
patients (n = 15, 13%; p = 0.09). In the resected cohort, the median OS was 
19.2 months and the estimated 1-, 3- and 5-year OS was 69%, 27% and 13%, 
respectively. Only 7 patients were alive at last follow-up with a median follow-up 
of 60 months. Three out of 7 patients (43%) were alive with recurrent disease, 
while 4 patients had no evidence of disease at a follow-up of 62, 68, 76, and 
98 months. In the non-resected cohort, the median OS was 12 months and the 
estimated 1-, 3- and 5-year OS was 49%, 7%, and 3%, respectively, which was 
significantly worse compared with the resected cohort (p < 0.001; figure 1). 
In Cox regression analyses, several patient and disease specific characteristics were 
assessed for their correlation with OS in the resected LN+ cohort (Table 3). Posi-
tive margin and LVI were associated with OS in univariate analysis, and remained 
associated with OS in multivariable analysis (HR 1.54, 95%CI 0.97 – 2.45, p 
= 0.067; HR 1.71, 95%CI 1.09 – 2.69, p = 0.019). When patients with R1 
resection margins were compared with the non-resected patients, no difference in 
median OS was found (17 months vs. 12 months; p = 0.086; figure 2). Median 
OS was also comparable between resected patients with LVI and non-resected 
patients (16 months vs. 12 months; p = 0.073; figure 3). 
Figure 1. Overall survival stratified for treatment group (p < 0.001)
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Figure 2. Overall Survival of Resected R1 Patients versus Non-Resected Patients (p = 0.086)
Figure 3. Overall Survival of Resected Lymphovascular Invasion Patients versus Non-Resected Pa-
tients (p = 0.073)
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Table 3. Univariable and Multivariable Proportional Hazards Regression Models in Patients with 
LN+ Disease Undergoing Resection.
Variable Name
Univariable Analysis Multivariable Analysis
HR 95%CI P-value HR 95%CI P-value
Sex (male) 1.01 0.66-1.55 0.959
Age 1.01 0.99-1.02 0.595
BMI 0.99 0.95-1.04 0.729
Clinical Jaundice 1.29 0.70-2.38 0.410
ASA
  I-II Ref - -
  III-IV 0.90 0.50-1.62 0.731
Drainage Preoperative
  None Ref - -
  Endoscopic 0.97 0.54-1.72 0.905
  Percutaneous 1.52 0.79-2.90 0.208
  Both 1.17 0.63-2.20 0.618
Major Resection (≥3 segments) 1.22 0.69-2.16 0.503
Margin Status
  R0 Ref. - - Ref - -
  R1 1.48 0.96-2.27 0.075 1.54 0.97-2.45 0.067
N2 Lymph Node metastases 0.83 0.36-1.90 0.653
Tumor size (mm) 1.00 0.99-1.02 0.804
Bismuth Classification
  I Ref. - -
  II 0.56 0.17-1.82 0.332
  IIIA 1.13 0.40-3.25 0.816
  IIIB 0.91 0.31-2.68 0.862
  IV 0.94 0.33-2.69 0.906
AJCC T-stage
  T1-T2 Ref. - -
  T3-T4 1.45 0.78-2.67 0.238
Lymphovascular Invasion 1.64 1.05-2.58 0.030 1.71 1.09-2.69 0.019
Adjuvant Chemotherapy 1.08 0.70-1.66 0.725
Adjuvant Radiotherapy 1.04 0.67-1.63 0.856
Chapter 3
84
Discussion
In an international cohort of 12 centers, LN+ patients had a median OS of 19 
months after resection of PHC. These data confirm that LN+ PHC has a poor 
prognosis.2,13-15 However, resection of LN+ PHC did not preclude 5-year OS 
(13%). A recent study reported that LN+ disease is virtually incurable, with an 
estimated disease-free survival of 0% after seven years.15 In the current study, 
7 patients who were alive at last follow-up were identified, of whom 4 had no 
evidence of disease after more than 5 years follow-up. 
OS after resection for LN+ PHC compared favorably with a 12 months median 
OS in patients who did not undergo resection because of locally advanced disease 
at exploratory laparotomy. Patients who underwent exploratory laparotomy were 
chosen, because of their relative comparability to the resected cohort. In contrast, 
median OS for non-operated patients has been reported as less than 6 months.19 
These patients were found to have vascular or biliary involvement precluding a 
complete resection with adequate liver remnant or had positive lymph nodes (N1 
or N2). The difference of 7 months between the resected and the non-resected 
cohorts may be attributable to both the resection in the resection cohort and 
more advanced disease in the non-resected cohort. Therefore, the actual benefit of 
resection for LN+ PHC patients is likely smaller than 7 months. 
The potential survival benefit of surgery must be weighed against the potential 
harm of surgery with a mortality of 5 to 15% in published Western series.11,12 A 
risk score by Wiggers et al. identified a high-risk subgroup of PHC patients with 
a 37% postoperative mortality risk based on age, preoperative cholangitis, future 
liver remnant, portal vein reconstruction, and incomplete drainage of the future 
liver remnant.20 
Recent advances in imaging techniques have made it possible to identify lymph 
node metastases preoperatively with an acceptable accuracy, with a positive pre-
dictive value of 80% and a negative predictive value of 84% using computed 
tomography and a short axis diameter of 10 mm.21,22 EUS/FNA can confirm 
nodal metastases in suspicious lymph nodes on imaging. This is recommended 
in most patients for N2 nodes (beyond the hepatoduodenal ligament, stage IVb) 
because of poor prognosis after resection. Biopsy of N1 nodes should be con-
sidered in patients with a high postoperative mortality risk because of advanced 
age (>70 years), small future liver remnant (<30%), or preoperative cholangitis. 
When positive N2 nodes are found during exploratory laparotomy the surgeon 
should also consider to withhold resection. In addition, withholding resection 
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can be considered in high-risk patients with positive N1 nodes during exploratory 
laparotomy; the small potential survival benefit of resection may not justify the 
risk of surgery. 
In addition to the above, LVI and positive resection margin were independent 
poor prognostic factors after resection of LN+ PHC. Both LVI and R1 resection 
have previously been identified as poor prognostic factors after PHC resection.14,23 
Unfortunately, LVI and margin status are more difficult to guide decision making 
because they are typically known only after resection. 
Patients in the resected cohort were much more likely to receive postoperative 
chemotherapy than patients in the non-resected cohort. The explanation for 
this difference is likely a combination of better postoperative performance status 
after resection and the willingness of both patients and physicians to administer 
adjuvant chemotherapy. This is contrary to phase III trials that support palliative 
chemotherapy more than adjuvant chemotherapy.24,25
This study has several limitations. Because of the retrospective nature of the study, 
the two cohorts differed in baseline tumor characteristics and the actual difference 
in OS between the resected and the non-resected cohort may be smaller than 7 
months. Secondly, work-up and decision-making differed across centers and over 
time. Finally, because of the small sample size of N2 disease in the observed cohort, 
definitive conclusions could not be drawn in the present study. The preoperative 
decision to perform an exploratory laparotomy and the intraoperative decision 
to perform or withhold a resection are influenced by many known and unknown 
factors. However, the presented data from 12 centers may be some of the best 
available data to guide decision making for patients with LN+ PHC.
In conclusion, patients with PHC who underwent a resection for LN+ disease 
had better OS than patients who did not undergo resection because of locally 
advanced disease at exploratory laparotomy. The actual benefit of resection in 
patients with LN+ PHC may be smaller than 7 months and should be weighed 
against considerable postoperative morbidity and mortality. 
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Abstract
Background: Although a useful metric for preoperative risk-stratification, frailty 
can be difficult to identify in patients prior to surgery. We sought to develop a 
preoperative frailty-risk model combining sarcopenia with clinical parameters to 
predict 1-year mortality using a cohort of patients undergoing gastrointestinal 
cancer surgery.
Methods: 1,326 patients undergoing a hepatobiliary, pancreatic or colorectal 
surgery between 2011 and 2014 were identified. Sarcopenia defined by psoas den-
sity was measured using preoperative cross-sectional imaging. Multivariable Cox 
regression analysis was performed to identify preoperative risk-factors associated 
with 1-year mortality and used to develop a preoperative risk-stratification score.
Results: Among all patients identified, 640 (48.3%) patients underwent pan-
creatic surgery, 347 (26.2%) underwent a hepatobiliary procedure and 339 
(25.5%) a colorectal procedure. Using sex-specific cut-offs, 398 (30.0%) patients 
were categorized as sarcopenic. Sarcopenic patients were more likely to develop 
postoperative complications versus non-sarcopenic patients (OR=1.80, 95% CI 
1.42-2.29; p<0.001). Overall 1-year mortality was 9.4%. On multivariable analy-
sis, independent risk factors for 1-year mortality included increasing age (65-75 
years: [Hazard Ratio; HR 1.81, 95%CI 1.05- 3.14) >75 years [HR 2.79, 95%CI 
1.55-5.02]), preoperative anemia Hb<12.5g/dL (HR 1.68, 95%CI 1.17-2.40), 
and preoperative sarcopenia (HR 1.98, 95%CI 1.36-2.88 all p<0.05). Using 
these variables, a 28-point weighed composite score was able to stratify patient by 
their risk for mortality 1-year following surgery (c-statistic=0.70). The proposed 
score outperformed other indices of frailty including the modified Frailty Index 
(c-statistic=0.55) and the Eastern Cooperative Oncology Group (ECOG) perfor-
mance score (c-statistic=0.57)(both p<0.05).
Conclusion: Sarcopenia was combined with clinical factors to generate a compos-
ite risk- score that can be used to identify frail patients at greatest risk for 1-year 
mortality following gastrointestinal cancer surgery.
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Introduction
Given advances in surgical technique and medical therapy, an increasing number 
of patients are being considered as surgical candidates for a wide array of gastroin-
testinal cancers.1-4 While perioperative mortality is relatively low, many patients 
are at risk for adverse postoperative outcomes due to the often complex nature of 
these procedures.4- 6 Furthermore, with an estimated 70 million patients expected 
to be 65 years or older by 2030, preoperative risk assessment and appropriate pa-
tient selection for these complex procedures has taken on increased importance.7 
Several studies have noted that physiological, rather than chronological, age is 
more strongly associated with perioperative outcomes.8-10  Specifically, the evalu-
ation of patient frailty – a physiological syndrome characterized by a cumulative 
decline across multiple physiological systems – has been proposed as an important 
metric to assess perioperative risk.11-14
A standard objective assessment of frailty to measure a patient’s physiological 
reserve can be difficult to define.15 Frailty can be measured by combining infor-
mation from a patient’s medical history, physical examination and assessment of 
physical / functional status.16 These proposed composite measures are, however, 
often time- consuming, cumbersome to record and rely on multiple subjective 
measurements.17,18 For example, the Frailty Index (FI) developed by the Cana-
dian Study of Health and Aging (CSHA) consists of a 70-item scale derived from 
patient history and physical examination.19,20 A more recent modified iteration 
of the frailty index proposed by Obeid et al. maps 11 characteristics from the FI 
to data from the National Surgical Quality Improvement Program (NSQIP).21 
Other groups, including our own, have proposed the use of sarcopenia (muscle 
wasting) as an alternative, objective, and easy to measure marker for patient 
frailty.22-25
To date, most data on patient physiological reserve, frailty, and sarcopenia have 
focused exclusively on short-term outcomes.13,14,26  Specifically, data on the use 
of the modified frailty index (mFI), as well as sarcopenia, to determine patient 
outcomes have been limited to reports on perioperative morbidity and mortal-
ity within the first 30- to 90-days following surgery.21,23 While information 
on immediate short-term outcomes is important, data to predict death within 
1-year of surgery are also relevant to patients and providers. Given that major 
gastrointestinal surgery can be associated with some degree of morbidity and loss 
of quality of life, accurate identification of patients who are the least likely to 
benefit from surgery would be valuable.27 Therefore, the objective of the current 
study was to identify factors, as well as assess the prognostic accuracy of the mFI, 
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in predicting 1-year mortality following hepato-pancreatico-biliary and colorectal 
surgery.  Specifically, we sought to develop a preoperative frailty-risk model using 
both clinical and morphometric parameters to predict 1-year outcomes of patients 
following major surgery.
Methods
Data Sources and Patient Population
Patients undergoing a hepatobiliary, pancreatic or colorectal resection for ma-
lignant disease between January1, 2011 and December 31, 2014 at the Johns 
Hopkins Hospital were identified using relevant International Classification of 
Disease – Clinical Modification (ICD-9-CM) procedure and diagnosis codes. Pa-
tients aged less than 18 years and patients undergoing emergent procedures were 
excluded from the study. For each patient record, detailed sociodemographic, 
clinicopathologic and laboratory data were extracted from hospital records. Spe-
cifically, sociodemographic and clinicopathologic data were collected including 
age, sex and race, as well as preoperative comorbidity, preoperative functional and 
performance status, body mass index (BMI), smoking status, procedure type, year 
of procedure, duration of intensive care unit (ICU) stay, length-of-stay for the 
index admission, and development of postoperative complications. Preoperative 
comorbidity was classified according to the Charlson Comorbidity Index (CCI)
(CCI=0-2 and CCI≥3).28 Functional and performance status were categorized 
according to the American Society of Anesthesiologists (ASA) physical classifica-
tion grade and the Eastern Cooperative Oncology Group (ECOG) performance 
score, respectively.29,30 To assess preoperative frailty, the mFI score was calculated 
for each patient using a composite score derived from 11 conditions identified by 
the CSHA mapped to the ACS-NSQIP database.21 Conditions included diabetes 
mellitus, chronic obstructive pulmonary disease (COPD), active pneumonia in-
fection, heart disease (defined as either a history of congestive heart failure within 
30 days before surgery or a history of myocardial infarction within the 6 months 
preceding surgery),  hypertension requiring medical treatment, peripheral vascular 
disease, altered sensorium, cerebrovascular disease (with and without neurological 
impairment) and impaired functional status.21 Using previously described meth-
odology, an mFI score was calculated for each patient as the proportion of the 
total number of conditions present from the 11 conditions that were measured.21 
For example, if a patient presented with a history of diabetes mellitus and a his-
tory of congestive heart failure within 30 days prior to surgery, their calculated 
mFI would be 0.18 (2 out of 11).21 To limit spurious analysis with low numbers, 
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patients with a mFI>0.36 were grouped together and represented a high mFI 
score.21
Image Analysis and Calculating Sarcopenia
For all patients who met inclusion criteria, preoperative abdominal computed 
tomography (CT) images within 90-days of surgery were reviewed and morpho-
metric measurements of sarcopenia, including TPA, TPV and HUAC were calcu-
lated. Using the Ultravisual software package (Merge Emageon, Birmingham, AL, 
USA), TPA was measured in a semi-automated fashion with a manual outlining of 
the psoas muscle borders at the level of the third lumbar vertebra (L3) where both 
iliac crests were clearly visible.24,25 Similarly, TPV was calculated using the AW 
Workstation Volume Viewer Software (GE Healthcare, Little Chalfont, UK) by 
three manual measurements at the level of the L3 vertebra on the first image where 
both iliac crests are clearly visible.22,31 To reduce potential bias due to vascular and 
/ or fatty infiltration, all measurements were performed with a density threshold 
setting between -30 and 110 Hounsfield Units (HU). For greater comparability, all 
measurements for TPA and TPV were normalized for height calculated as (height 
[m] x height [m]). HUAC, a measure of muscle density and fatty infiltration, was 
calculated for both right and left psoas muscles using the methodology described 
by Joglekar et al.23 Right and left psoas muscles were evaluated and the average 
psoas density was used to calculate the final HUAC: right Hounsfield unit calcula-
tion (RHUC) = (right Hounsfield unit*right psoas area) / (total psoas area); left 
Hounsfield unit calculation (LHUC) = (left Hounsfield unit*left psoas area) / 
(total psoas area); and final HUAC = (right Hounsfield unit calculation + left 
Hounsfield unit calculation) / 2.23 Optimum stratification based on sensitivity 
analyses was performed using log-rank statistics to define the optimal sex-specific 
cut-offs for TPA, TPV and HUAC associated with the primary outcome of inter-
est (1-year mortality).
Statistical Analysis
Continuous variables were reported as medians with interquartile range (IQR), 
while categorical variables were reported as whole numbers and percent-
ages. Univariable comparisons for continuous variables were performed using the 
Kruskal-Wallis test, and for categorical variables using the Pearson χ2 test. Mul-
tiple imputations were performed using the MICE package for R version 3.0.3 
(www.r-project.net) to account for missing data for preoperative Hb (14.8%), 
ECOG score (16.9%), CCI (1.3%) and ASA (3.8%).
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The primary outcome of the study was 1-year mortality, calculated from the date 
of surgery to the date of death or last available follow-up, as appropriate. 1-year 
mortality was estimated using the Kaplan-Meier method and differences in sur-
vival between patient groups were compared using the log-rank test. To identify 
preoperative risk factors for 1-year mortality, multivariable Cox-proportional haz-
ards regression analysis was performed using a backward stepwise selection based 
on Akaike Information Criterion (AIC). Model performance was assessed using 
Harrell’s concordance index (C- index) and bootstrap resampling was performed 
to quantify model overfit. Regression coefficients from multivariable regression 
analysis were reported as hazard ratios (HR) with 95% confidence intervals (95% 
CI); beta coefficients from the multivariable model were subsequently used to 
develop a nomogram to predict the probability of 1-year mortality following sur-
gery. All statistical analyses were performed using STATA version 14.0 (StataCorp, 
College Station, TX) or R version 3.0.3 (http://www.r-project.org). Statistical 
significance was defined as p<0.05. The study was approved by the Johns Hopkins 
University Institutional Review Board.
Results
Baseline Demographic and Clinicopathologic Characteristics
A total of 1,326 patients were identified who met inclusion criteria (Table 1). The 
median age of the study cohort was 62.5 years (IQR 53-70) with a majority of 
patients being male (n=730, 55.1%) and Caucasian (n=1,115, 84.1%). The me-
dian BMI for all patients was 26.1 kg/m2 (IQR 23.1-29.9); 9.8% (n=111) of the 
cohort were either active smokers or had a previous smoking history. Comorbidity 
was common as 42.7% (n=559) of patients presented with an age-adjusted CCI 
of ≥3. All patients had a malignant indication for surgery and were operated on 
with curative intent.  At the time of surgery, 347 (26.2%) patients underwent a 
hepatectomy, while 640 (48.3%) had a pancreatic resection, and 339 (25.5%) a 
colorectal resection (Table 2).
Over a third of patients presented with an mFI score of 0 (n=501, 37.8%) with 
approximately 29.1% of patients presenting with an mFI score of ≥0.18. Among 
all patients, the median TPA, TPV and HUAC was 7.8 cm2/m2 (IQR 6.4-9.5), 
27.8 cm3/m2 (IQR 21.8-34.3), and 45.0 HU (IQR 36.7-51.0), respectively 
(Supplemental Figure 1). Given that HUAC performed slightly better on sen-
sitivity analyses, as well as its relative clinical ease to measure compared with 
TPV or TPA, HUAC measurements were utilized for subsequent morphometric 
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Table 1. Clinicopathologic and Operative Characteristics of the Cohort by Sarcopenia
Characteristic All patients 
(n=1,326)
Patients without 
sarcopenia* 
(n=928)
Patients with 
sarcopenia* 
(n=398)
p 
Value
Age, yr, median (IQR) 62.5 (53.0-70.0) 59.0(51.0-68.0) 68.0(61.0-75.0) <0.001
Sex, n (%) 0.99
Female 596 (44.9) 417 (44.9) 179 (45.0)
Male 730 (55.1) 511 (55.1) 219 (55.0)
Race, n (%) 0.006
White 1115 (84.1) 761 (82.0) 354 (88.9)
Black 104 (7.8) 84 (9.1) 20 (5.0)
Others 107 (8.1) 83 (8.9) 24 (6.0)
BMI, kg/m2, median (IQR) 26.1 (23.1-29.9) 26.0 (22.9-29.9) 26.5 (23.5-30.3) 0.08
Smoking status (n=1,138), n (%) 0.05
Nonsmoker 1027 (90.2) 723 (91.4) 304 (87.6)
Smoker 111 (9.8) 68 (8.6) 43 (12.4)
Charlson Index (n=1,309) 2.0 (1.0-3.0) 2.0 (1.0-3.0) 3.0 (2.0-4.0) <0.001
0-2 750 (57.3) 610 (66.5) 140 (35.7)
≥ 3 559 (42.7) 307 (33.5) 252 (64.3)
ASA (n=1,275), n (%) <0.001
1 8 (0.6) 6 (0.7) 2 (0.5)
2 366 (28.7) 299 (33.8) 67 (17.2)
3 866 (67.9) 566 (64.0) 300 (76.9)
4 34 (2.7) 14 (1.6) 20 (5.1)
5 1 (0.1) 0 1 (0.3)
Modified Frailty Score, n (%) <0.001
0.00 501 (37.8) 398 (42.9) 103 (25.9)
0.09 439 (33.1) 306 (33.0) 133 (33.4)
0.18 270 (20.4) 169 (18.2) 101 (25.4)
0.27 82 (6.2) 38 (4.1) 44 (11.1)
0.36 23 (1.7) 13 (1.4) 10 (2.5)
≥0.45 11 (0.8) 4 (0.4) 7 (1.8)
ECOG functional status (n=1,102), n (%) <0.001
0 587 (53.3) 433 (55.7) 154 (47.4)
1 491 (44.6) 336 (43.2) 155 (47.7)
2 21 (1.9) 7 (0.9) 14 (4.3)
3 2 (0.2) 0 (0.0) 2 (0.6)
4 1 (0.1) 1 (0.1) 0 (0.0)
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assessments of sarcopenia. Sensitivity analyses were performed to determine 
sex-specific cut-offs to define sarcopenia (HUAC <39.9 HU for male patients 
and HUAC < 38.1 HU for female patients). Using these sex-specific cut- offs 
for HUAC, 398 (30.0%) patients were categorized as sarcopenic (male: n=219, 
55.0% vs. female: n=179, 45.0%).
Frailty and Sarcopenia
Patients with sarcopenia were more likely to present with a poor functional / per-
formance status, as well as be classified as frail according to the mFI. Specifically, 
compared with patients without sarcopenia, patients presenting with sarcopenia 
were more likely to have a CCI score ≥3 (sarcopenia vs. no sarcopenia: 64.3% 
[n=252] vs. 33.5% [n=307], p<0.001), as well as present with a worse preoperative 
ECOG functional status score (ECOG ≥1: 52.6% [n=171] vs. 44.3% [n=344], 
p=0.01). Similarly, while only 5.9% (n=55) of non-sarcopenic patients presented 
with an mFI score ≥0.27, roughly 1 in 6 sarcopenic patients presented with an 
mFI ≥0.27 (15.3% [n=61], p<0.001).
Sarcopenic patients were more likely to develop postoperative complications ver-
sus non-sarcopenic patients (49.5% [n=197] vs. 35.2% [n=327]; OR=1.80, 95% 
CI 1.42-2.29; p<0.001).  In addition, sarcopenic patients had a higher risk of 
suffering a severe, high-grade postoperative complication (Clavien-Dindo grade 
III-V: sarcopenic, 29.2% [n=116] vs. non-sarcopenic, 15.3% [n=142]; OR=2.28, 
95% CI 1.72-3.01; p<0.001). Of note, a decreasing HUAC (i.e. increasing sarco-
penia) was associated with worse postoperative outcomes as patients in the lowest 
Table 1. Clinicopathologic and Operative Characteristics of the Cohort by Sarcopenia (continued)
Characteristic All patients 
(n=1,326)
Patients without 
sarcopenia* 
(n=928)
Patients with 
sarcopenia* 
(n=398)
p 
Value
TPA, cm2/m2, median (IQR) 7.8 (6.4-9.5) 8.0 (6.6-9.8) 7.3 (6.0-9.0) <0.001
TPV, cm3/m2, median (IQR) 27.8 (21.8-34.3) 29.1 (22.8-35.7) 24.3 (20.2-30.5) <0.001
HUAC, HU, median (IQR) 45.0 (36.7-51.0) 48.3 (44.4-53.4) 32.7 (27.2-35.9) <0.001
Metastasis, n (%) <0.001
M0 1050 (79.2) 705 (76.0) 345 (86.7)
M1 276 (20.8) 223 (24.0) 53 (13.3)
*Sarcopenia was quantified using the Hounsfield Unit Average Calculation (HUAC). Sex-specific cut-
offs (male: 39.9 HU, female: 38.1 HU) that defined a significant association between low HUAC with 
1-year mortality were ascertained by stratification analyses and patients who were below these cut-offs 
were classified as having sarcopenia.
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sex specific percentiles for HUAC were the most likely to develop postoperative 
complications, as well as have a longer ICU and overall LOS (Figure 1a). Interest-
ingly, the correlation of mFI with short-term perioperative clinical outcomes was 
less pronounced (Figure 1b and Supplemental Table 1).
Factors Associated with 1-Year Mortality
Among all patients, overall mortality within 1-year of surgery was 9.4% (n=125) 
(pancreatectomy: 12.0% vs. hepato-biliary: 9.8% vs. colorectal: 4.1%; p<0.001). 
Table 2. Operative details and outcomes of the cohort by sarcopenia
Characteristic All patients 
(n=1,326)
Patients 
without 
sarcopenia 
(n=928)
Patients with 
sarcopenia 
(n=398)
p Value
Preoperative Hb, g/dL, median (IQR) 12.9  
(11.6-14.1)
13.0  
(11.8-14.1)
12.7  
(11.1-13.9) 0.005
Preoperative Cr, median (IQR) 0.8 (0.7-1.0) 0.8 (0.7-1.0) 0.8 (0.7-1.0) 0.72
Preoperative chemotherapy, n (%) 404 (30.5) 312 (33.6) 92 (23.1) <0.001
Preoperative radiotherapy, n (%) 191 (14.4) 149 (16.1) 42 (10.6) 0.04
Procedure type, n (%) <0.001
Hepatectomy 347 (26.2) 266 (28.7) 81 (20.4)
Pancreatectomy 640 (48.3) 408 (44.0) 232 (58.3)
Colorectal resection 339 (25.6) 254 (27.4) 85 (21.4)
Year of procedure, n (%) 0.09
2011 204 (15.4) 138 (14.9) 66 (16.6)
2012 474 (35.8) 319 (34.4) 155 (38.9)
2013 436 (32.9) 309 (33.3) 127 (31.9)
2014 212 (16.0) 162 (17.5) 50 (12.6)
LOS, days, median (IQR) 7.0(5.0-12.0) 7.0(5.0-11.0) 9.0(6.0-14.0) <0.001
ICU days, days, median (IQR) 1.0(0.0 -1.0) 1.0(0.0-1.0) 1.0(1.0-2.0) <0.001
Complication, n (%) 524 (39.5) 327 (35.2) 197 (49.5) <0.001
I 108 (20.6) 80 (24.5) 28 (14.2)
II 158 (30.2) 105 (32.1) 53 (26.9)
III 178 (34.0) 102 (31.2) 76 (38.6)
IV 67 (12.8) 35 (10.7) 32 (16.2)
V 13 (2.5) 5 (1.5) 8 (4.1)
Readmission, n (%) 211 (15.9) 138 (14.9) 73 (18.3) 0.11
1-year mortality, n (%) 125 (9.4) 60 (6.5) 65 (16.3) <0.001
LOS, length of stay
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While 1-year mortality was not associated with sex or race, patients older than 65 
years demonstrated an increased risk of death within 1-year (referent 55 years; 65-
75 years: HR 2.57, 95% CI 1.52-4.33; >75 years: HR 4.61, 95% CI 2.67-7.97; 
both p<0.001)(Table 3). Similarly, patients presenting with a preoperative Hb 
<12.5 g/dL demonstrated a two-fold increased risk of mortality at 1-year follow-
ing surgery (HR 2.34, 95% CI 1.60-3.44, p<0.001).  On univariable analysis, 
patients presenting with an ECOG performance score of ≥1 demonstrated a 72% 
increased risk for mortality within 1-year of surgery (HR 1.72, 95% CI 1.13-2.59 
p=0.01).  Of note, mFI score assessed at the time of initial surgery was not associ-
ated with 1-year mortality (HR 1.73, 95% CI 0.31-9.60, p=0.53). In contrast, 
patients with sarcopenia demonstrated a 2.6 times greater risk for mortality within 
1-year of surgery (HR 2.61, 95% CI 1.83-3.71, p< 0.001).
Figure 1: Postoperative clinical outcomes including the development of postoperative complica-
tions, prolonged length-of-stay, prolonged intensive care unit stay, and 1-year mortality by (A) 
Lean muscle mass percentile (sarcopenia) measured by Hounsfield units average calculation (B) 
modified Frailty Index score.
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On multivariable analysis, after controlling for competing risk factors, several fac-
tors remained associated with 1-year mortality. On multivariable analysis, while 
patients aged 55-65 years did not have an increased risk of 1-year mortality, patients 
65- 75 years had an 80% increased risk (HR 1.81, 95% CI 1.05-3.14,p=0.03), 
while patients >75 years demonstrated an almost 3 times greater risk (HR 2.79, 
95% CI 1.55-5.02, p=0.001). Preoperative anemia, defined as Hb level<12.5 g/
dL prior to the initial surgery, was also associated with an increased risk of death 
within 1-year (HR 1.68, 95% CI 1.17- 2.40, p=0.01).  In addition, sarcopenia 
was independently associated with higher risk of 1-year mortality (HR 1.98, 95% 
CI 1.36-2.88, p<0.001). Model diagnostics demonstrated good discriminatory 
ability of the multivariable model with an AUC of 0.70 and no overfit was noted 
upon bootstrap resampling. When compared with mFI (0.55) and ECOG alone 
Figure 2: Area under the receiver operating characteristic (ROC) curve demonstrating improved dis-
crimination with inclusion of sarcopenia measured by Hounsfield unit average calculation (HUAC).
Figure 3: Nomogram to calculate the 1-year mortality of patients undergoing complex gastroin-
testinal surgery.
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(0.57), the multivariable model demonstrated an improved discrimination with 
the inclusion of sarcopenia (Figure 2).
Development of Nomogram and Risk-stratification of Patients
Regression coefficients from the multivariable analysis were used to assign each 
independent parameter associated with 1-year mortality (age, preoperative Hb, 
ECOG and sarcopenia) a specific weighted score (Figure 3).  A higher total points 
based on the sum of the assigned number of points for each factor in the nomo-
gram was associated with a worse 1-year prognosis. For example, a 65-year-old 
male patient with a preoperative Hb 13 g/dL, ECOG 1, and HUAC 30 HU 
would have a total of 17 points (age= 6 points, Hb=0 points, EGOC=4 points, 
sarcopenia=7) for a predicted 1-year mortality of 20%. Similarly, a 55-year old 
female patient who presented with a Hb 9 g/dL, ECOG 0, and HUAC 40 HU 
would have a total of 8 points (age=3 points, Hb=5 points, EGOC=0 points, 
sarcopenia=0) for a predicted 1-year mortality of 9%.
To further assess the discriminative ability of the model, the predicted probability 
of 1-year mortality was plotted as Kaplan-Meier curves stratified by quartiles of 
predicted probability calculated from the nomogram (Figure 4).  Patients with the 
lowest predicted 1-year mortality (quartile 4) did substantially worse (1-year mor-
tality 23.6%) compared with patients in other quartiles (1-year mortality: quartile 
1, 4.2% vs. quartile 2, 6.5% vs. quartile 3, 12.3%, all p<0.001). Discrimination 
Figure 4: One-year mortality stratified by quartile of predicted probability as calculated by the 
proposed nomogram.
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ability of the final model for 1-year mortality was also assessed using the C-statistic 
(overall C-index: 0.70) and was comparable among the different procedures (C-
index: pancreatectomy, 0.70 vs. hepato- biliary, 0.70 vs. colorectal 0.79). The 
accuracy of the model and potential model overfit were assessed by bootstrap 
validation with 1,000 resampling. The bootstrapped calibration plot for the pre-
diction of 1-year mortality did not demonstrate overfit (Supplemental Figure 2).
Discussion
While surgery remains the cornerstone of curative-intent therapy for cancer, 
morbidity, long length-of-stay, and an increased risk of mortality can offset any 
potential oncological benefit of surgery.4,32,33  In addition, expanding indications 
for surgical resection coupled with an aging population make preoperative patient 
selection and risk assessment an increasingly important topic.34  As such, there has 
been a growing interest in developing preoperative tools to identify patients who 
may be the most vulnerable to poor postoperative outcomes.27 Commonly used 
tools including ASA score and ECOG status have been criticized for focusing only 
on a limited number of organ systems, being subjective and failing to measure 
“true” physiologic reserve.9,17 More recently, frailty has been proposed as a more 
comprehensive metric of physiologic reserve.35  Assessing frailty can, however, be 
cumbersome and lack objectivity, thereby limiting its implementation into the 
clinical setting.14  In an attempt to make frailty more clinically applicable, Obeid 
et al. proposed an mFI with a more limited number of factors that were available in 
the NSQIP dataset.21 In addition, our group and others, have proposed the assess-
ment of sarcopenia as a more objective measurement of physiologic reserve.23,25,31 
Past studies have, however, largely investigated only short-term outcomes within 
30- or 90-days of surgery.23,25,31  When determining the benefit or “success” of 
an operation, 1-year survival may be an important metric for patients and provid-
ers.36,37  In the current study, using a cohort of 1,326 patients undergoing com-
plex gastrointestinal surgery for hepato-biliary, pancreatic and colorectal cancer, 
we assessed the role of clinical and morphometric data to predict 1-year  mortality. 
Sarcopenia, as measured by psoas density / HUAC, was a strong independent 
predictor of 1-year mortality risk (HR 2.61 95%CI 1.83-3.71).  In fact, sarcope-
nia outperformed other measures of frailty/physiological reserve including ECOG 
functional status and the mFI in predicting 1-year mortality (AUC: sarcopenia: 
0.62 vs. ECOG: 0.57 vs. mFI: 0.55). Using both clinical (age, Hb level, ECOG 
status) and morphometric (sarcopenia) parameters, a parsimonious and clinically 
applicable risk-stratification tool was developed to identify patients at greatest risk 
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for 1-year mortality following gastrointestinal surgery. The proposed nomogram 
performed well on internal validation (AUC 0.70).
Most frailty tools are based on cumbersome and exhaustive measurements of 
largely subjective data, thereby limiting the widespread applicability of frailty 
assessment in the preoperative setting.14,26 In addition, outcome prediction fol-
lowing oncological surgery may be confounded by potential physiological decline 
associated with tumor burden and adjuvant therapies.10,35 Given this, any defini-
tion of frailty should account for changes over time and remain clinically relevant 
independent of the underlying disease process.20,38 Given the complexity of 
assessing frailty, several proposed definitions have included many variables, with 
some having up to 70 different  factors.39 While exhaustive and comprehensive, 
these definitions may be limited due to computational tractability.35,40,41 For ex-
ample, as the number of variables increases, the interactions between variables also 
increases exponentially resulting in an overall low predictive power.35  As such, 
other authors have proposed modified frailty scores such as the mFI.21,39  The mFI 
has only 11 factors, yet suffers from some of the same problems with definition 
(e.g. “altered” sensorium).  In addition, while some studies have demonstrated 
that mFI was associated with short-term outcomes, no previous study had assessed 
whether mFI could predict mortality at 1-year.21,39  Rather, in the current study, 
mFI was in fact a very poor predictor of 1-year mortality with an AUC of only 
0.55 (Figure 2).
Rather than using clinical scores such as the mFI or measures of functional reserve 
such as hand-grip strength or walking speed, measurement of lean muscle mass 
has been proposed as a more objective measure of physiological reserve.22,25,31,42 
Sarcopenia, defined as lean muscle mass wasting, can be assessed in several ways 
(i.e. TPA, TPV, HUAC).23,31,42,43 In the present study, each of these methods 
was used to calculate sarcopenia from preoperative cross-sectional imaging. Psoas 
density, which perhaps is the easiest means to calculate sarcopenia, was utilized. 
Consistent with previous reports that assessed short-term postoperative clinical 
outcomes, we noted that sarcopenia was associated with an increased risk of ad-
verse perioperative outcomes.25,42  In fact, as the severity of sarcopenia increased, 
there was a higher incidence of postoperative complications, as well as a greater 
likelihood for a longer ICU and overall LOS. Perhaps of more interest, sarcopenia 
was also a strong predictor of 1- year mortality. Patients who were sarcopenic had 
over a 2.5-fold increased risk of mortality within the first year following surgery. 
Of note, sarcopenia demonstrated the best ability to predict 1-year mortality 
compared with the mFI, ASA grade, CCI, as well ECOG performance score.
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A particular strength of the study was that it took into account both clinical and 
morphometric variables when determining risk of 1-year mortality.  On multivari-
able analysis, several clinic factors including age, anemia, and ECOG status were 
each independently associated with 1-year mortality.  Combining these clinical 
factors with sarcopenic morphometric data, a parsimonious nomogram based on 
a 28-point composite score was proposed to identify patients at greatest risk of 
1-year mortality.  When stratified into quartiles, the proposed nomogram was able 
to categorize patients into distinct groups at variable risk of 1-year mortality.  In 
fact, when patients were stratified according to their calculated score, the 1-year 
mortality varied widely from 4.3% to 23.6% among low and high risk patients, 
respectively (Figure 4).  The nomogram demonstrated good discrimination with 
a C-statistic of 0.70 for predicting 1-year mortality.  Taken together, the data 
strongly suggest that the proposed nomogram can be used in the preoperative 
setting to identify patients at high risk of 1-year mortality.  Such information 
may be helpful to patients and providers when discussing the anticipated relative 
benefits and risks of major gastrointestinal surgery.
Several limitations should be considered when interpreting data from the current 
study. Despite a large sample size of over 1,000 patients, data were derived from 
a single institutional experience.  In addition, while the nomogram was internally 
validated, external validation in an independent cohort of patients is required. 
We were also unable to comment on and account for other important patient 
outcomes such as postoperative quality of life, loss of productivity and return to 
function.  Each of these outcomes are important patient-centered factors that 
warrant future examination.
In conclusion, using a large, single center cohort of patients who underwent 
gastrointestinal surgery, several clinical and morphometric variables predicted 
1-year mortality. When predicting 1-year mortality, sarcopenia outperformed 
other metrics of physiological reserve such as mFI, ASA, and ECOG. A limited 
number of easy and readily available clinical parameters combined with an objec-
tive measurement of sarcopenia resulted in a nomogram that accurately predicted 
1-year mortality and performed well on internal validation. Future studies will 
need to externally validate the proposed nomogram, as well as examine other 
important metrics of surgical “success” such as patient quality of life.
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Supplemental  Figure 1: Sex-specific distributions for (a) total psoas area (b) total psoas volume 
(c) Hounsfield units average calculation.
Supplemental Figure 2:  Calibration plot for calculated nomogram to assess patient frailty.
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Abstract
Introduction: While a known determinant of poor postoperative outcomes, 
frailty can be difficult to identify in patients prior to surgery. We sought to develop 
a preoperative frailty-risk model to predict mortality among patients≥65 years.
Methods: Clinical and morphometric data including total psoas area (TPA), 
total psoas volume (TPV) and psoas density (Hounsfield Unit Average Calcula-
tion [HUAC]) were collected for 518 patients undergoing HPB surgery between 
2012-2014. Multivariable Cox-proportional hazards regression was used to iden-
tify preoperative risk factors associated with 1-year mortality.
Results: Median patient age was 72 (i.q.r. 68-76) years, 55.6% patients were 
men, and half the cohort had multiple comorbidities (Charlson Comorbidity 
Index [CCI] ≥4, 55.6%). TPA cut offs to define sarcopenia were 552.7mm2/m2 in 
women and 702.9mm2/m2 in men; cut offs for TPV were 18.2cm3/m2 in women 
and 26.2cm3/m2 in men while HUAC cut offs were 31.1 HU in women and 33.3 
HU in men. Overall 1-year mortality was 14.1%. On multivariable analysis, risk 
factors associated with 1-year mortality included CCI≥4 (HR 4.58, 95%CI 2.47-
8.52, p<0.001), malignant disease (HR 6.4, 95%CI 2.33-17.53, p<0.001) and 
sarcopenia (HR 1.92, 95%CI 1.15-3.22, p=0.01). A weighed 25-point composite 
score was developed to stratify patients at risk of 1-year postoperative mortality. 
One-year mortality was noted to be 2.2% among patients scoring 0-10 (low-
risk), 14.4% among patients scoring 11-20 (intermediate-risk) and 23.3% among 
patients scoring between 21 and 25 (high-risk, p<0.001).
Conclusion: Clinical and morphometric measures of frailty accurately predict the 
risk of 1-year mortality following HPB surgery among elderly patients and can be 
used to appropriately risk- stratify patients.
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Introduction
Each year over 30,000 patients aged ≥65 years undergo hepato-pancreatico-biliary 
(HPB) surgery in the United States.1 Although surgery is the cornerstone of mul-
timodality therapy for many HPB disease processes, postoperative outcomes can 
be compromised by the high morbidity associated with surgery.2,3 In particular, a 
subset of elderly patients may be at higher risk to develop postoperative complica-
tions as well as mortality due to loss of physiological functional and physical 
reserves.4 Given the potential heterogeneity in the aging surgical population with 
regard to postoperative outcomes, there is great interest in developing more robust 
methodologies for risk-stratification prior to surgery.4 Accurate identification of 
elderly patients at risk for perioperative morbidity and mortality may identify ap-
propriate patients for prehabilitation, as well as better inform patient and provider 
decisions regarding the potential benefits of surgery.5
Frailty, defined as decreased physiologic reserve, has been proposed as a potential 
means to assess a patient’s overall health status.6,7 The concept of frailty has, 
however, only largely been applied to nonsurgical patients.8-10 The small number 
of studies examining frailty among surgical patients have noted an association 
with postoperative complications, as well as longer length of stay, and additional 
interventional procedures.4,11-13 Many of these studies were limited in using sub-
jective measures / indices, as well as cumbersome clinical measurements to assess 
frailty.4,12,13 These proposed parameters are time consuming and therefore may 
be impractical for use in the preoperative surgical setting.4,12,13 Furthermore, the 
lack of standardized practices and external validation has limited the widespread 
use of frailty to quantify and assess patients undergoing complex surgery.4
Recently sarcopenia, or muscle wasting has been identified as an objective, easy 
to measure surrogate for frailty.14-19 Sarcopenia may be associated with outcomes 
among patients undergoing several different surgical procedures.14-19  Most 
often sarcopenia has been defined by measuring total psoas area (TPA) or, less 
commonly, total psoas volume (TPV) or Hounsfield Units Average Calculation 
(HUAC).15-20  There is debate, however, regarding which parameter is most 
appropriate to measure sarcopenia, with conflicting results among several stud-
ies.15-20 Furthermore, previous studies have not examined frailty using a combina-
tion of clinical and morphometric parameters.4,12,15-20 As such, there is a dearth 
of information on the assessment of frailty in elderly patients using conventional 
clinical risk-stratification factors combined with more objective measurements of 
sarcopenia.21 Given this, the objective of the current study was to evaluate the 
ability of TPA, TPV and HUAC to predict 1-year mortality among a cohort of 
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elderly patients undergoing HBP surgery. In addition, we sought to develop a 
preoperative risk- stratification tool that combined clinical and morphometric 
factors to predict and identify elderly patients at greatest risk for early mortality 
following HPB surgery.
Methods
Data Sources and Patient Population
This cross-sectional study was performed using data from a prospectively main-
tained database of patients undergoing abdominal surgery at the Johns Hopkins 
Hospital. As previously described, information within this database is updated 
monthly, and verified by institutional quality review.22,23 Patients undergoing 
liver or pancreatic surgery were identified using International Classification of 
Disease – Ninth Revision – Clinical Manifestation (ICD-9-CM) procedure codes 
“50.22,” “50.3,” “52.51,” “52.52,” “52.53,” “52.59,” “52.6,” and “52.7.” To limit 
the analysis to elderly patients, only patients 65 years or older were included in 
the analyses. Additionally, to enhance the homogeneity of the patient population, 
only patients undergoing surgery on an elective basis were included in the study 
cohort. Further, as the primary outcome of the study was 1-year postoperative 
mortality, only patients undergoing surgery prior to July 1, 2014 were included 
in the analysis.
Sociodemographic and pathological data including age, sex, race, body mass index 
(BMI), American Society of Anesthesiologists (ASA) physical classification grade 
and preoperative comorbidity were collected for each patient.24 Preoperative 
comorbidity was defined according to the Charlson Comorbidity Index (CCI); 
categorizing patients presenting with a CCI score ≥4 with “severe comorbidi-
ty.”25 Similarly, BMI was categorized according to the World Health Organization 
classification of BMI (normal; <25 kg/m2, overweight; 25-30 kg/m2 and obese; 
>30 kg/m2) while preoperative anemia was defined by gender specific cut offs of 
hemoglobin<13.5 g/dL for men and hemoglobin<12.0 g/dL among women.26 The 
study was approved by the Johns Hopkins University Institutional Review Board.
Image Analysis
Preoperative (≤90 days) abdominal CT images were reviewed for the 518 patients 
who met inclusion criteria. Using the Ultravisual software package (Merge Ema-
geon, Birmingham, AL, USA), sarcopenia was initially assessed by measuring TPA 
at the level of L3 where both iliac crests were clearly visible.16,17 As previously 
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described, measurements were performed in a semi-automated fashion with 
manual outlining of the psoas muscle borders (Figure 1a).15-17
Similarly, TPV was assessed using AW Workstation Volume Viewer Software (GE 
Healthcare, Little Chalfont, United Kingdom).15,19 Specifically, TPV was calcu-
lated using three manual measurements at the level of L3 on the first image where 
both iliac crests were visible by hand-tracing the borders of the entire psoas muscle 
(Figure 1b).15,19 Three measurements were performed to assess the total psoas 
length. All measurements were performed in a semi- automated fashion with the 
density threshold setting between −30 and 110 Hounsfield Units (HU) to exclude 
vascular and fatty infiltration areas from the volumetric calculations.15,19 TPA was 
normalized for height (height [cm] x height [cm]) while TPV was normalized for 
height calculated as (height [cm] x weight [kg]) / 3600).15,19 HUAC, a measure 
of muscle density and fatty infiltration, of the psoas muscle was calculated using 
the methodology described by Joglekar et al.20 Specifically, right and left psoas 
muscles were evaluated and the average calculation was used for the final HUAC 
calculation; Right Hounsfield Unit Calculation (RHUC) = (Right Hounsfield 
Unit*Right Psoas Area) / (Total Psoas Area), Left Hounsfield Unit Calculation 
(LHUC) = (Left Hounsfield Unit*Left Psoas Area) / (Total Psoas Area), and 
HUAC = (Right Hounsfield Unit Calculation +Left Hounsfield Unit Calculation) 
/ 2 (Figure 1a).20
Figure 1. Sarcopenia measurement at level L3 using (a) total psoas area (TPA) and Hounsfield 
Units density measurement (HUAC) and (b) total psoas volume (TPV).
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Statistical Analysis
Continuous variables were reported as medians with interquartile range while 
categorical variables reported as whole numbers and percentages. As previously 
reported and validated, to obtain sex-specific categorical cut offs for sarcopenia, 
optimum stratification was assessed through a series of sensitivity analyses and 
sarcopenia was defined in categorical analyses as the lowest quartile.14,15,27 TPA 
cut offs used to define sarcopenia were 702.9 mm2/m2 and 552.7 mm2/m2 among 
males and females, respectively. Similarly, sarcopenia was defined as TPV<26.2 cm3/
m2 in male patients and TPV<18.2 cm3/m2 among females, while HUAC<33.3 
HU in males and HUAC<31.1 HU in females were used to defined sarcopenia ac-
cording to HUAC. Overall survival was analysed using the Kaplan-Meier method, 
and differences in survival assessed by the log-rank test.
To identify preoperative factors predictive of 1-year all-cause mortality a multivari-
able Cox proportional hazards model was built. The inclusion of clinicopathologic 
risk factors into the multivariable model was assessed using results from a stepwise 
backward selection methodology based on the Akaike Information Criterion 
(AIC) as well as using results from the Lasso regression (Supplemental Table). As 
similar variables were selected according to each methodology, the final multivari-
able model was built to include all clinically relevant, preoperative variables to 
generate the most parsimonious as well as the most clinically applicable predic-
tion model.28 Model calibration was evaluated by Harrell’s concordance index 
(C-index). Bootstrap validation was performed by drawing random samples from 
the original data set with replacement; specifically, 150 iterations were performed 
to assess for model overfitting.29,30 Point estimates were reported as hazard ra-
tios (HR) with 95% confidence intervals (95 % CI) as appropriate. Regression 
coefficients obtained from the multivariable model were subsequently used to 
generate a weighted score to predict the probability of 1-year mortality. All tests 
were two-sided and P<0.05 was used to define statistical significance. Statistical 
analyses were performed using STATA version 14.0 (StataCorp, College Station, 
TX) and R version 3.0.3 (http://www.r-project.org).
Results
Patient characteristics
Among the 518 patients who met inclusion criteria, the median age was 72 
(i.q.r. 68-76) years with a majority of patients being men (n=288, 55.6%) and 
Caucasian (n=435, 84.0%). A pancreatic resection was performed in 424patients 
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(81.8%) and 94 patients underwent a hepato- biliary resection (18.2%). Baseline 
characteristics of the patients are shown in table 1.
Table 1. Baseline characteristics of patients undergoing hepato-pancreatico-biliary surgery
Characteristic Total 
(n=518)
Hepato-biliary 
(n=94)
Pancreatic 
(n=424)
P
Age, years, median (IQR) 72.0 
(68.0-76.0)
72.5 
(68.0-77.0)
71.0 
(68.0-76.0)
0.517
Sex
Female 230 (44.4) 31 (33.0) 199 (46.9) 0.014
Male 
Race
White
288 (55.6)
435 (84.0)
63 (67.0)
75 (79.8)
225 (53.1)
360 (84.9)
0.235
Black 39 ( 7.5) 11 (11.7) 28 ( 6.6)
Others 
CCI, n (%)
0-3
44 ( 8.5)
230 (44.4)
8 ( 8.5)
23 (24.5)
36 ( 8.5)
207 (48.8)
<0.001
≥ 4 288 (55.6) 71 (75.5) 217 (51.2)
BMI, Kg/m2, median (IQR) 
ASA (n=471)
1-2
25.8 
(23.4-28.8)
105 (20.3)
26.0 
(23.8-28.4)
16 (17.0)
25.7 
(23.2-28.8)
89 (21.0)
0.56
0.381
3-4 412 (79.7) 78 (83.0) 334 (79.0)
Coexisting Condition, 
n (%) CHF 7 ( 1.6) 0 ( 0.0) 7 ( 1.9) 0.198
Pulmonary 51 (11.5) 3 ( 3.6) 48 (13.3) 0.012
PVD 36 ( 8.1) 8 ( 9.5) 28 ( 7.8) 0.593
HTN 268 (60.2) 53 (63.1) 215 (59.6) 0.551
DM 114 (25.6) 23 (27.4) 91 (25.2) 0.681
Renal 
Primary Diagnosis
Benign
18 ( 4.0)
130 (25.1)
4 ( 4.8)
10 (10.6)
14 ( 3.9)
120 (28.3)
0.711
<0.001
Malignant 388 (74.9) 84 (89.4) 304 (71.7)
Preoperative Hemoglobin, g/dL, 
median (IQR)
12.9 
(11.8-14.2)
12.8 
(11.8-14.3)
13.0 
(11.8-14.2)
0.654
1-year mortality 73 (14.1) 19 (20.2) 54 (12.7) 0.059
CCI, Charlson comorbidity index ASA, American Society of Anesthesiologist; CHF, congestive heart 
failure; PVD, peripheral vascular disease; HTN, hypertension; DM, diabetes mellitus; Hb, Hemoglo-
bin; EBL, Estimated Blood Loss
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TPV, TPA, HUAC and Sarcopenia
Preoperative imaging was used to calculate morphometric parameters for sar-
copenia among patients undergoing HPB surgery. Among the study cohort, 
the median TPA and TPV corrected for height were noted to be 723.0 (i.q.r. 
618.5-891.8) mm2/m2 and 25.8 (i.q.r. 20.9- 31.7)cm3/m2, respectively. When 
stratified by sex, the median TPA and TPV were both noted to be higher among 
men compared with women (TPA; 852.6 [i.q.r. 702.9-971.0] mm2/m2 vs. 635.3 
[i.q.r. 552.7-722.1] mm2/m2, TPV; 30.5 [i.q.r. 26.2-35.5] cm3/m2 vs. 21.0 [i.q.r. 
18.2-24.1] cm3/m2, p<0.001). Similarly, the median HUAC was noted be 40.9 
(i.q.r. 32.5-47.3) HU; the median HUAC was also noted to be higher among 
males (41.1 [i.q.r. 33.3-47.5] HU vs. 40.5 [i.q.r. 31.1-46.3] HU, p=0.29). Due to 
this potential confounding by sex, sex-specific quartiles for each parameter were 
developed that categorized patients in the lowest sex-specific quartile as sarcope-
nic. Examining the entire cohort, 112 (25.3%) patients were sarcopenic defined 
by TPA, 117 patients (25.0%) had sarcopenia defined by TPV and 112 (25.3%) 
patients presented with sarcopenia defined by the HUAC. Using all 3 parameters, 
the proportion of patients categorized preoperatively as sarcopenic did not vary 
between patients undergoing hepato-biliary or pancreatic surgery.
Preoperative Risk Factors Associated with 1-year all-cause Mortality
Among all patients included in the study cohort, the all-cause 1-year mortality 
was 14.1%. Of note, patients undergoing pancreatic or hepato-biliary procedures 
demonstrated a similar risk of mortality (p>0.05). Patients categorized as sarcope-
nic using the measurements for TPV and HUAC demonstrated a 78% and 92% 
greater risk of mortality, respectively (TPV; HR 1.78, CI 95% 1.05-3.0, p=0.03, 
HUAC; HR 1.92, CI 95% 1.15-3.22, p=0.01). In contrast, sarcopenia defined by 
TPA tended to be associated with 1-year survival (HR 1.62, CI 95% 0.96- 2.75, 
p=0.07, Table 2).
To further identify factors predictive of 1-year mortality following HPB surgery, 
a multivariable Cox proportional hazards regression model was built adjusting for 
patient and disease characteristics. A stepwise backward selection model based on 
AIC was used to select  for the most parsimonious model that included preopera-
tive comorbidity as defined by the CCI, indication for surgery (benign vs. ma-
lignant) and sex (Table 3). To further evaluate the predictive effect of sarcopenia, 
TPV, TPA and HUAC were each subsequently added to the model. Selection of 
the final model was based on comparisons of discrimination via Harrell’s c- sta-
tistics (Table 3). On multivariable analysis after adjusting for patient and disease 
characteristics, patients with severe preoperative comorbidity classified as CCI≥4 
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Table 2. Univariable analysis for factors associated with 1-year mortality following Hepato-Pancre-
atico-Biliary Surgery in the Elderly
1-year mortality  Univariable 
Factors selected (%) HR 95% CI P value
Sex
Female 26 (11.3) Ref - -
Male 47 (16.3) 1.41 0.87-2.28 0.16
CCI
≤3 12 (5.2) Ref - -
>3 61 (21.2) 4.58 2.47-8.52 <0.001
Diagnosis
Benign 4 (3.1) Ref - -
Malignant 69 (17.8) 6.40 2.33-17.53 <0.001
Sarcopenia by TPA
No 40 (12.0) Ref - -
Sarcopenic 21 (18.8) 1.62 0.96-2.75 0.07
Sarcopenia by TPV
No 43 (12.3) Ref - -
Sarcopenic 21 (18.0) 1.78 1.05-3.00 0.03
Sarcopenia by HUAC
No 38 (11.5) Ref - -
Sarcopenic 23 (20.5) 1.92 1.15-3.22 0.01
Factors not selected  
Age
65-79 60 (13.2) Ref - -
≥80 13 (20.6) 1.63 0.89-2.97 0.11
ASA
1-2 10 (9.5) Ref - -
3-4 63 (15.3) 1.71 0.88-3.34 0.11
BMI
≤25 kg/m2 32 (14.2) Ref - -
25-30 kg/m2 22 (11.9) 0.80 0.46-1.38 0.42
>30 kg/m2 13 (15.1) 0.93 0.49-1.77 0.82
First Hb at admission
>10g/dL 67 (14.1) Ref - -
≤10g/dL 6 (13.6) 1.16 0.51-2.69 0.72
Procedure type
Hepatectomy 19 (20.2) Ref - -
Pancreatectomy 54 (12.7) 0.61 0.36-1.03 0.07
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demonstrated an almost 3 times greater risk of mortality within 1 year following 
surgery (HR 2.91, CI 95% 1.45-5.77, p=0.002), while patients undergoing sur-
gery for a malignant disease process demonstrated an almost 4 times greater risk 
of mortality following surgery (HR 3.94, CI 95% 1.17-13.30, p=0.03). Of note, 
patients presenting with sarcopenia as defined by HUAC demonstrated an 85% 
increased risk in mortality following surgery (HR 1.85, CI 95% 1.1-3.1, p=0.02). 
Areas under the receiver operating characteristic curve (AUROC) were used to 
quantify relative increments in the discriminatory ability of the final model with 
and without sarcopenia defined using HUAC (Figure 2). Of note, the inclusion of 
sarcopenia improved the discriminatory ability of the prediction model (p<0.001, 
Figure 2). Bootstrap validation of the model with 150 iterations demonstrated 
minimal evidence of model overfit.
Development of Risk-stratification Score
Point estimates obtained from the final multivariable model (including sarcopenia 
defined by HUAC) were used to generate a 25 point weighted risk-stratification 
score to predict preoperatively the risk of mortality among elderly patients under-
going HPB surgery.
Specifically, each parameter was assigned a weighted score (male sex; 3 points, 
CCI≥4; 8 points, malignant disease; 10 points, sarcopenia defined by HUAC; 4 
points, Figure 3) and risk of mortality was categorized relative to the total score. 
Table 3. Multivariable Cox proportional regression analysis
TPA TPV HUAC
ScoreHR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Factors selected
Sex
   Female Ref - - Ref - - Ref - - 0
   Male 1.38 0.81-2.35 0.23 1.42 0.84-2.38 0.19 1.42 0.84-2.41 0.19 3
CCI
   0-3 Ref - - Ref - - Ref - - 0
   ≥ 4
Diagnosis
   Benign
2.98
Ref
1.50-5.91
-
0.002
-
3.07
Ref
1.51-6.26
-
0.002
-
2.91
Ref
1.47-5.77
-
0.002
-
8
0
   Malignant 3.85 1.13-13.06 0.03 3.52 1.04-11.96 0.04 3.94 1.17-13.30 0.03 10
Sarcopenia
   No Ref - - Ref - - Ref - - 0
   Sarcopenic 1.60 0.94-2.71 0.08 1.64 0.97-2.77 0.06 1.85 1.10-3.10 0.02 4
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One-year mortality was noted to be 2.2% among patients scoring 0-10 (low risk), 
14.4% among patients scoring 11-20 (intermediate risk) and 23.3% among for 
patients scoring between 21 and 25 (high risk, p<0.001, Figure 3).
Figure 2. Area under the receiver operator curve characteristics demonstrating improved dis-
crimination from 0.69 to 0.72 with inclusion of sarcopenia measured by HUAC.
Figure 3. 1-year survival among patients undergoing HPB surgery stratified according to risk- strat-
ification weighted score.
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Discussion
Although mortality following HPB surgery has decreased dramatically over the 
past two decades, recent reports suggest that mortality among elderly patients 
undergoing HPB procedures still remains as high as 5 times greater than that 
for the overall population.2,3,31 Given the heterogeneity in physiological reserve 
and therefore postoperative outcomes within the aging surgical population, ap-
propriate risk stratification among the elderly is critical to help better predict 
and potentially avoid the high observed mortality.11,12,21 Using a cohort of 518 
patients aged ≥65 years, the present study identified preoperative morphometric 
and clinical parameters predictive of 1-year all-cause mortality following complex 
HPB surgery. Of note, among this elderly cohort of patients, despite most patients 
being preoperatively classified as high-risk according to their ASA score, there was 
significant heterogeneity in 1-year mortality risk. The current study was important 
because an accurate, risk-stratification tool with appropriate discrimination and 
calibration to identify patients at greatest risk for 1-year mortality using clinical 
and morphometric data was developed. In particular, with the inclusion of sar-
copenia, a surrogate for patient frailty, we were able to identify those patients at 
highest risk for short-term mortality. Identification of such patients may assist 
in directing these individuals to interventions such as prehabilitation prior to 
surgery.5
While the use of frailty measures to appropriately risk-stratify patients has 
been widely recognized for medical conditions, the use of similar metrics for 
surgical patients has remained limited at best. A small number of studies have 
assessed the role of preoperative frailty among elderly patients undergoing sur-
gery.4,11,12,21  These studies have been limited, however, in their approach in that 
most included only limited clinical measurements, as well as subjective definitions 
of frailty.4,10,13 In the current study, we used sarcopenia or muscle wasting as a 
metric to measure preoperative patient frailty / physiological reserve. Although 
not widely used, previous research has demonstrated sarcopenia to be an accurate, 
objective measure of frailty, with sarcopenic patients being at increased odds of 
postoperative complications and mortality.15-18,20 The present study is unique in 
that it risk-stratifies patients undergoing HPB surgery using a clinical risk score 
that combined clinical and morphometric factors to assess patient frailty in an 
elderly population. In the past, the use of sarcopenia has been limited by disagree-
ment in definitions regarding how to measure muscle mass / wasting.15,20 For 
example, while previous research has suggested the use of total psoas area (TPA) 
as a means to quantify and measure patient frailty, more recent work has suggested 
that total psoas volume (TPV) and psoas density (HUAC) may be more accurate 
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means to measure sarcopenia and therefore frailty.16,17,20,32 In the current study, 
it was noted that the use of psoas density was a more accurate measure of patient 
frailty compared with both TPV and TPA, and also independently predicted early 
mortality at 1- year. In a report by Joglekar et al. of patients undergoing pancre-
atic surgery, HUAC rather than other measures of sarcopenia was independently 
predictive of postoperative complications, longer length of stay and longer ICU 
stays.20 A measure of radiation attenuation, HUAC can be     readily calculated 
from preoperative cross-sectional imaging that is routinely performed prior to 
HPB surgery.20 Additionally, while TPA and TPV can sometimes be difficult to 
measure in obese patients, HUAC is able to account for fat infiltration thereby 
facilitating assessment among obese patients.33-35 Taken together, findings from 
the current study, as well as other published evidence, strongly suggest that pre-
operative radiological assessment of sarcopenia may help identify patients who 
are frail and therefore at high risk of mortality. In turn, such data may be used to 
facilitate health-care decision-making, and allow surgeons, patients, and caregivers 
to better manage perioperative expectations. For example, accurate preoperative 
identification of frail patients may allow identification of those individuals most 
at risk for postoperative complications and permit early intervention to improve 
short term outcomes following HPB surgery.5
The appropriate and accurate preoperative identification of frail patients is par-
ticularly important among elderly patients undergoing surgery.10-12,21 Due to 
substantial heterogeneity in disease presentation and variable physiological effects 
of aging, standard indications and guidelines for treatment are often not gener-
alizable to the elderly population.4 Specifically, multiple chronic comorbidities, 
polypharmacy, dysregulation of physiological systems, altered hormonal function 
and decreased immune responses can all contribute to the variable presentation 
and therefore outcomes among older patients undergoing surgery.36-40 Further, 
given that the proportion of elderly patients is expected to increase four-fold 
within the next ten years, preoperative identification and intervention for those 
elderly patients most at risk is critical.41 Older, frail patients are at greater risk for 
developing postoperative complications that often result in significant functional 
disability requiring labour-intensive and costly support in the form of additional 
procedures, greater intensity of care and the need for nursing assistance at dis-
charge.41 
In the current study, a 25 point composite score using 4 easy and readily available 
parameters to appropriately identify patients at greatest risk for 1-year mortality 
after surgery is proposed. Of note, all cause 1-year mortality ranged widely from 
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2.2% to 23.3% among low and high-risk patients, respectively. While previous 
studies have proposed the assessment of frailty or physiologic reserve via subjective 
clinical assessments such as exhaustion and decreased   activity, this study combines 
morphometric and clinical parameters to develop an objective risk- stratification 
tool to identify frail, elderly patients.4,11,12,21 Specifically, sarcopenic patients 
(defined by HUAC), demonstrated an 85% greater risk of mortality, while the 
inclusion of sarcopenia measured by HUAC increasing the discriminative power 
of the model by about 3%. This incremental increase is consistent with previously 
studies that have assessed the effect of frailty specific parameters in predicting 
1-year mortality.42 For example, a recent systematic review of patients undergoing 
cardiac surgery noted that the addition of frailty specific parameters resulted in 
a mean incremental increase of 4% in the discriminative power of conventional 
risk scores.42  These authors concluded that the use of composite frailty measures 
represents a more accurate method for identifying frail patients.42
The present study had several limitations. The current analyses were limited only 
to HPB procedures. As such, future work is necessary to assess the performance 
of the proposed score among patients undergoing a wider variety of surgical 
procedures. In addition, it is possible that due to the omission of disease-specific 
parameters as well as additional postoperative measures including functional status 
and quality of life, certain important factors predictive of mortality were unac-
counted for. Finally, given that the current study was performed at a single center, 
the risk-stratification score requires further external validation in an independent 
dataset. Internal validation with bootstrapping techniques did, however, suggest a 
good model fit with minimal overfitting.
This study demonstrates that sarcopenia as measure by HUAC is an accurate 
measure of frailty among elderly patients undergoing complex HPB surgery and 
is an independent predictor of 1-year mortality. In addition, a 25 point risk-
stratification score that incorporated clinical and morphometric parameters ac-
curately identifies elderly patients at the highest risk for 1-year morality following 
surgery. As such, the proposed score represents a convenient manner for clinicians 
to help identify those elderly patients who are most likely to be frail and therefore 
at the highest risk of suffering an early death within 1 year of HPB surgery.
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Supplementary Table: Comparison of variables included in the Cox regression model (Stepwise 
regression using AIC vs. Lasso) with their corresponding regression coefficients
Characteristic Stepwise (AIC) Lasso 
HR (95% CI) HR (95% CI)
Age Not selected 1.36 (0.70-2.63)
Sex 1.42 (0.84-2.41) 1.38 (0.81-2.35)
CCI 2.91 (1.47-5.77) 2.88 (1.45-5.71)
ASA Not selected Not selected 
Malignancy 3.94 (1.17-13.30) 3.79 (1.12-12.80)
BMI Not selected Not selected
Preoperative Hemoglobin Not selected Not selected
Procedure type Not selected Not selected
Sarcopenia* 1.85 (1.10-3.10) 1.90 (1.14-3.15)
*defined using HUAC (Hounsfield Unit Average Calculation)
AIC: Akaike Information Criterion , CCI: Charlson comorbidity index, ASA: American Society of 
Anesthesiologists (ASA) physical classification grade, BMI: Body Mass Index
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Abstract
Background Many prognostic models have been proposed to predict disease-free 
survival (DFS) or overall survival (OS) for patients after resection of hepatobiliary 
or pancreatic (HPB) cancer. The objective of this systematic review was to evaluate 
the performance of these prognostic models on external validation. The secondary 
objective was to assess methodological study quality regarding model derivation.
Methods The PRISMA guidelines were followed. All external validation studies of 
prognostic models for patients with resected primary or secondary malignant HPB 
tumors were identified. Model performance was assessed by model discrimina-
tion and calibration. Quality assessment of the model derivation involved cohort 
description, statistical analyses, reporting of results, and model performance.
Results In total, 49 external validation studies were identified, which overall vali-
dated 70 different prognostic models; 14 for Colorectal Liver Metastases, 29 for 
Hepatocellular Carcinoma, 10 for Pancreatic Carcinomas and 17 for Biliary Can-
cers. Since some models were validated multiple times for both OS and DFS; 181 
validations were performed in total. In CRLM 1 model was identified with good 
performance (AUC/C-index >0.70). Only 14 (36.8%) models for hepatocellular 
carcinoma had good performance on validation. Other hepatobiliary malignancy 
models demonstrated moderate performance as well. Model calibration was rarely 
assessed; 42 validations (23.2%) performed no calibration at all, 120 validations 
(66.3%) only reported survival curves, and 19 validations (10.5%) detailed cali-
bration curves. Methodological quality of derivation studies was poor; 19 (42%) 
of the derivation studies adequately reported the handling of missing data and 
only 7 (16%) studies used continuous prognostic factors in the model. 
Discussion Most prognostic models in HPB surgery suffer from poor method-
ological quality and poor performance on external validation.
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Introduction
Many prognostic models have been proposed to predict survival for individual 
patients after resection of hepatobiliary or pancreatic cancer.1-9 More accurate 
prediction of outcomes may improve shared decision-making and personalized 
medicine.1-9 For example, postoperative models can be used to guide adjuvant 
therapy and surveillance for recurrent disease. The performance of a prognostic 
model is determined by discrimination and calibration.10 Discrimination is the 
ability of the model to determine which patient is high-risk and which patient is 
low-risk. Calibration is the agreement between the observed and predicted out-
comes for individual patients.10 Model performance should be judged at external 
validation prior to clinical use. Non-validated models are at a risk of overestimat-
ing predictive ability, a risk known as optimism.10
Developing a prognostic model (model derivation) is a complex process. A recent 
systematic review found that the majority of prognostic models in high-impact 
journals do not follow methodological recommendations limiting their applica-
bility and reliability.11 As such, we sought to perform a systematic review to iden-
tify studies that externally validated one or more prognostic models for survival 
among patients who underwent a resection for hepatobiliary or pancreatic cancer. 
We sought to assess model performance at external validation, as well as determine 
the methodological quality of the studies in which the prognostic models were 
developed.
Methods
The PRISMA Statement was followed for the reporting of this systematic review 
(www.prisma-statement.org). A comprehensive search of Embase, Medline, Web 
of Science, the Cochrane database, and Google Scholar was performed, using the 
search terms provided in supplemental document A. The last search was conducted 
on November 15th, 2017. Eligible studies performed an external validation of one 
or more prognostic models for disease-free survival (DFS) or overall survival (OS) 
among patients who underwent a resection of primary or secondary cancer of the 
liver, pancreas, or bile ducts. The tumor types included Colorectal Liver Metastases 
(CRLM), Hepatocellular Carcinoma (HCC), Pancreatic Duct Adenocarcinoma 
(PDAC), Pancreatic Neuro-Endocrine Tumor (PNET), Intrahepatic Cholangio-
carcinoma (ICC), Perihilar Cholangiocarcinoma (PHC), and Distal Cholangio-
carcinoma (DCC). All studies written in the English language and published after 
1990 were considered. Non-original articles (i.e. reviews or expert opinions) were 
excluded. Studies with prognostic models containing prognostic factors that are 
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not used in clinical practice (e.g., RNA/DNA sequencing data or liquid biopsies) 
were also excluded. Studies were excluded if no model performance measures were 
reported.12 Studies with patients treated with transplantation, ablation, or other 
techniques other than resection were also excluded. Finally, studies were excluded 
if they were applied to patients after recurrence of malignancy.
Validation studies
Two reviewers (SB and BGa) independently assessed the abstracts of all stud-
ies identified by the search. Eligibility was determined by reviewing the full 
manuscript of potentially relevant studies. Disagreement between the reviewers 
was resolved by discussion. Descriptive, methodological, and outcome data from 
each validation study were extracted using a standard form by two reviewers (SB 
and BGa) and independently validated by a third reviewer (JV). If a validation 
study validated more than one prognostic model, data was extracted for each 
validated model. Descriptive statistics included type of malignancy, publication 
date, method of treatment, number of prognostic factors, sample size, type of 
outcome, and performance (discrimination and/or calibration assessment). 
Performance of the prognostic models at external validation was evaluated by 
discrimination and calibration. Discrimination was assessed using the area under 
the curve (AUC) of the receiver operating characteristic (ROC), Harrell’s con-
cordance index (c-index), the Brier score, or a similar measure.10,13 Because the 
c-index was the most commonly reported discrimination measure, it was used as 
the principal measure of external validity. The c-index is the probability, that for 
two random patients, the patient with the worst predicted survival had the worst 
observed survival. A c-index of 0.5 indicates no predictive discrimination and a 
value of 1.0 indicates perfect separation of patients with different outcomes.13 
For binary outcomes, i.e. studies in which time to event is disregarded, the AUC 
equals the c-index.13 An AUC/c-index of < 0.6 was considered poor quality, while 
a c-index between 0.6-0.7 was considered moderate quality, and a c-index above 
0.7 was considered good quality. Calibration is the agreement between observed 
outcomes and predictions for individual patients. Calibration is assessed using 
the calibration plot, intercept and/or slope. Because a number of the proposed 
models do not provide an estimate of OS or DFS, assessment of the calibration 
of the models in validation studies was made difficult. For example, the AJCC 
staging systems imply a worse prognosis for higher stages, but do not accompany 
that prediction with a survival estimate. Survival curves can be used to grossly 
compare prognosis per risk group in the validation study with prognosis and 
model estimates in the derivation study.
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Derivation studies
The included validation studies performed an external validation of one or more 
prognostic models. Using the reference lists of these studies, we identified the 
corresponding publications describing the development (i.e. derivation) of these 
models. To determine the methodological quality of these models, the following 
data was extracted: publication date, participant information, candidate prog-
nostic factors information, outcome information, statistical power information, 
selection of prognostic factors, handling of missing values, presentation of results, 
and model performance and validation. No consensus guideline exists to deter-
mine the quality of model derivation studies. Therefore, a review by participants 
of the Cochrane Prognostic Studies group was used as a guideline.11 Based on 
this review we systematically performed a quality assessment considering cohort 
description, statistical analyses, reporting of results, and model performance.
Results
Validation studies
Electronic searches identified 7,779 results (Figure 1). After removing duplicates, 
5,147 studies remained, of which 181 full-text articles were screened. Of the full-
text articles, 48 external validation studies met the inclusion criteria. These 48 
studies performed 181 model validations; 134 for OS and 47 for DFS. The total 
number of patients in which a model was externally validated ranged from 42 to 
21,512 patients. The median number of patients in which CRLM models were 
validated was 286 (range: 97-1151). The median number of patients in which a 
validation was performed was 774 (range: 42-3138) for HCC and 540 for hepa-
tobiliary tumors (range: 75-21,512). All external validation studies are referenced 
in Table 1.
Derivation models
The validation studies validated 70 different prognostic models. Of the 70 included 
models, 27 (39%) were validated in only 1 study, whereas the rest was validated in 
2 or more studies. These models were validated 35 times with DFS as the outcome 
and 61 times with OS as the outcome; 35 models were only validated for OS, 9 
models only for DFS, and 26 models for both outcomes. The median number of 
prognostic factors in the models was 4 (range: 2-14). In 45 prognostic models 
(64%), statistical methods were used for model derivation; 25 models (36%) were 
consensus based. Of the statistically derived models, 14 were for predictions in 
CRLM, 19 for HCC, 3 for pancreatic carcinoma and 9 for cholangiocarcinoma. 
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Consensus based models included various editions of the American Joint Com-
mittee on Cancer (AJCC) TNM staging for HCC, ICC, PHC, DCC, and PDAC. 
Other well-known consensus based models for HCC included the Barcelona 
Clinic Liver Cancer (BCLC), the International Hepatopancreatobiliary Associa-
tion (IHPBA) HCC staging, the Japan Integrated Score (JIS), and the Chinese 
HCC staging system. For pancreatic neuroendocrine tumors consensus based 
models included the ENETS pancreatic neuro-endocrine tumor classification and 
the WHO pancreatic neuro-endocrine tumor classification (both the 2004 and 
2010 edition).  
Figure 1. Prisma Flow Diagram, to find studies that validate prognostic models after resection of 
HPB cancer. 
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Performance of models at validation - discrimination
Table 1A-D present the performance of 70 derivation models that were validated 
in 48 external validation studies. Across all types of cancer and outcomes, 30 
models (31%) performed poorly at external validation with an AUC or c-index 
below 0.60, 43 models (45%) had moderate performance with a c-index between 
0.6 and 0.7, and 23 models (24%) had a good performance (green background 
in Table 1).
For CRLM, only 1 out of 14 (7%) models (Kanemitsu’s preoperative prog-
nostic model) reached an average c-index of 0.7 on external validation for OS 
(Table 1A).14 However, this model was only validated in one study of 113 pa-
tients.15 The Clinical Risk Score by Fong et al. was the only model validated in 
more than two different patient cohorts, but performed poorly with an average 
c-index of 0.57 for DFS and 0.54 for OS.16
For HCC, models were validated for 38 different outcomes (n=11 DFS; n=27 
OS). In total 15 models (40%) showed good discriminative ability in repeated 
validation efforts (depicted in green in Table 1B). The model with the highest 
c-index was the LCSGJ staging (0.89 for OS), however it was only validated in 
1 cohort of 42 patients. The highest c-index in models that were validated in 
multiple cohorts was JIS for OS (0.76), in a total number of 3115 patients over 
5 studies.
Among patients with pancreatic cancer (Table 1C), the pancreatoduodenectomy 
prognostic index (PPI) was validated with a c-index of 0.74. Only one large vali-
dation study was identified (n = 21,512 patients). For pancreatic neuro-endocrine 
tumors, the WHO 2010 and the modified WHO 2010 achieved a c-index of 0.70 
and 0.87 respectively, although in small cohorts (205 patients and 127 patients 
respectively). Four studies were validated twice (MSKCC Staging, AJCC 7th, 
ENETS and WHO 2010).
For biliary cancers 24 different models and outcomes were validated (Table 1D). 
Most AJCC staging systems performed sub-par, with a c-index <0.7. Only for 
distal cholangiocarcinoma (DCC), the 5th and 7th AJCC staging systems reached 
an average c-index of 0.7 or higher. For ICC and DCC, 2 statistics based models 
had good discrimination (c-index > 0.7) at validation (Wang’s nomogram and 
Yeh’s nomogram). However, the validation cohort for Yeh’s model was small. Most 
of the available models were only validated once or twice, except the AJCC 6th 
and 7th edition, the LCSGJ staging, Okabayashi staging and Wang nomogram.
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Performance of models at validation - calibration
Kaplan-Meier survival estimates of the different risk groups were reported in 
137 out of the 181 validation settings. In contrast, calibration plots or tables, 
for comparing predicted with observed survival for individual patients were only 
reported in 19 validations (10.5%), for 14 models (20%). Finally, calibration was 
not reported at all in 42 validations (23.2). 
Quality assessment of derivation studies
In the majority of the 39 derivation studies, detailing the derivation of 45 statistics-
based models, the cohort was well described (Table 2A). All studies reported clear 
inclusion criteria (n=45; 100%) and defined an inclusion period (n=45; 100%). 
A detailed description of the derivation cohort (n=43; 96%) and its follow-up 
(n=35; 78%) were provided in most studies. Prospective studies were a minority, 
with 71% (n=32) of studies describing a retrospective cohort.
Reporting of methods and analyses of the derivation studies is shown in Table 2B. 
Although the main outcome was OS in the majority of derivation studies, the 
definition of survival (e.g., calculated from diagnosis or resection) was only pro-
vided in 28 (62%) studies. Most studies (n=38, 84%) dichotomized or categorized 
continuous prognostic factors resulting in loss of information. Moreover, interac-
tion of prognostic factors was rarely evaluated (n=5; 11%). Particularly models 
pertaining to CRLM cancer surgery were conducted in large prospective cohorts, 
with more than 15 events per prognostic factor in the multivariable analysis in 
79% (n=11) of the studies. This was the case in 60% (n=27) of all studies. Han-
dling of missing data was not adequately reported in most studies (n=26; 58%).
In the majority of the assessed studies, selection of the prognostic factors for the 
final model was conducted based on statistical analysis (Table 2C). The statistical 
methods were accurately described with clear criteria for selecting prognostic fac-
tors in 80% of studies. Univariable correlations between risk factors and outcomes 
were described in two thirds of the studies (67%), whereas multivariable correla-
tion of the prognostic factors included in the model was described in fewer studies 
(n=29; 64%).
Evaluation of model performance in the derivation studies differed in quality 
(Table 2D). While about half of the studies analyzed discrimination using c-
indices or AUC (n=25; 56%), presentation of the calibration of the models was 
lacking in 56% (n=25) of derivation studies. The Brier score, a measure for overall 
model performance, was missing in all derivation studies. Validity assessment using 
149
Quality of Prognostic Models in HPB Surgery
bootstrapping techniques or internal validation was performed in approximately 
half of the derivation studies (n=20; 44%). External validation in derivation stud-
ies was performed in 14 studies (31%). For all reported characteristics one point 
could be earned, except for statistical selection of prognostic factors, resulting in a 
maximum total of 17 points. The average number of points achieved was 10/17. 
The c-index at validation was weakly associated with the number of points at 
derivation of the models (Figure 2A and 2B).
Table 2 Reporting of cohort description (A), analyses (B), results (C), and performance (D) in the 
model derivation studies. The numbers in the table are percentages. Percentages 0-32 are col-
ored red, 33-65 are colored yellow, and 66 and up colored in green
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Table 2 Reporting of cohort description (A), analyses (B), results (C), and performance (D) in the 
model derivation studies. The numbers in the table are percentages. Percentages 0-32 are 
colored red, 33-65 are colored yellow, and 66 and up colored in green 
 
 
  
A
Number of Studies
Prospective Cohort
Inclusion Criteria Clear
Baseline Characteristics
Recruitment Dates
Follow-Up Reported
Colorectal Liver Metastases 14 29 100 93 100 93
Hepatocellular Carcinoma 19 42 100 100 100 58
Pancreas Carcinoma 3 33 100 100 100 100
Biliary Malignancies 9 0 100 89 100 89
Overall 45 29 100 96 100 78
B
Outcome Definition
Interaction Tested
Continuous Predictors Used
Sample Size >15 per Predictor
Missing Data Reported
Handling of Missing Data
Colorectal Liver Metastases 79 14 14 79 21 50
Hepatocellular Carcinoma 74 5 11 58 16 37
Pancreas Carcinoma 0 0 33 67 33 67
Biliary Malignancies 33 22 22 33 0 33
Overall 62 11 16 60 16 42
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C
Based on Statistical Analysis
Clear Method for Variable Selection 
Univariable Results Presented
Multivariable Results Presented
Colorectal Liver Metastases 100 86 71 71
Hepatocellular Carcinoma 79 95 74 47
Pancreas Carcinoma 100 67 0 67
Biliary Malignancies 100 44 67 89
Overall 91 80 67 64
D
Calibration Analyzed
Discrimination Analyzed
Validity Assessment
External Validity Assessment
Total Score
Colorectal Liver Metastases 36 50 36 7 10
Hepatocellular Carcinoma 47 53 79 42 10
Pancreas Carcinoma 33 67 33 33 9
Biliary Malignancies 56 67 67 44 9
Overall 44 56 60 31 10
151
Quality of Prognostic Models in HPB Surgery
Figure 2A. C-index of OS as a function of derivation study quality
 
Figure 2B. C-index of DFS as a function of derivation study quality
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Discussion
We identified 70 validated prognostic models for survival of patients after resec-
tion of CRLM, hepatobiliary or pancreatic cancers. Most prognostic models had 
poor performance (c-statistic <0.70) on external validation or were validated only 
in small cohorts (n<500). Exceptions include several HCC models (IHPBA, JIS, 
MSKCC, and SLICER), the Wang model for ICC, and the 7th edition of AJCC 
staging for DCC.8,17-21 No prognostic model demonstrated a good performance 
at external validation in a large cohort for CRLM, PDAC, PNET, and PHC. 
Model quality was poor as reflected by inadequate handling of missing data 
and unnecessary dichotomization of continuous prognostic factors. Quality at 
validation was relatively poorer still in models for DFS, presumably because most 
studies were retrospective and follow-up was not protocolized.
For all hepatobiliary and pancreatic cancers, many models for the same outcome 
(OS, DFS) were available. The availability of multiple models for each type of 
cancer reflects the trend of making new models rather than validating existing 
models.22-24 Small cohort size in derivation studies has contributed to poor model 
performance. Typically, performance may seem good in small derivation cohorts, 
but performance is often poor when applied to an external dataset for validation. 
This can partially be remedied by employing proper internal validation methods, 
most notably bootstrapping12,25 and internal-external cross-validation (e.g., in 
multicenter studies each participating hospital’s patients can be left out once).25,26 
Small cohort size is also a problem for external validation. For example, the aver-
age validation cohort of CRLM was only about 200 patients, while each year 
about 1 million people are diagnosed with colorectal cancer. A consequence of 
the small sample size of validation cohorts is the observed disagreement on model 
performance between external validations with small sample size.
The limited methodological quality of derivation studies also contributed to poor 
performance. Almost all derivation studies employed stepwise variable selection 
procedures. This method leads to spurious results in small studies, as the chance 
of biased cohort selection and lack of power increase.10 Furthermore, informa-
tion on missing data and the way it was handled was often lacking. Commonly, 
regression analysis has been performed using standard statistical software packages 
with complete cases only, whereas patients with any missing values are excluded, 
reducing statistical power.10,27,28 Especially if systematic differences between com-
plete and incomplete cases exists, analysis of complete cases only induces selection 
bias. If the missing data is related to patient characteristics, imputation of data 
is the most suitable way to minimize bias.10,29 Appropriate handling of missing 
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data when developing a prognostic model, might help improve its performance 
in external patient cohorts. Furthermore, the exact approach of the multivariable 
model development was often not reported. Dichotomizing continuous prognostic 
factors at arbitrary cutoffs also contributed to bias and less power.30 The majority 
of studies presented the final model in a simplified form, such as a risk score or 
a nomogram. Although this makes a model easy to interpret, precision is lost by 
rounding numbers in a risk score or imprecise and cumbersome measurement of 
outcomes using a nomogram.30 
The goal of prognostic models is to improve shared decision-making and personal-
ized medicine. For example, a patient with excellent predicted OS is unlikely 
to benefit from adjuvant systemic chemotherapy or intensive surveillance for 
recurrent disease. However, most prognostic models report individual outcomes 
based on patient and tumor characteristics, regardless of subsequent treatment. 
“Predictive” models are necessary to determine and compare individual outcomes 
of various treatment options.31 Without such “predictive” models, the individual 
predicted survival advantage of adjuvant chemotherapy can only be inferred from 
OS and DFS reported by prognostic models.
Historically, models have been developed with the ease of clinical use in mind. 
Therefore, many prognostic models have been simplified into simple risk scores 
and nomograms; for example, the Clinical Risk Score and Milan criteria. These 
models are still in use, but meet very few of the current recommendations for 
deriving a prognostic model.16,32 Such simplifications are no longer necessary; 
for example, web-based calculators can calculate the exact individual outcomes. 
Ideally, prognostic models are integrated in a patient information system that 
automatically assembles all relevant prognostic factors (e.g., age and tumor stage) 
into individual predicted outcomes.
Future research should focus first on validating existing models in large cohorts. If 
existing models have poor performance (discrimination or calibration) at external 
validation with large cohorts, new models should be developed using large (in-
ternational) cohorts. Prognostic models with readily available patient and tumor 
characteristics (e.g., age and tumor stage) are also important as a benchmark for 
novel prognostic biomarkers.33,34 An exquisite model based on the expression of 
50 genes is only relevant for prognostication if it results in a clinically meaningful 
improvement of the best available model with readily available patient and tumor 
characteristics.
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Our study has several limitations. First, we only assessed externally validated 
prognostic models. Consequently, we may have excluded recent promising prog-
nostic models that have not yet been validated. Secondly, calibration of models 
is difficult to quantify and summarize; consequently, we only evaluated whether 
calibration was reported at all.
In conclusion, prognostic models for survival after resection of hepatobiliary and 
pancreatic cancer mostly have poor methodological quality and poor performance 
on external validation. Guidelines for reporting prognostic models (i.e. TRIPOD 
statement) should be followed. Guidelines for deriving and validating prognostic 
models are needed. Future research should focus on external validation of existing 
models in very large cohorts, rather than deriving new models in small cohorts.
Acknowledgement: Wichor M. Bramer’s help with constructing the search term 
is gratefully acknowledged.
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Abstract
Introduction: We sought to validate the commonly used prognostic models and 
staging systems for intrahepatic cholangiocarcinoma (ICC) in a large multi-center 
patient cohort.
Methods: The overall (OS) and disease free survival (DFS) prognostic discrimina-
tory ability of various commonly used models were assessed in a large retrospective 
cohort. Harrell’s concordance index (c-index) was used to determine accuracy of 
model prediction. 
Results: Among 1,054 ICC patients, median OS was 37.7 months and 1-, 3- and 
5-year survival, were 78.8%, 51.5% and 39.3%, respectively. Recurrence of dis-
ease occurred in 454 (43.0%) patients with a median DFS of 29.6 months. One-, 
3- and 5- year DFS were 64.6%, 46.5 % and 44.4%, respectively. The prognostic 
models associated with the best OS prediction were the Wang nomogram (c-index 
0.668) and the Nathan staging system (c-index 0.639). No model was proficient 
in predicting DFS. Only the Wang nomogram exceeded a c-index of 0.6 for DFS 
(c-index 0.602).  The c-index for the AJCC staging system was 0.637 for OS and 
0.582 for DFS.
Conclusions: While the Wang nomogram had the best discriminatory ability 
relative to OS and DFS, no ICC staging system or nomogram demonstrated excel-
lent prognostic discrimination. The AJCC staging for ICC performed reasonably, 
although its overall discrimination was only modest-to-good. 
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Introduction
Intrahepatic cholangiocarcinoma (ICC) occurs in approximately 1-2 per 100,000 
persons, making it the second most common primary hepatic malignancy.1-3 
Although ICC mostly develops as a well-differentiated carcinoma, only a minority 
(15%) of patients presents with resectable disease at the time of diagnosis.4 Com-
plete surgical resection remains the only option for cure. The estimated median 
survival after resection of ICC ranges from 27 to 36 months.5-9 Postoperative 
survival estimates for individual patients can have consequences with regards to 
surveillance strategies and decisions about adjuvant chemotherapy.10
The most common staging for ICC is the TNM system in the American Joint 
Committee on Cancer (AJCC) staging manual.11  While the AJCC staging system 
is widely adopted, TNM categorization can be limited in providing individual 
patient-specific prognosis among patients with biliary cancers.  As such, several 
groups have proposed new prognostic models and nomograms.12-13 In addition, 
some groups including the Liver Cancer Study Group of Japan (LCSGJ)14, the 
Society of Hepatobiliary Surgery Japan (SHPBSJ)15, Okabayashi et al.,16 and 
Nathan et al.17 have offered a wide range of different staging systems that have 
been proposed to discriminate overall survival (OS) better.  External validation 
of these proposed prognostic staging schemes has been largely lacking, however. 
When developing a prediction model, there is an inherent risk of overestimating 
both its accuracy and generalizability. External validation of any staging proposal 
is therefore necessary in large, multicenter cohorts of patients. Since only a few 
prognostic ICC models have been tested in such cohorts, further evaluation of 
these models is important. As such, the objective of the current study was to 
define the predictive ability of the available proposed prognostic models for pa-
tients with resected ICC in a large cohort of patients from multiple international 
high-volume centers. 
Methods
All patients undergoing resection for ICC between January 1, 1990, and July 1, 
2016 at one of 12 participating major hepatobiliary institutions in the United 
States, Asia, Oceania and Europe were identified (Johns Hopkins University, 
Baltimore, Maryland; Emory University, Atlanta, Georgia; Stanford University 
Medical Center, Stanford, California; University of Virginia Health System, 
Charlottesville, Virginia; Fundeni Clinical Institute, Bucharest, Romania; Beau-
jon Hospital, Clichy, France; Curry Cabral Hospital, Lisbon, Portugal; Eastern 
Hepatobiliary Surgery Hospital, Shanghai, China; Ottowa General Hospital, 
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Ottowa, Canada; Royal Prince Alfred Hospital, Sydney, Australia; San Raffaele 
Hospital, Milan, Italy; Erasmus University Medical Centre Rotterdam, Rotter-
dam, the Netherlands). Patient records in each participating center were assessed 
retrospectively and entered into a central standardized registry for each institution.
Sociodemographic and clinicopathologic data were collected and included age, 
sex and race, tumor size, histologic grade, presence of nodal metastases, final re-
section margin and the presence of vascular and/or perineural invasion. A minor 
hepatectomy was defined as a hepatic resection of less than 3 Couinaud segments. 
Margin status was categorized as R0 for tumor negative resection margins, R1 for 
microscopically positive margins and R2 for macroscopically positive margins. 
Only patients undergoing surgery for histologically confirmed ICC were included 
in the study population; patients who did not undergo resection were excluded. 
Patients who underwent transplantation were also excluded. The respective insti-
tutional review boards of each participating institution approved this study. 
Included Models
Seven frequently used postoperative nomograms and staging systems for resected 
ICC patients were selected for this study. The prognostic models included those 
proposed by Wang et al.,18 the AJCC TNM 7th edition,11 Hyder et al.,13 Liver 
Cancer Study Group of Japan (LCSGJ)14, the Society of Hepatobiliary Surgery 
Japan (SHPBSJ)15, Okabayashi et al.,16 and Nathan et al.17, which are summa-
rized in Table 1.
Statistical analysis
Categorical variables were described as whole numbers and percentages while 
continuous variables were reported as medians with interquartile (IQR) range. 
Percentages for each variable were calculated based on available data, excluding 
missing values. Univariable comparison of categorical variables was performed 
using the Pearson chi-square test. Univariable comparison of continuous variables 
was performed using the Mann-Whitney U-test. In order to ascertain the validity 
of our results we performed additional multiple imputations for the Wang (51.8% 
missing) and Hyder (23.9% missing) nomograms, the only models with larger 
numbers of missing patients. Since c-indices cannot be pooled using Rubin’s rules, 
we provided the median and range.19
The primary outcome of the study was overall survival (OS). The secondary 
outcome was disease-free survival (DFS). OS was calculated as the time from the 
date of surgery to the date of death or date of last available follow-up, while DFS 
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was calculated from the date of surgery to the date of first-known radiographically 
or pathologically confirmed metastasis. Both survival estimates were determined 
using the Kaplan-Meier method. The log-rank test was used to compare the strata 
of the prognostic models. Cox regression was performed to evaluate the effect of 
well-known prognostic variables in this particular cohort of patients. Each of the 
variables included in the models Schoenfeld residuals were plotted, in order to 
evaluate if the proportional hazards assumption was not violated. A sub-analysis 
among the patients who had a mass-forming ICC was conducted for the SHPBSJ 
and Okabayashi staging systems, because these staging systems were originally 
developed in cohorts of patients with mass-forming ICC.15,16
Model performance was assessed using Harrell’s concordance index (c-index). The 
c-index provides the probability that, in a randomly selected pair of patients, in 
which one patient dies before the other, the patient who died first had the worse 
predicted outcome from the nomogram. Analyses were performed using SPSS 
22.0 (IBM, New York) and R version 3.03 (http://www.r-project.org) with the 
rms package. All tests were 2-sided and p<0.05 defined statistical significance.
Results
Cohort description
1,054 patients who underwent resection for ICC and met the inclusion criteria 
were identified (Table 2). Median patient age was 59 years (IQR 51, 68) and 
the majority of patients were male (n=568, 53.9%). Most patients had an ASA 
classification of II (n=486, 52.0%) or III (n=274, 29.3%). At the time of surgery, 
six out of ten patients underwent a major hepatectomy involving more than 3 
Couinaud segments (n=60, 59.9%). Almost half of patients underwent a formal 
portal lymphadenectomy (n=463, 45.1%). On final pathology, the majority of 
patients had an R0 resection (n=882, 86.4%). Morphologically, most patients 
had a mass-forming ICC (n=892; 92.1%), while a minority had a papillary (n=31; 
3.2%) or periductal infiltrating (n=45; 4.5%) growth pattern. Lymph node metas-
tases were noted in 17.5% of patients (n=184). 
For each prognostic model, patients were allocated into the different risk groups, 
based on disease characteristics (Tables 3 and 4). The number of missing values 
which resulted in patients excluded from analysis was small in most prognostic 
models. More specifically, 99 (9.4%) of patients were not included in the AJCC 
TNM staging, 33 (3.1%) in the LCSGJ staging, 42 (4.0%) in the SHPBS staging, 
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Table 2. Baseline characteristics of the validation cohort (n = 1,054)
Variable n (%) / median (IQR)
Gender
Male 568 (53.9)
Female 485 (46.1)
Age, years 59 (51-68)
Race
Caucasian 626 (61.6)
African-American 39 (3.8)
Asian 329 (32.4)
Other 22 (2.2)
ASA
I 104 (11.1)
II 486 (52.0)
III 274 (29.3)
IV 71 (7.6)
BMI 25.4 (22.6-28.2)
Period of Treatment
1990-2000 35 (3.4)
2001-2005 115 (11.1)
2006-2010 422 (40.8)
2011-2016 463 (44.7)
Type of Resection
Minor Hepatectomy (<3 segments) 419 (40.9)
Right Hepatectomy 167 (16.3)
Left Hepatectomy 193 (18.8)
Extended Right Hepatectomy 128 (12.5)
Extended Left Hepatectomy 96 (9.4)
Central Hepatectomy 21 (2.1)
Number of tumors 1 (1-1)
Morphologic Type
Mass-forming 892 (92.1)
Papillary 31 (3.2)
Periductal Infiltrating 45 (4.6)
Tumor size (cm) 6.1 (4.3-9.0)
Major Vascular Invasion 100 (9.7)
Microvascular Invasion 257 (25.6)
Perineural Invasion 152 (16.4)
Invasion of Adjacent Organs 77 (7.5)
Satellite Lesions 233 (22.6)
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25 (2.4%) in the Okabayashi staging, and 91 (8.6%) in the Nathan staging sys-
tem. The nomograms by Wang (51.8% missing) and Hyder (23.9% missing)  had 
a considerably higher proportion of missing patients. In the Wang nomogram, 
the median points score was 40.1 (IQR 23.2, 63.6). One hundred twenty-seven 
patients (25.0%) were allocated in the group <23.4 points, 255 (50.1%) in the 
group 23.4-64.9, and 127 in the group >64.9. Of note, the main reason the 
Wang nomogram could not be determined for a subset of patients (n=548), were 
missing values for both CEA and CA19-9.
In the AJCC 7th staging schema, the majority of patients were allocated into 
stage I and II (n = 692, 72.2%). In the LCSGJ staging system, almost 6 out of 
every 10 patients were allocated in stage II (n = 607, 59.3%), which was identical 
to the allocation using the SHPBSJ staging system. In the Okabayashi staging 
system, 61.8% of the patients had stage I disease and 299 (29.0%) had stage III 
disease, while only 94 patients were allocated into the other stages. In the staging 
by Nathan, 398 (41.2%) patients had stage I disease, 360 (37.2%) had stage II 
disease and 209 (21.6%) had stage III or IV disease. Patients had an average score 
of 12.9 (IQR 10.9-15.9) when using Hyder’s nomogram. 
Overall survival and disease free survival
After a median follow-up of 27 months, nearly half of patients were deceased 
(n=521, 49.7%). Median OS was 37.7 months and 1-, 3- and 5-year survival, 
were 78.8%, 51.5% and 39.3%, respectively. Recurrence of disease occurred in 
454 (43.1%) patients during follow-up. Median disease-free survival was 29.6 
months and 1-, 3- and 5- year DFS were 64.6%, 46.5 % and 44.4%, respectively. 
Table 2. Baseline characteristics of the validation cohort (n = 1,054) (continued)
Variable n (%) / median (IQR)
Intrahepatic Metastases 75 (7.3)
Lymphadenectomy 463 (45.1)
Lymph Nodes Harvested 2 (0-5)
Lymph Node Metastases 184 (17.5)
Extrahepatic Metastases 40 (3.8)
Margin Status
R0 882 (86.4)
R1 134 (13.1)
R2 5 (0.5)
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Components of the prognostic models of interest were evaluated separately for 
prognostic ability with regards to OS and DFS (Table 3). Except for age and cir-
rhosis, all variables were associated with OS. Of note, direct invasion of adjacent 
organs (HR: 2.76, 95%CI 2.11-3.60, p < 0.001) and distant metastases (HR: 
2.64, 95%CI 1.67-4.19, p < 0.001) were the factors most strongly associated with 
OS. The continuous variable CA19-9 had the best c-index of 0.634. With regards 
to DFS, tumor diameter >2 cm was strongly associated with risk of disease recur-
rence (HR: 2.10, 95%CI 1.12-3.92). Plotted Schoenfeld residuals demonstrated 
that the proportional hazards assumption was not violated for any of the variables.
Comparison of scoring systems
Data on the performance of the models regarding the OS prediction are presented 
in Table 4 and Figure 1; the ability of the models to predict DFS is presented in 
Table 5 and Figure 2. Although there was a decline in OS and DFS with each 
progressive stage in most models, the highest stage was not always associated with 
the worst survival.  For example, in the higher stages of several models, no dif-
ferences in OS and DFS were observed (Figures 1 and 2). The Wang nomogram 
was the only prognostic model in which incremental, clear differences among the 
survival curves in the bottom quartile, interquartile range and the upper quartile 
were identified for both OS and DFS. 
The prognostic models providing the best prediction of OS at all time points were 
the Wang nomogram and the Nathan staging system. These prediction methods 
also yielded the highest c-statistics (0.668 and 0.639). No model exceeded a c-
index of 0.7 for OS. The ability of the models to predict DFS is presented in 
Table 5 and Figure 2. No model was proficient in predicting DFS. The only model 
to exceed a c-index of 0.6 for DFS, which indicates fair discrimination, was the 
nomogram by Wang and colleagues. For both OS and DFS, the Hyder nomogram 
had the lowest predictive capacity. Both the SHPBSJ (OS c-index: 0.606, DFS 
c-index: 0.558) and the Okabayashi staging systems (OS c-index: 0.600, DFS 
c-index: 0.558) did not perform better within the mass-forming ICC sub-cohort. 
The imputed datasets for the Wang and Hyder nomograms did not show large 
differences, compared to the complete case analysis. The Wang nomogram had a 
c-index of 0.674 (0.670-0.680) for OS and 0.601 (0.597-0.604) for DFS, which 
seemed to be similar to the estimate in the complete-case analysis. For the Hyder 
nomogram, the c-index for OS was 0.614 (0.613-0.616) and the c-index for DFS 
was 0.542 (0.541-0.548).
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Figure 1. Overall survival stratified by the different prognostic models. A) Wang Nomogram Score, 
B) AJCC 7th edition stage, C) LCSGJ stage, D) SHPBS stage, E) Okabayashi stage, F) Nathan stage, 
G) Hyder nomogram score
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Figure 2. Disease free survival stratified by the different prognostic models. A) Wang Nomogram 
Score, B) AJCC 7th edition stage, C) LCSGJ stage, D) SHPBS stage, E) Okabayashi stage, F) Nathan 
stage, G) Hyder nomogram score
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Discussion
Prognostic models are frequently used in order to determine prognosis and predict 
adverse outcomes in malignant HPB surgery.18,20-27 Because of the vast differ-
ence in characteristics among individual patients diagnosed with ICC, different 
approaches in adjuvant therapy, follow-up, and further surgical treatment can 
be tailored to individual patients with the help of these models.12,28-30 In this 
study, we examined the ability of established nomograms and staging systems to 
predict OS and DFS in one of the largest Western cohorts of ICC to date. We 
quantified the predictive ability of each nomogram using Harrell’s concordance 
index. Although the included prognostic models varied considerably, some vari-
ables were included in multiple models. Notably, vascular invasion, lymph node 
metastases, and number of lesions were included in all prognostic models. These 
risk factors had significant prognostic value in our cohort as well. After evaluat-
ing model performance, we noted that no single model reached the threshold 
for good discrimination (i.e. a c-index of 0.7) for both OS and DFS. The most 
often used AJCC TNM staging system performed reasonable compare with the 
other prognostic models (OS c-index: 0.637, DFS c-index: 0.582). In line with 
previous studies,10,18 the nomogram by Wang and colleagues performed the best 
in predicting OS (c-index 0.668) and DFS (c-index 0.607).
ICC prognostic models have been developed in different populations for differ-
ent purposes. While the AJCC staging includes all ICC patients, other models 
pertain only to patients who have undergone surgical resection. For example, the 
nomogram by Wang et al. was designed to predict individual OS after resection of 
ICC.18 Prognostic factors in this model included CEA, CA19-9, vascular invasion, 
presence of lymph node metastases, direct invasion and local metastases, number 
of tumors, and tumor diameter. A similar nomogram was developed by Hyder et 
al. Risk factors for survival after resection in this model included age, number of 
tumors, tumor diameter, cirrhosis, lymph node metastases, and macrovascular 
invasion.13 A notable feature of the Hyder nomogram was that it categorized 
patients who did not undergo a lymphadenectomy as Nx, instead of N0 like the 
other prognostic models.  Other staging systems, such as those examined in the 
current study, were proposed as an alternative to the AJCC and included the Liver 
Cancer Study Group of Japan (LCSGJ)14, the Society of Hepatobiliary Surgery 
Japan (SHPBSJ)15, Okabayashi et al.,16 and Nathan et al. staging systems.17 Simi-
lar to nomograms, these staging systems sought to better differentiate prognosis 
among patients and more individualized prognostication.  One difference in the 
SHPBSJ and the Okabayashi staging systems versus the other staging systems 
was the inclusion of only patients with mass-forming ICC, the most common 
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ICC morphology.15,16 Although the prognostic models differed considerably and 
used different cut-offs and units for the variables, the included factors included 
in the models had marked overlap. Vascular invasion, lymph node metastases and 
number of lesions were included in all prognostic models. These risk factors have 
been associated with worse prognosis in many previous studies.10 On the other 
hand, age and cirrhosis were included only in the nomogram by Hyder et al. 
Interestingly, tumor size was been removed from the T-stage in the 7th edition of 
the AJCC staging system, but was included in 4 out of the 7 prognostic models, 
indicating its importance in prognostication.  To this point, tumor size has been 
re-introduced into the new, recently published 8th edition AJCC ICC staging 
system. 
Due to the low incidence of ICC compared with other HPB malignancies, 
derivation studies for prognostic models often have lacked statistical power. 
Underpowered studies are at a risk of over-fitting the model to the data, causing 
decreased reproducibility. The current study is important because it externally 
evaluated current ICC models in a large and multicenter cohort. In particular, the 
data suggested that most prognostic models lacked the ability to identify patients 
with higher risk of recurrence or mortality, as demonstrated by the relatively low 
c-statistic associated with the different models. In previous studies by Doussot et 
al. and Nathan et al. similar poor results were demonstrated, although the sample 
size of the study cohorts were smaller than the current study.10,17  Although mul-
tiple well-known prognostic factors are used in the prognostic models, accurate 
estimation of their impact on survival remains elusive. The most commonly used 
prognostic factors were patient- and tumor-specific factors, with a limited number 
of factors such as number of tumors and vascular invasion. In addition, these 
factors were often analyzed in a binary fashion in many models, further limiting 
their predictive ability. It stands to reason that the potential prognostication of 
ICC, a complex biological process, based on a small number of binary predictors 
whose impact has only been measured in small cohorts, is limited. 
In order to improve the predictive ability of current and new prognostic mod-
els, new determinants of biological processes in the form of biomarkers will be 
needed. Biomakers such as CEA and CA19-9 have previously been correlated with 
tumor processes and clinical outcomes.31,32 Only the Wang nomogram, however, 
utilized these biomarkers in a prognostic model. The superior discriminating abil-
ity of the Wang nomogram may relate to the importance of these biomarkers in 
prognostic models.  In addition, a recent meta-analysis identified several other 
immunohistochemistry biomarkers associated with ICC.33 To this end, some 
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investigators have proposed that a composite biomarker profile that combines 
clinical factors (CEA and CA19-9) with pathological biomarkers may improve 
the accuracy of prognostic models and guide treatment in patients with resected 
ICC.34 The potential of this approach has been proven with the recent successes of 
biomarker based prediction in breast cancer and colorectal cancer.35,36
Results of the current study should be interpreted in the context of several limita-
tions. The inclusion of multiple centers did not allow for the standardization of 
operative approach or treatment-based protocols.  The multi-center nature of the 
study does add to the generalizability, allowing the findings to be applied across 
a wide range of patient populations.  Another limitation was the unavailability of 
preoperative values of CEA and CA19-9 in a number of patients.  The lack of CEA 
and CA19-9 data was likely related to the varied clinical practice across centers, 
as well as the relatively recent identification of CEA and CA19-9 as important 
prognostic factors. We believe these missing values did not influence our results, 
as analysis after multiple imputations led to the same results. Additionally, due to 
the small number of patients with a tumor morphology, other than mass-forming 
ICC, we were unable to assess prognostic models for each morphology separately. 
Finally, not all patients underwent lymphadenectomy and therefore the “true” 
nodal status of these patients could not be determined.  It is likely that a subset of 
these patients did indeed harbor occult nodal metastasis. 
In conclusion, while the Wang nomogram had the best discriminatory ability 
relative to OS and DFS, no staging system or nomogram demonstrated excellent 
prognostic discrimination. The most widely adopted AJCC staging for ICC per-
formed reasonably compared with other prognostic models, although its overall 
discrimination was only modest-to-good. Further research into the optimization 
of ICC prognostic models, possibly with inclusion of specific biomarkers, is war-
ranted.
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Abstract 
Background: While traditional survival analyses focus on factors determined at 
the time of surgery, conditional survival (CS) estimates prognosis relative to time 
following treatment. We sought to compare actuarial and CS among patients 
undergoing curative intent surgery for hilar cholangiocarcinoma.
Methods: 242 patients undergoing surgery between 2000 and 2014 were identi-
fied using a multi-institutional database. CS was calculated as the probability of 
surviving an additional 3 years, given that the patient had already survived “x” 
years from surgery.
Results: Median patient age was 67 years (IQR: 57-73) and most patients were 
male (n=140, 57.9%). Lymph node metastases were noted in 79 (32.6%) pa-
tients while an R0 margin was obtained in 66.1% (n=160). Median OS was 22.3 
months. Actuarial survival decreased over time from 46.3% at 2 years following 
surgery to 18.2% at 5 years; in contrast, the 3-year CS (CS3) increased with time 
(CS3 at 2 years was 39.3% versus 54.4% at 5 years). CS3 exceeded actuarial sur-
vival for high-risk patients with patients with perineural invasion demonstrating 
an actuarial survival of 15.4% at 5 years versus CS3 of 37.6% at 2 years following 
surgery (Δ=22.2%).
Conclusions: CS provides a more accurate, dynamic estimate for survival, espe-
cially among high-risk patients.
197
Conditional Survival PHC
Introduction
Hilar cholangiocarcinoma (HC) is the most common malignancy arising from 
the biliary tract accounting for 50-67% of all cases of cholangiocarcinoma.1,2 
Despite only 25% of patients presenting with resectable disease at the time of 
diagnosis, complete surgical resection remains the only option for cure with an 
estimated 5-year survival ranging from 11-42%.3,4 Given the poor prognosis 
associated with HC, appropriate risk-stratification of patients is important to 
inform decisions pertaining to cure, surveillance and palliation. Currently, there 
exist two commonly used prognostic classification tools for patients with HC: the 
Bismuth-Corlette Classification and the American Joint Committee on Cancer 
(AJCC) Classification System.5,6 While these prognostic classification schemes 
have identified important risk factors for HC including nodal disease and margin 
status, their ability to predict long-term survival remains limited. Specifically, 
constructed using traditional survival estimates, these prognostic classification 
systems are unable to account for changes in survival probability relative to the 
time elapsed from diagnosis.7 Under such circumstances, conditional survival 
(CS), which accounts for the changing probability of survival over time, has been 
identified as a more clinically relevant measure to predict long-term survival.8,9 
CS is based on the underlying premise that as a patient survives past a given time 
point, the survival probability changes compared to the time of initial diagnosis.10 
As such, CS has been proposed as a more clinically useful measure to predict 
long-term survival compared with traditional survival estimates. Furthermore, the 
use of CS estimates to predict long-term survival may help facilitate appropri-
ate risk-stratification of patients, as well as determine more accurate end-points 
for future randomized, controlled trials. In prospective studies, CS estimates 
can be taken into account in order to approximate the impact of elapsed time 
on the study population, because the group after extended follow up may differ 
significantly from the group that was originally randomized. To this point, previ-
ous reports on patients undergoing surgery for lung, pancreatic and breast cancer 
have demonstrated more accurate estimates for disease-free and overall survival 
using CS.8,9,11,12 However, to our knowledge, no previous research has assessed 
CS among patients undergoing surgery for HC. Given this, the aim of the cur-
rent study was to define conditional survival among patients undergoing curative 
intent surgery for HC. Additionally, we sought to assess the prognostic ability of 
previously established risk factors relative to the time elapsed after surgery.
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Methods
Data Sources and Patient Population
Patients undergoing surgery for hilar cholangiocarcinoma between January 1, 
2000 and December 31, 2014 at one of ten institutions participating in the 
Extrahepatic Biliary Malignancy Consortium were identified (Johns Hopkins 
University, Baltimore, Maryland; Emory University, Atlanta, Georgia; Stanford 
University, Stanford, California; University of Wisconsin, Milwaukee, Wisconsin; 
Ohio State University, Columbus, Ohio; Washington University, St. Louis, Mis-
souri; Vanderbilt University, Nashville, Tennessee; New York University, New 
York, New York; University of Louisville, Louisville, Kentucky; Wake Forest 
University, Winston-Salem, North Carolina). Only patients with histologically 
confirmed hilar cholangiocarcinoma and patients who underwent curative intent 
surgery for their primary tumor were included. Patients who died within 30 days 
of surgery were excluded. 
Standard demographic and clinicopathologic data were collected for each patient 
including age, sex, race, primary tumor size, AJCC 7th Edition stage and T-stage, 
histologic grade, presence of nodal disease, final resection margin, and the pres-
ence of vascular and / or perineural invasion. Tumor size was defined as the largest 
diameter of the tumor in the resected specimen. If multiple tumors were resected, 
the largest diameter was used to define tumor size. Histologic grade was defined 
as either well, moderate, or poorly differentiated with the highest histologic grade 
used to define tumor grade among patients with multiple resected specimens. 
Margin and nodal status were determined using the final postoperative pathologic 
report. Margin status was considered to be R1 when microscopic tumor remnants 
were present in the resection margin, and R0 when this was not the case. Lymph 
node metastases were scored as either present or absent. Additionally, treatment 
specific information including the extent of surgery, receipt of lymphadenectomy, 
as well as the receipt of pre- or postoperative chemo- or radiotherapy were also 
collected for each patient. A major liver resection was defined as the removal 
of three or more Couinaud segments. Postoperative complications were scored 
according to the Clavien-Dindo classification. The institutional review board of 
each participating institutional approved this study. 
Statistical analysis
Summary statistics were provided as whole numbers and percentages for categori-
cal variables and medians with interquartile range (IQR) for continuous variables. 
The primary outcome of interest was OS, defined as the time interval between the 
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date of surgery and the date of death or last available follow-up, as appropriate. 
Estimates for OS were calculated using the Kaplan-Meier method. Differences 
in survival between patient groups were assessed using the Mantel-Haenszel test. 
A Cox proportional hazards model was built to identify potential risk factors for 
overall survival. Specifically, patient and disease factors evaluated included age, 
sex, primary tumor size, T-stage, histologic grade, lymph node metastases, margin 
status, and tumor invasion (vascular and / or perineural). Results from the Cox 
models were subsequently reported as hazard ratios (HR) and corresponding 95% 
confidence intervals (CI). 
Conditional survival was defined as the probability of surviving an additional 
number of “y” years given that a patient had already survived for “x” years and was 
calculated as CS(y|x)=S(x+y)/S(x), with S(x) representing the OS at x years estimated 
using the Kaplan-Meier method. For example, the CS for surviving another year 
among patients who had already survived 4 years, CS(1|4), was calculated by divid-
ing the 5-year Kaplan-Meier survival estimate S(5) by the 4-year Kaplan-Meier 
survival estimate S(4). In some cases we were unable to give an estimate of 3-year 
conditional survival, because no events occurred within the 3-year interval. In 
these cases we did not give an estimation.8,9,13,14 Differences in CS were assessed 
using linear regression and standardized differences. Standardized differences (d) 
can be used as the index to contrast 2 rates such that d < 0.1 represents very 
small differences; 0.1 ≤ d < 0.3, small differences; 0.3 ≤ d < 0.5, moderate differ-
ences, and d ≥ 0.5, considerable differences. All analyses were performed using 
SPSS 22.0 (IBM, New York). All tests were 2-sided and p<0.05 defined statistical 
significance.
Results
Demographic and Clinicopathologic Characteristics
A total of 242 patients who underwent curative intent surgery for HC and met 
inclusion criteria were identified (table 1). The median patient age was 67 years 
(IQR 57-73) with a majority of patients being male (n=140, 57.9%) and Cau-
casian (n=184, 78.3%). Neoadjuvant chemotherapy was administered to 4.1% 
(n=10) of patients, whereas only 2.5% (n=6) of patients received neoadjuvant 
radiotherapy. At the time of surgery, the majority (n=179, 74.9%) of patients 
underwent a major hepatic resection; 239 (98.8%) patients underwent an open 
resection, whereas 1 patient underwent a laparoscopic resection and 2 patients 
underwent a laparoscopic resection that was converted to an open procedure. A 
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Table 1. Demographic and Clinicopathologic Characteristics
Variable N, (%) / Median (IQR)
Age, y 67 (57-73)
< 65 110 (45.5)
≥ 65 132 (54.5)
Sex
Male 140 (57.9)
Female 102 (42.1)
Race
Caucasian 184 (78.3)
African American 17 (7.2)
Other 34 (14.5)
BMI 25.1 (22.2-28.6)
Functionally Independent 217 (98.2)
Comorbidities
Hypertension 99 (43.2)
History of Cardiac Disease 26 (11.4)
Diabetes 36 (15.7)
Preoperative Jaundice 190 (79.2)
Type of Resection
Minor Resection (< 3 Couinaud Segments) 60 (25.1)
Major Resection (≥ 3 Couinaud Segments) 179 (74.9)
Margin Status
R0 160 (66.1)
R1 82 (33.9)
Tumor Size 2.5 (1.8-3.9)
≤ 2.5 cm 116 (51.1)
> 2.5 cm 111 (48.9)
Grade
Well Differentiated 43 (19.1)
Moderately/poorly differentiated 182 (80.9)
Bismuth-Corlette Class
I 28 (12.6)
II 37 (16.6)
IIIa 58 (26.0)
IIIb 47 (21.1)
IV 53 (23.8)
AJCC 7th Edition Stage
Stage I & II 114 (58.2)
Stage III & IV 82 (41.8)
AJCC T-stage
T1-T2 157 (80.1)
T3-T4 39 (19.9)
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portal vein resection was performed in 19 (7.9%) patients; 4 patients had a formal 
segmental portal vein resection and reconstruction. On final histopathology, 82 
(33.9%) patients had a positive (R1) surgical margin. The median tumor size was 
2.5 cm (1.8-3.9) and the majority of tumors were classified as moderately dif-
ferentiated (n=131, 58.2%). Nodal disease was observed in 79 (32.6%) patients 
while 160 (77.3%) patients had tumors with perineural invasion. 
Following surgery, 150 (64.4%) patients developed a postoperative complication, 
83 (56.4%) of which were classified as grade III or higher.  The most common 
complications were intra-abdominal abscesses and fluid collections requiring 
percutaneous drainage, which were observed in 18.6% (n=43) and 21.8% (n=51) 
of patients, respectively. 
Factors Associated with Overall Survival
The median actuarial OS among all patients was 22.3 months with an estimated 
1-, 3- and 5-year OS of 75.6% (95%CI 69.9-81.2), 46.3% (95%CI 39.3-53.0) 
and 18.2% (95%CI 12.6-24.6), respectively (Figure 1).  On Cox regression 
analyses, several patient and disease specific characteristics were associated with a 
worse OS. Specifically, age at diagnosis >65 years (HR 1.36, 95%CI 1.01-1.85, 
p=0.04), a greater T-stage (AJCC 7th T-Stage III or IV; HR 1.73; 95% CI 1.14-
2.61; p=0.009), presence of nodal metastasis (HR, 1.71; 95% CI, 1.24-2.36, 
p=0.001), and overall advanced disease stage (AJCC Stage III-IV; HR 1.81; 95% 
CI 1.27-2.58, p=0.001) were each associated with worse OS.
Comparison of Overall and Conditional Survival
In contrast to actuarial OS, which was observed to decrease from the time of 
surgery, estimates for CS increased over time as surviving patients accrued more 
survival time (Figure 2). For example, while actuarial OS decreased from 26.6% at 
Table 1. Demographic and Clinicopathologic Characteristics (continued)
Variable N, (%) / Median (IQR)
Lymph Node Metastases
No 163 (67.4)
Yes 79 (32.6)
Lymphovascular Invasion
No 118 (60.8)
Yes 76 (39.2)
Perineural Invasion
No 47 (22.7)
Yes 160 (77.3)
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Figure 1. Overall survival among all patients undergoing curative intent surgery for hilar cholan-
giocarcinoma.
 
261 
 
Figure 2 
  
0
10
20
30
40
50
60
0 1 2 3 4 5
3-
y 
Su
rv
iv
al
, %
Time After Surgery, y
Conditional Actuarial
Figure 2. A comparison of 3-year actuarial survival and 3-year conditional survival among all pa-
tients undergoing a curative intent surgery for hilar cholangiocarcinoma.
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4 years to 9.9% at 8 years following surgery, 3-year conditional survival (CS3) was 
noted to increase from 35.0% at 1-year versus 54.4% at 5-years following surgery. 
Of note, the 3-year CS estimates given the patient had already survived for 1-, 2-, 
and 5-years were 35.0%, 39.3%, and 54.4%, respectively (Table 2).
Table 2. Conditional Survival
Total Survival 
Time, y
If the Patient Has Survived. %
1 y 2 y 3 y 4 y 5 y 6 y 7 y
1
2 60.8
3 44.9 73.9
4 35.0 57.5 77.8
5 23.9 39.3 53.2 68.4
6 17.6 28.9 39.2 50.4 73.6
7 14.7 24.2 32.7 42.1 61.5 83.6
8 13.0 21.4 28.9 37.2 54.4 73.9 88.4
Patients who reach a certain survival point after resection of intrahepatic cholangiocarcinoma given 
that they have already survived a certain amount of time (%). For example, if a patient has survived to 
3 years, the survival probability of reaching 5 years of total survival is 53.2%.
To further compare differences in actuarial OS versus CS, additional analyses 
were performed stratified by clinicopathologic characteristics such as age, nodal 
status, depth of invasion, as well as margin status and tumor stage. As expected, 
older patient age, the presence of nodal metastasis, perineural invasion, T3/T4 
disease, as well as advanced overall AJCC stage were all associated with decreased 
actuarial OS (all p<0.05, Table 3). For example, patients with nodal metastases 
had a substantially worse 5-year actuarial OS (8.7%) versus patients without nodal 
disease (22.7%) (p=0.001).  Similarly, the 5-year actuarial OS for patients with 
stage I/II disease was 27.7% compared with 5.8% for patients with stage III/IV 
disease (p=0.001). Interestingly, CS3 estimates exceeded actuarial OS for patients 
in high-risk subgroups (Figures 3a-e). For example, among patients who had an 
R1 margin at the time of surgery, the “all comer” observed 5-year actuarial OS 
was 8.4%; however, among patients who had an R1 margin but survived to year 2 
following surgery, the chances of being alive an additional 3 years (i.e. CS3, based 
on being alive for 2 years a cumulative total of 5 years from surgery) was 22.8% 
(Δ=14.4%)(Table 4).  Differences in actuarial versus CS were also noted among 
patients with tumors characterized by adverse biologic features.  For example, 
among patients with perineural invasion the calculated actuarial 5-year OS was 
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Table 3. Overall Survival Stratified by Risk Factors
Variable
Patient Survival, % P 
Value*1 y 3 y 5 y 8 y
All Patients 75.6 (159) 34.2 (58) 18.2 (23) 9.9 (9)
Age, y
< 65 81.2 (78) 36.8 (29) 20.7 (12) 11.4 (4) 0.048
≥ 65 70.7 (80) 31.9 (28) 15.9 (10) 8.7 (4)
Sex
Male 80.8 (96) 31.8 (32) 17.8 (12) 8.3 (4) 0.687
Female 68.8 (62) 37.0 (25) 18.6 (10) 12.2 (5)
Margin Status
R0 77.7 (109) 37.5 (39) 23.6 (19) 11.9 (7) 0.056
R1 71.4 (49) 27.7 (18) 8.4 (3) - (1)
Tumor Size
≤ 2.5 cm 73.2 (77) 35.4 (30) 21.3 (13) 5.0 (2) 0.744
> 2.5 cm 79.3 (74) 35.3 (26) 17.3 (10) 15.4 (8)
Grade
Well Differentiated 77.6 (31) 42.6 (15) 17.8 (4) 0.0 (0) 0.562
Moderately/poorly differentiated 73.7 (114) 30.3 (36) 17.8 (15) 12.7 (7)
AJCC Stage
Stage I & II 79.3 (75) 45.6 (32) 27.7 (15) 18.2 (7) 0.001
Stage III & IV 68.5 (48) 21.1 (11) 5.8 (2) 0.0 (0)
AJCC T-stage
T1-T2 74.6 (98) 40.1 (39) 24.3 (16) 14.3 (6) 0.008
T3-T4 75.0 (25) 15.3 (4) 0.0 (0) 0.0 (0)
Lymph Node Metastases
No 80.3 (112) 40.1 (45) 22.7 (19) 13.2 (9) 0.001
Yes 66.2 (46) 22.3 (12) 8.7 (3) 0.0 (0)
Lymphovascular Invasion
No 82.9 (80) 41.7 (32) 24.2 (14) 6.1 (2) 0.067
Yes 67.1 (45) 26.1 (12) 15.2 (5) - (3)
Perineural Invasion
No 85.9 (34) 47.8 (15) 34.5 (10) 21.6 (3) 0.040
Yes 72.3 (102) 29.8 (33) 15.4 (14) 5.9 (3)
Overall survival Kaplan-Meier estimates, the numbers provided are percentages of patients alive. Num-
ber of patients at risk is depicted between the parentheses. *P-value is determined using the Mantel-
Haenszel test.
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only 15.4% versus an estimated CS3 at 2 years of 37.6% (Δ=22.2%).  Similarly, 
patients with nodal disease had an estimated 5-year actuarial OS of 8.7% based 
on actuarial data calculated from the time of their operation.  In contrast, among 
patients with nodal metastasis who had survived 2 years, the estimate that these 
patients would still be alive in another 3 years was much higher, with an estimated 
CS3 of 29.7% (Δ=21.0%).   
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Figure 3. A comparison of 3-year conditional survival by (a) age (b) margin status (c) AJCC 7th 
edition tumors stage (d) presence of lymph node metastases (e) presence of perineural invasion
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Discussion
HC is the most common malignancy of the biliary tract, accounting for up to 
two-thirds of all cases of cholangiocarcinoma.1,2 HC has traditionally been as-
sociated with a poor prognosis with 5-year survival ranging from 11-42% among 
patients following curative surgical resection. Given this, identifying high-risk 
patients is important to guide decisions pertaining to treatment, surveillance and 
/ or palliation. Although prognostic classification systems have been proposed 
for HC, these schemes are limited because data are only derived from the time of 
surgery.15 As such, these traditional survival estimates do not account for changes 
Table 4. 3 Year Conditional Survival Stratified by Risk Factor
Variables
Time Elapsed Since Operative Resection
0 y 1 y 2 y 3 y 4 y 5 y
All Patients 34.2 35.0 39.3 39.2 42.1 54.4
Age, y
< 65 36.8 35.7 39.9 45.1 49.0 55.1
>= 65 31.9 34.2 38.3 34.2 35.5 54.7
d 0.10 0.03 0.03 0.23 0.27 0.01
Margin Status
R0 37.5 42.1 46.1 44.3 41.6 50.4
R1 27.7 21.4 22.8 30.3 53.8 -
d 0.21 0.46 0.51 0.29 -0.25 -
AJCC Stage
I & II 45.6 41.2 48.9 51.3 55.0 65.7
III & IV 21.1 24.5 17.3 27.5 34.5 -
d 0.54 0.36 0.71 0.50 0.42 -
AJCC T-stage
T1-T2 40.1 39.7 48.7 52.1 62.9 58.8
T3-T4 15.3 15.3 - - - -
d 0.58 0.57 - - - -
Lymph Node Metastases
No 40.1 40.5 41.4 40.4 40.6 58.7
Yes 22.3 21.9 29.7 39.0 60.0 -
d 0.39 0.41 0.25 0.03 -0.40 -
Perineural Invasion
No 47.8 44.2 56.9 60.3 56.8 62.6
Yes 29.8 30.1 37.6 31.9 35.9 38.3
d 0.38 0.29 0.40 0.59 0.43 0.50
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in survival probability over time accrued from the initial diagnosis.8,9 In contrast, 
CS estimates account for changes in survival probabilities over time and therefore 
may be more accurate in predicting long-term survival.8,9 Although previously 
reported for patients with bladder, gastric and colon cancer, to the best of our 
knowledge no previous report has assessed conditional survival among patients 
with HC. The current study is important because we were able to define CS 
estimates for patients undergoing curative intent surgery for HC using a large, 
multi-centric cohort of patients. Of note, CS estimates increased over time and 
were consistently higher than traditional OS estimates. To further explore differ-
ences in conditional and actuarial survival estimates, additional stratified analyses 
were performed using certain demographic and clinicopathologic characteristics. 
Interestingly, CS estimates were consistently higher among all patient strata with 
the magnitude of differences between CS and actuarial OS estimates highest 
among patients with high-risk factors traditionally associated with a worse OS 
such as perineural invasion and nodal metastasis. 
In describing prognosis following surgery, most studies report survival based on a 
Kaplan Meier survival curve determined from factors derived at the time of surgery. 
While traditionally used to estimate survival, such curves have been criticized as 
being inaccurate due to their “static” nature.7  Rather than being fixed, in reality, 
the odds that a patient survives for an additional future period of time changes 
as the patients accrues survival time.8,9 As such, in order to be more clinically 
meaningful to patients and providers, survival data should chart the way the odds 
of survival change over time. Unlike traditional survival estimates, CS estimates a 
patient’s survival odds given the pre-condition of having already survived a certain 
length of time. In fact, for a wide range of advanced cancers, including cancers with 
a particularly poor prognosis, there is evidence that the odds actually do improve 
with time.9,13,14,16,17  Our group has previously demonstrated that CS estimates 
may provide critical quantitative information about the changing probability of 
survival over time among patients with gastric cancer, gastrointestinal stromal tu-
mors, pancreatic cancer, as well as intrahepatic cholangiocarcinoma.9,14,16,17  For 
example, among patients with intrahepatic cholangiocarcinoma, we previously 
noted that, while actuarial OS decreased over time from 39% at 3 years to 16% at 
8 years, the 3-year CS increased over time among those patients who survived.14 
Specifically, the CS3 at 5 years (i.e. the probability of surviving to postoperative 
year 8 after having already survived to postoperative year 5) was 65% compared 
with a predicted 8-year actuarial OS of 16%. Of course, time since diagnosis is 
not the only factor that can affect prognosis, as clinical and tumor specific factors 
can also be drivers of long-term outcome. 
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In the current analysis of 242 patients, the median actuarial overall survival was 
22.3 months. Consistent with previous reports, the current study identified pa-
tient age, T-stage, nodal status, presence of perineural invasion, margin status, as 
well as overall AJCC stage as important adverse prognostic factors.18-20  Perhaps 
of greater interest, data from the current study demonstrated that these clinical 
and tumor characteristics were not “universally” associated with a prohibitively 
poor prognosis.  In fact, while a lower actuarial survival was noted among patients 
demonstrating these adverse prognostic factors, the greatest improvement in CS 
was also noted among these subgroups of patients. For example, patients with 
nodal disease demonstrated an increase in CS of over 20% compared with pa-
tients who did not have nodal metastases.  The reasons for differences in actuarial 
versus CS survival estimates is likely related to the fact that traditional actuarial 
estimates of survival are disproportionately influenced by high-risk patients many 
of whom may die within the first few years of surgery.  However, those patients 
with high risk features who do live longer have in a sense “out-lived” some of 
the prognostic impact of these initial adverse factors.14  In turn, the prognosis 
of patients who initially had the worse prognostic factors, but who are still alive 
after a period of time, are the most likely to have their future long-term prognosis 
inaccurately predicted using traditional actuarial survival estimates. As such, the 
use of CS to provide information on long-term prognosis is likely to be valuable 
in estimating long-term survival for patients with diseases that traditionally have 
a poor prognosis, such as HC.
Several limitations should be considered when interpreting results from the cur-
rent study. Inherent to all retrospective analyses, there may have been a selection 
bias regarding the diagnosis and treatment of patients.  In addition, the use of data 
from a multi-institutional cohort did not allow for the standardization of opera-
tive and / or perioperative approach among centers. However, given the rarity of 
HC, the use of data from multiple centers ensured a uniquely large sample size 
while also making our results more generalizable.
In conclusion, using a large, multi-institutional cohort of patients, we observed 
that overall survival following curative intent surgery for HC varied as a function 
of the survival time accrued since surgical resection. The relative improvement in 
CS estimates was greatest among that subgroup of patients with high risk factors. 
CS estimates can be used to provide important quantitative information regard-
ing the changing probability of survival over time among patients with HC.  In 
turn, CS may facilitate more accurate prognostication while also aiding in clinical 
decision making. 
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Abstract
Background: While survival after malignancies is traditionally reported as 
actuarial survival, conditional survival (CS) may be more clinically relevant by 
accounting for “accrued” survival time as time progresses.  We sought to compare 
actuarial and CS among patients with gallbladder carcinoma (GBC).
Methods: 312 patients who underwent curative intent surgery for GBC between 
2000 and 2014 were identified using a multi-institutional database. Overall sur-
vival (OS) was estimated using the Kaplan-Meier method. CS was calculated as 
the probability of surviving an additional 3 years at year “x” after surgery using 
the formula CS3=S(x+3)/Sx.
Results: Among all patients, the median actuarial OS was 24.8 months (IQR 13.3-
88.9). While actuarial survival decreased over time, 3-year CS (CS3) increased, 
with CS3 at 2 years after surgery noted to be 61.8% compared with the 5-year 
actuarial OS of 31.6%. Factors associated with reduced actuarial OS were positive 
margin status (HR=3.61, 95%CI=2.47-5.26), increasing tumor size (HR=1.02, 
95%CI=1.01-1.02), higher tumor grade (HR=2.98, 95%CI=1.47-6.04), residual 
disease at re-resection (HR=2.78, 95%CI=1.49-3.49, p<0.001), and lymph node 
metastasis (HR=1.95, 95%CI=1.39-2.75, all p<0.001). The calculated CS3 ex-
ceeded the actuarial survival within each high-risk patient subgroup. For example, 
patients with residual disease at re-resection had an actuarial survival 23.1% at 5 
years versus a CS3 of 56.3% in patients alive at 2 years (Δ=33.2%).
Conclusion: CS provides a more accurate, dynamic estimate for survival, espe-
cially among high-risk patients. CS estimates can be used to accurately predict 
survival and guide clinical decision-making.
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Introduction
With an annual incidence of 2.2 per 100,000, gallbladder cancer (GBC) repre-
sents the most common cancer of the biliary tract and the sixth most common 
malignancy of the gastrointestinal tract.1-4 However, there are marked variations 
in incidence and risk factors for GBC by gender, ethnicity and geographical re-
gion.1-5 For example, while one of the most common causes of cancer mortality 
in India and Chile, GBC is less frequently encountered in the United States and 
Europe.1-4 The relative rarity of GBC in these regions has therefore limited large, 
randomized clinical trials to guide management, with most previous reports being 
single-institutional, retrospective series.5-8 Furthermore, previous reports have 
often categorized GBC with other biliary tract cancers, making the applicability 
of the existing literature questionable.9
Although less than 10% of all patients are amenable to surgery, complete surgical 
resection remains the only option for cure, with a 5-year survival  ranging from 
5-26%.8,10-14 Despite the adoption of a radical surgical approach, a majority of 
patients who undergo a potentially curative surgical resection eventually develop 
recurrent metastatic disease.8,10,11 Given this, reliable prognostic tools are required 
to aid patients and surgeons in decisions pertaining to surgery, adjuvant therapy, 
surveillance and palliation. Currently three prognostic classification schemes are 
commonly used to predict survival among patients with GBC; the Nevin staging 
system, the Japanese Society of Biliary Surgery (JSBS) staging system and the 
American Joint Committee on Cancer (AJCC) prognostic schema.15-17 While 
these classification tools offer an important overall prognostic assessment, each 
is limited in the ability to predict long-term survival accurately. Specifically, con-
structed using data collected at the time of surgery / diagnosis, these prognostic 
schemes are unable to account for the varied prognosis among patients who have 
already survived for a period of time after surgery.18 To this point, previous research 
from our own group as well as others has demonstrated that traditional estimates 
for overall survival (OS) rely too heavily on static risk factors determined at the 
time of surgery and are therefore disproportionately influenced by patients who 
die shortly following surgery.18-25 Given this, conditional survival (CS), which 
accounts for the time a patient has already survived following surgery / diagnosis, 
has been proposed as a more accurate estimate of long-term survival.21-23 
While the use of CS in predicting long-term survival has been assessed among 
patients with colorectal, bladder and pancreatic cancer, to the best of our knowl-
edge, no previous research has reported on the use of CS among patients with 
GBC.18-2523,26 Therefore, the aim of the current study was to define conditional 
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survival among patients with GBC using a large, multi-institutional cohort of 
patients. In particular, we sought to assess the impact of relevant patient and 
disease-specific characteristics on CS among patients undergoing surgery for GBC.
Methods
Data Sources and Patient Population
Sociodemographic and clinicopathologic data was collected for all patients un-
dergoing surgery for GBC between January 1, 2000, and December 31, 2014 
at ten academic institutions in the US (Johns Hopkins University, Baltimore, 
Maryland; Emory University, Atlanta, Georgia; Stanford University, Stanford, 
California; University of Wisconsin, Milwaukee, Wisconsin; Ohio State Univer-
sity, Columbus, Ohio; Washington University, St. Louis, Missouri; Vanderbilt 
University, Nashville, Tennessee; New York University, New York, New York; 
University of Louisville, Louisville, Kentucky; Wake Forest University, Winston-
Salem, North Carolina). Specifically, sociodemographic data collected included 
age, sex and race while clinicopathologic characteristics recorded included tumor 
size, AJCC-T-stage, histologic grade, presence of nodal disease, final resection 
margin and the presence of vascular and / or perineural invasion. Tumor size was 
defined using the diameter of the largest tumor within the resected specimen as 
per the 7th edition of the AJCC staging system. Histologic grade was defined as 
either well, moderate, or poorly differentiated. Using the final pathologic report, 
the presence of disease at the resection margin (R0: no disease at resected margin, 
R1: presence of disease at the resected surgical margin) and the presence of lymph 
node metastases was determined.
Only patients undergoing a curative intent surgery for histologically confirmed 
GBC were included in the final study population. To minimize potential con-
founding, patients who died within 30 days of their surgery were excluded from 
further analysis. This study was approved by the institutional review board of each 
participating institution.
Statistical analysis
Categorical variables were described as whole numbers and percentages while 
continuous variables were reported as medians with interquartile (IQR) range. 
OS was calculated as the time from the date of surgery to the date of death or 
date of last available follow-up and estimated using the Kaplan-Meier method. 
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The Mantel-Haenszel test was used to compare differences in OS between patient 
groups. Associations between OS and potential risk factors (size of primary tumor, 
AJCC T-stage, histologic grade, lymph node metastases, margin status, and tumor 
invasion and the presence of residual disease requiring re-resection) were evalu-
ated using Cox proportional hazards regression analyses and reported as hazard 
ratios (HR) with corresponding 95% confidence intervals (95% CI). Conditional 
survival was calculated as the probability of surviving an additional number of 
“y” years given that a patient has already survived for “x” years using the formula 
CS(y|x)=S(x+y)/S(x), with S(x) representing OS at x years.18 Differences in CS were 
compared using linear regression analyses and standardized differences (d).27,28 
All analyses were performed using SPSS 22.0 (IBM, New York). A p<0.05 was 
used to define statistical significance.
Results
Demographic and Clinicopathologic Characteristics
A total of 312 patients were identified who met inclusion criteria. Among the en-
tire cohort, the median age was 66 years (IQR 56-73) with two-thirds of patients 
being female (n=208, 66.7%; Supplemental Table 1). The most common race / 
ethnicity was Caucasian (n=208, 71.7%) followed by African-American (n=39, 
13.4%) and Asian (n=20, 6.9%). Although 93.6% (n=250) of patients were clas-
sified as functionally independent at the time of surgery, comorbidities were com-
monly noted among the study cohort. Specifically, hypertension (n=157, 58.8%), 
diabetes mellitus (n=66, 24.7%), and a history of heart disease (n=32, 11.9%) 
were the most commonly noted comorbidities with 52 (19.5%) patients being 
either active smokers or having quit smoking in the 6 months prior to surgery. 
The most commonly performed surgery was a radical cholecystectomy (n=240, 
77.2%) with a majority of patients undergoing an open surgery (n=285, 91.9%). 
A negative microscopic margin (R0) was obtained in 85.4% of patients (n=264). 
The median tumor size was 3.0 cm (2.0-5.0) and a majority of tumors were clas-
sified as either T1 (n=24, 8.2%) or T2 (n=126, 43.2%) based on the 7th edition 
AJCC staging system. Similarly, most tumors were graded as either moderately- 
(n=141; 53.8%) or poorly- (n=91; 34.7%) differentiated. Lymph node metastases 
were noted in 122 (45.7%) patients and lymphovascular or perineural invasion 
noted in 49.4% (n=89) and 52.8% (n=94) of patients, respectively. 
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Actuarial Overall Survival and Risk Factors for Overall Survival
The median actuarial OS among all patients was 24.8 months (IQR 13.3-88.9) 
with 1-, 3-, and 5-year survival being 76.9%, 40.7%, 31.6%, respectively. OS 
was noted to decrease from 76.9% (95%CI 71.2-81.6) 1 year following surgery 
to 31.6% (95%CI 24.9-38.6) at postoperative year 5. At 10 years following 
surgery, survival was only 18.4% (95%CI 10.9-27.4, Figure 1a). On Cox pro-
portional hazards analyses, a microscopically positive surgical margin (HR 3.61, 
95%CI 2.47-5.26, p<0.001), increasing tumor size (HR 1.02; 95%CI 1.01-1.02, 
p<0.001), worse tumor grade (HR 2.98, 95%CI 1.47-6.04, p=0.002), the pres-
ence of residual disease requiring re-resection (HR 2.78, 95%CI 1.49-3.49, 
p<0.001), and lymph node metastases (HR 1.95, 95%CI 1.39-2.75, p<0.001) 
were all associated with a worse OS. 
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Figure 1. (a) Actuarial overall survival for the entire study cohort (b) Comparison of 3-year actu-
arial overall survival and 3-year conditional survival. 
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Comparison of Actuarial and Conditional Survival 
While the actuarial OS was noted to decrease with time, CS increased with time 
from the date of surgery. Specifically, the 3-year conditional survival (CS3), de-
fined as the probability of surviving an additional 3 years, increased from 48.6% 
among patients who were still alive at 1 year following surgery to 61.8% among 
patients who were alive 2 years following surgery.  In fact, among patients who 
had survived to 5 years following surgery the chance of survival to year 8 (i.e. CS3 
based on 5-year survival) was 78.2% (Figure 1b, Table 1). 
Table 1. Conditional Survival Entire Cohort
Total Survival Time, 
y
If the Patient Has Survived. %
1 y 2 y 3 y 4 y 5 y 6 y 7 y
1  
2 66.4  
3 52.9 79.6  
4 48.6 73.2 91.9  
5 41.1 61.8 77.6 84.5  
6 37.3 56.2 70.5 76.7 90.8  
7 36.0 54.2 68.1 74.1 87.7 96.5  
8 32.1 48.3 60.7 66.0 78.2 86.1 89.2
The effect of patient and disease-specific characteristics on CS versus OS was then 
assessed via subgroup analyses of patients according to prognostic factors associated 
with survival on Cox regression analysis (Figure 2a-h). Factors including positive 
margin status, increasing tumor size, worse histological grade, a higher tumor T 
stage, lymph node metastases and lymphovascular or perineural invasion, as well 
as the presence of residual disease at re-resection were all associated with a worse 
OS. For example, 5-year actuarial survival was 38.0% (95%CI 10.9-27.4) among 
patients with a microscopically negative margin compared with 3.5% (95%CI 
0.3-14.7) among patients with a positive surgical margin. Similarly, among pa-
tients without residual disease, 5-year actuarial survival was 46.7% (95%CI 32.9-
59.4) compared with 23.1% (95%CI 12.4-35.8) among patients with residual 
disease (Table 2). In contrast, CS3 estimates were noted to increase with time from 
surgery among each patient subgroup and exceeded the OS within each strata. For 
example, patients with T3/T4 tumors demonstrated an actuarial survival of 9.7% 
at 8 years compared with a CS3 at 5 years of 75.2% (Δ=65.5%, Table 3). Similarly, 
patients with residual disease at re-resection demonstrated an 8-year actuarial OS 
of 15.0% compared with a CS3 at 5 years of 64.9% (Δ=49.9%).  Patients with 
lymph node metastases demonstrated an 8-year actuarial OS of 14.4% versus a 
CS3 at 5 years of 65.8% (Δ=51.4%). Of note, differences in CS3 and OS were less 
pronounced among patients within lower risk strata.
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Figure 2. A comparison of actuarial overall survival and 3-year conditional survival stratified by 
risk factor
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Table 2. Overall Survival Stratified by Risk Factor
Variable
Patient Survival, %
P Value2 y 5 y 8 y
All Patients 51.1 31.6 24.7  
Age, y  
< 65 53.6 37.5 27.0  
>= 65 49.0 26.4 22.7 0.427
Sex  
Female 49.2 30.5 21.9  
Male 54.8 34.0 31.4 0.642
Type of Resection  
Minor 55.1 34.2 26.4  
Major 22.6 0.0 0.0 0.002
Margin Status  
R0 57.9 38.0 29.6  
R1 14.0 3.5 - <0.001
Tumor Size  
<= 2.5 cm 59.1 41.8 38.0  
> 2.5 cm 38.4 21.0 21.0 0.007
Grade  
Well Differentiated 83.3 53.2 53.2  
Moderately differentiated 49.0 31.0 21.3  
Poorly differentiated 34.4 22.4 17.9 0.002
AJCC T-stage  
T1-T2 73.0 50.2 40.6  
T3-T4 26.8 12.9 9.7 <0.001
Lymph Node Metastases  
No 64.0 41.6 34.6  
Yes 37.8 21.9 14.4 <0.001
Lymphovascular Invasion  
No 67.6 34.0 30.2  
Yes 29.5 15.9 12.7 <0.001
Perineural Invasion  
No 68.2 41.4 37.6  
Yes 35.8 15.3 11.5 <0.001
Incidentally Discovered  
No 31.0 23.5 20.9  
Yes 61.3 35.3 26.2 0.001
Residual Disease Re-resection  
No 75.3 46.7 38.5  
Yes 41.0 23.1 15.0 <0.001
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Table 3. 3-year Conditional Survival Stratified by Risk Factor
Variables
Time Elapsed Since Operative Resection
0 y 1 y 2 y 3 y 4 y 5 y 
All Patients 40.7 48.6 61.8 70.5 74.1 78.2
Type of Resection  
Minor 43.9 52.4 62.1 70.6 73.0 77.2
Major 18.1 18.9 59.7 74.6 - -
D 0.58 0.75 0.05 -0.09 - -
Margin Status  
R0 45.4 51.2 65.6 75.8 78.6 77.9
R1 14.0 22.1 25.0 25.0 33.3 -
D 0.73 0.63 0.89 1.18 1.03 -
Tumor Size  
<= 2.5 cm 51.1 58.7 70.7 74.4 78.0 90.9
> 2.5 cm 32.1 37.7 54.7 65.4 79.8 -
D 0.39 0.43 0.34 0.20 -0.04 -
Grade  
Well Differentiated 62.0 70.3 63.9 85.8 - -
Moderately/Poorly differentiated 35.8 43.3 63.9 65.6 68.2 73.4
D 0.54 0.57 0.00 0.48 - -
AJCC T-stage  
T1-T2 58.5 62.0 68.8 78.6 78.9 80.9
T3-T4 19.1 26.8 48.1 67.5 77.7 75.2
D 0.88 0.76 0.43 0.25 0.03 0.14
Lymph Node Metastases  
No 54.5 60.5 65.0 76.3 74.9 83.2
Yes 26.9 37.2 57.9 61.0 56.5 65.8
D 0.59 0.48 0.15 0.34 0.39 0.41
Lymphovascular Invasion  
No 52.0 47.1 50.3 58.1 73.8 88.8
Yes 22.7 37.9 53.9 55.9 55.9 79.9
D 0.64 0.19 -0.07 0.04 0.38 0.25
Perineural Invasion  
No 57.3 61.6 60.3 65.6 72.9 90.8
Yes 26.2 31.9 42.7 43.9 54.8 75.2
D 0.66 0.62 0.36 0.45 0.38 0.43
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Discussion
Although less than 10% of patients are amenable to surgery, complete surgical 
resection remains the only option for cure for patients with GBC with less than 
a third of patients surviving to 5 years.1-4 Given the relative rarity of GBC in the 
United States and Europe, there are relatively few data reporting on long-term 
survival following surgery for GBC. In addition, most reports on GBC utilize 
data from single-institutional, retrospective series that often categorize GBC with 
other biliary tract cancers, thereby limiting the applicability of the data.5-7 The 
current study is important in that it reports on long-term survival among a large 
cohort of patients undergoing surgery for GBC at 10 academic centers in the US. 
Using Cox proportional hazards regression analysis we were able to identify risk 
factors associated with a worse OS including advanced T-stage, the presence of 
nodal disease and a microscopically positive surgical margin. Perhaps of greater 
importance, we assessed the use of conditional survival to estimate long-term 
survival among a cohort of 312 patients who underwent resection and noted that 
survival increased among the subset of patients who survived varied periods of 
time from surgery. Furthermore, marked differences in conditional and actuarial 
survival were also observed when patients were categorized based on the observed 
risk factors. Interestingly, while conditional survival was consistently higher than 
actuarial survival among all patient subgroups, the effect was most pronounced 
among patients in those subgroups characterized by high risk factors.
For patients undergoing curative intent resection of GBC, the median actuarial 
survival was only 24.8 months. In addition, several patient and disease charac-
teristics were strongly associated with worse long-term prognosis. Specifically, 
microscopically positive margins, increasing tumor size, a worse tumor grade, the 
Table 3. 3-year Conditional Survival Stratified by Risk Factor (continued)
Variables
Time Elapsed Since Operative Resection
0 y 1 y 2 y 3 y 4 y 5 y 
Incidentally Discovered  
No 29.6 42.4 75.8 70.6 75.5 88.9
Yes 46.0 50.5 57.6 70.0 73.0 74.2
D -0.34 -0.16 0.39 0.01 0.06 0.39
Residual Disease Re-resection    
No 59.0 61.4 62.0 79.2 84.9 82.4
Yes 30.6 38.2 56.3 58.8 53.0 64.9
D 0.60 0.48 0.12 0.45 0.73 0.41
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presence of residual disease, as well as the presence of lymph node metastases 
were all associated with a worse OS. Similar to data in the current study, Duffy 
and colleagues reported a median actuarial survival of 30.3 months in a single-
institutional review of patients with GBC.7 Factors associated with a decreased 
survival also included microscopically positive margins on final histopathology, as 
well as residual disease at the time of re-resection.7  Similarly, de Aretxabela et al. 
also noted a worse actuarial survival among patients undergoing surgical resection 
for tumors classified as AJCC 7th Edition T3/T4 disease.5,29 Collectively, results 
from the current study and previous reports highlight the ability of using certain 
risk factors to classify patients into different prognostic subgroups thereby aiding 
in patient and provider decision making. 
Currently, these risk factors have been incorporated into three existing prognostic 
schemes to risk-stratify patients undergoing surgery for GBC: the Nevin staging 
system, the Japanese Society of Biliary Surgery prognostic scheme and the AJCC 
staging system.15-17 These staging systems, however, may be limited because each 
one relies exclusively on data collected at the time of surgery and therefore can-
not account for survival time accrued after surgery. In contrast, estimates for CS 
define survival probability, given the pre-condition of having already survived a 
certain length of time. To this point, in the current study, we sought to investigate 
the use of CS in predicting long-term survival following surgery for GBC. In 
contrast to actuarial survival, which was noted to decrease with time, estimates 
for CS improved as the life-time accrued from the date of surgery increased. In 
fact, upon stratified analyses, the difference between predicted actuarial survival 
and CS was greater among that strata of patients who had tumors characterized by 
traditionally poor risk factors.  For example, among patients with T3/T4 tumors, 
8-year actuarial survival was only 9.7% compared with a CS3 at 5 years of 75.2%. 
Similarly, patients with nodal metastasis demonstrated an 8-year actuarial survival 
of 14.4% versus a CS3 at 5 years of 65.8%.  In effect, these data suggest that 
among patients who had T3/T4 or nodal disease who survived to 5 years, that 
these patients had a markedly better chance of living an additional 3 years than 
what would have been predicted at the time of surgery (Δ65.5% and Δ51.4%, re-
spectively).  These results are consistent with previous reports from our own group, 
as well as others, highlighting the potential for inaccurately estimating prognosis 
among patients who have survived a period of time following surgery.21-26  In fact, 
the greatest increase in CS – and therefore difference from actuarial survival – was 
among patients who had the highest initial risk of death suggesting that as the 
time from surgery increases, the prognostic impact / importance of certain risk 
factors collected at the time of surgery decreases.19 Under these circumstances, the 
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use of CS which accounts for life years accrued can serve as a more valuable tool 
in predicting long-term survival. 
Results of the current study should be interpreted with the following limitations. 
First, while the use of a large multi-institutional database allowed for a large sample 
size and therefore an adequately powered analysis, we were unable to control for 
differences in clinical and operative practices between the 10 centers. As such, 
this may have resulted in some residual confounding of our results. Second, given 
the retrospective nature of the analysis, we were unable to exclude any selection 
bias that may have occurred regarding the treatment of patients. However, to 
minimize this, we included only patients undergoing curative intent surgery as 
well as those who did not die within the immediate postoperative time period (30 
days). Furthermore, multiple sub-analyses were performed by prognostic factors 
to minimize the potential effect of differences in patient characteristics. 
In conclusion, estimates for overall survival were observed to be dynamic and 
increased with time from surgery. Patients presenting with factors associated with 
a poor prognosis demonstrated the most appreciable increase in conditional versus 
actuarial survival. Conditional survival can therefore be used to provide a more ac-
curate estimate for long-term prognosis among patients who have already survived 
over time and may serve as an important tool to inform patients and providers 
regarding adjuvant therapy, surveillance and palliation.  
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Supplemental Table 1
Variable N, (%) / Median (IQR)
Age, y 66.2 (55.9-73.0)
< 65 147 (47.1)
≥ 65 165 (52.9)
Sex
Male 208 (66.7)
Female 104 (33.3)
Race
Caucasian 208 (71.7)
African American 39 (13.4)
Other 44 (14.9)
BMI 27.5 (23.2-31.7)
Functionally Independent 250 (93.6)
Comorbidities
    Hypertension 157 (58.8)
    History of Cardiac Disease 32 (11.9)
    Diabetes 66 (24.7)
Preoperative Jaundice 40 (14.4)
Type of Resection
    Minor Resection (< 3 Couinaud Segments) 280 (90.0)
    Major Resection (≥ 3 Couinaud Segments) 31 (10.0)
Margin Status
R0 264 (85.4)
R1 45 (14.6)
Tumor Size
≤ 2.5 cm 84 (42.4)
> 2.5 cm 114 (57.6)
Grade
Well Differentiated 30 (11.5)
Moderately/poorly differentiated 232 (88.5)
AJCC T-stage
T1-T2 158 (54.1)
T3-T4 134 (45.9)
Lymph Node Metastases
No 145 (54.3)
Yes 122 (45.7)
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Supplemental Table 1 (continued)
Variable N, (%) / Median (IQR)
Lymphovascular Invasion
No 91 (50.6)
Yes 89 (49.4)
Perineural Invasion
No 84 (47.2)
Yes 94 (52.8)
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Abstract
Background
Although radical re-resection for gallbladder cancer (GBC) has been advocated, 
the optimal extent of re-resection remains unknown. The current study aimed 
to assess the impact of common bile duct (CBD) resection on survival among 
patients undergoing surgery for GBC.
Methods
Patients undergoing curative-intent surgery for GBC were identified using a 
multi-institutional cohort of patients. Multivariable Cox-proportional hazards 
regression was performed to identify risk factors for a poor overall survival (OS).
Results
Among the 449 patients identified, 26.9% underwent a concomitant CBD resec-
tion. The median number of lymph nodes harvested did not differ based on CBD 
resection (CBD, 4 [IQR: 2–9] vs. no CBD, 3 [IQR: 1–7],  P  =0.108). While 
patients who underwent a CBD resection had a worse OS, after adjusting for 
potential confounders, CBD resection did not impact OS (HR =1.40, 95%CI 
0.87–2.27, P =0.170). Rather, the presence of advanced disease (T3: HR =3.11, 
95%CI 1.22–7.96,  P  =0.018; T4: HR =7.24, 95%CI 1.70–30.85,  P  =0.007) 
and the presence of disease at the surgical margin (HR =2.58, 95%CI 1.26–
5.31, P=0.010) were predictive of a worse OS.
Conclusions
CBD resection did not yield a higher lymph node count and was not associated 
with an improved survival. Routine CBD excision in the re-resection of GBC is 
unwarranted and should only be performed selectively.
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Introduction
Each year, it is estimated that 2.2 per 100,000 patients are diagnosed with gallblad-
der cancer (GBC) making it the sixth most common cancer of the gastrointestinal 
tract and the most common malignancy of the biliary tract in the United States 
1,2. Patients may be diagnosed incidentally following a routine cholecystectomy or 
may present late after symptoms develop 3,4. Regardless of presentation, the best 
option for potential cure among patients with GBC is complete surgical resection. 
Prognosis following surgical resection remains poor, however, with 5-year survival 
ranging from 10% to 90% depending on disease factors such as tumor grade, 
stage of disease, and the presence of lymph node metastasis 5-7.
Surgery for GBC typically involves a partial hepatectomy that can range from 
resection of the gallbladder fossa to a more formal anatomic resection of segments 
4b and 5 to an extended right hepatectomy 8,9. Furthermore, any oncologic-
directed operation for GBC should include a regional lymphadenectomy to assess 
for nodal disease to establish prognosis and the potential need for adjuvant therapy 
1,10. The role for excision of the common bile duct (CBD) is, however, more 
controversial 11-13. Due to a limited body of research as well as the variation in 
clinical practices among Eastern and Western centers, information on the role and 
potential benefit of CBD resection for GBC remains limited 3,11-18. For example, 
data from several previous reports have suggested that routine CBD resection be 
performed at the time of surgery, while other studies argue for a more selective 
approach 3,4,8-10,19. Accurate data on outcomes relative to the extent of resection, 
including the CBD, as well as data evaluating the impact of factors on clinical 
outcomes may help guide decisions. Therefore, the objective of the current study 
was to evaluate factors associated with resection of CBD resection, as well as assess 
the impact of CBD on peri-operative and long-term outcomes among patients 
undergoing curative-intent surgical resection of GBC using a large, multi-center 
database.
Methods
Data Sources and Study Population
Patients diagnosed with gallbladder cancer between January 1, 2000 and Decem-
ber 31, 2014 were identified using data collected from the Extra-hepatic Biliary 
Consortium. The Extra-hepatic Biliary Consortium represents a collaborative 
effort among 10 high-volume, academic medical centers across the United States 
(Johns Hopkins University, Baltimore, Maryland; Emory University, Atlanta, 
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Georgia; Stanford University, Stanford, California; University of Wisconsin, Mil-
waukee, Wisconsin; Ohio State University, Columbus, Ohio; Washington Uni-
versity, St. Louis, Missouri; Vanderbilt University, Nashville, Tennessee; New York 
University, New York, New York; University of Louisville, Louisville, Kentucky; 
Wake Forest University, Winston-Salem, North Carolina). Sociodemographic and 
clinicopathologic data were collected on all patients diagnosed with a malignancy 
of the biliary tract. Specifically, sociodemographic data included age, sex, and 
race, while clinicopathologic data included American Society of Anesthesiologists 
(ASA) physical performance score, preoperative functional status, tumor size, 
American Joint Commission on Cancer (AJCC) T-Stage, histological grade, pres-
ence of lymph node metastasis, presence of vascular and/or perineural invasion 
as well as the presence of disease at the final surgical resection margin (R0: no 
disease at resected margin, R1: presence of disease at the resected surgical margin) 
20. Tumor size, tumor grade, the presence of lymph node metastasis, and disease at 
the resection margin were determined using the final histopathology report. Ad-
ditionally, operative details pertaining to the type and extent of surgical resection 
were also recorded for each patient.
Only patients undergoing a curative intent surgical resection for histologically 
confirmed GBC were included within the study cohort. Patients who had macro-
scopic disease at the resection margin (R2 disease), presence of disease within N2 
nodes and patients with metastatic disease were excluded from the final analysis 
assessing the survival benefit of CBD resection. Incidental disease was defined 
as the identification of GBC following a routine cholecystectomy while non-
incidental disease was defined by the suspicion of gallbladder carcinoma prior to 
surgery. Overall survival (OS) was calculated from the date of initial surgery to 
the date of death or last follow-up, as appropriate. Death was confirmed for each 
patient using patient records as well as social security numbers/records. This study 
was approved by the Johns Hopkins Institutional Review Board as well as the 
institutional review boards of each institution participating in the Extra-hepatic 
Biliary Consortium.
Statistical Analysis
Categorical variables were presented as whole numbers and percentages, and 
compared using Pearson’s chi-squared test. Continuous variables were described as 
medians with interquartile (IQR) range and compared using the Kruskal–Wallis 
test. OS was estimated using the Kaplan–Meier method and compared between 
patient groups using the log–rank test. Factors associated with OS were examined 
using multivariable Cox proportional hazards regression analysis. Results from 
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the multivariable analysis were presented as hazard ratios (HR) with correspond-
ing 95% confidence intervals (95%CI). A P-value <0.05 was used to determine 
statistical significance. All analyses were performed using STATA version 14.0 
(StataCorp, College Station, TX).
Results
Baseline Demographic and Disease Characteristics
A total of 449 patients were identified who underwent surgical resection for GBC 
(Table I). The median age of all patients was 66.3 years (IQR: 57.1–73.1), while 
over two-thirds of patients were female (n =292, 65.0%) and white (n =305, 
67.9%). Although most patients were functionally independent at the time of 
surgery (n =363, 80.9%), comorbidity was common among the study cohort as 
63.3% (n =191) of patients were classified as either ASA physical classification 
grade III or IV. At the time of diagnosis, the median CA-19-9 was 26.8 units/ml 
(IQR: 14.5–172.6) while the median preoperative serum albumin and bilirubin 
were 3.7 g/dl (IQR: 3.2–4.1) and 0.7 mg/dl (IQR: 0.5–1.6), respectively. Among 
all patients, a radical cholecystectomy (n =343, 76.4%) was the most commonly 
performed operation followed by a simple cholecystectomy (n =46, 10.4%), and 
a more formal hepatectomy (n =46, 10.4%).
Comparison of Patient Characteristics by Common Bile Duct Resection
Among patients who were included in the final analysis, a CBD resection was 
performed in 109 patients (34.2%). While patient demographics were compa-
rable among patients who did and did not undergo a CBD resection, there were 
several differences in disease characteristics between the two patient groups (Table 
II). For example, patients who underwent a CBD resection were more likely to 
present with an advanced AJCC T-stage (AJCC T3 or T4: CBD, 57.0% vs. no 
CBD, 40.8%, P =0.002). Patients who underwent a CBD resection were more 
likely to undergo a concomitant lymphadenectomy; specifically, while 94.5% of 
patients who underwent a CBD resection had a least one lymph node sampled, 
only 81.5% of patients who did not undergo a CBD resection had a lymphad-
enectomy (P<0.001). Of note, the median number of lymph nodes harvested was 
comparable among patients who did and did not under go a CBD resection (me-
dian lymph nodes harvested: CBD, 4 [IQR: 2–9] vs. no CBD, 3 1-7, P =0.108). 
Patients who underwent CBD resection were, however, more likely to have lymph 
node metastasis. Specifically, among patients who underwent CBD resection, over 
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one-half of patients (n =57, 52.3%) had lymph node metastasis versus only a third 
of patients (n =68, 32.4%) who did not undergo a CBD resection (P <0.001).
Table 1 Baseline Characteristics by Common Bile Duct Resection
Characteristic
No CBD resection CBD resection
P-value
Total
328 73.10% 121 26.90% 449 100.00%
Age, years, median (IQR) 66.6 (56.8–73.29) 67.1 (58.9–72.9) 0.883 66.3 (57.1–73.1)
Sex         0.064    
 Male 123 37.5 34 28.1   157 35
 Female 205 62.5 87 71.9   292 65
Race         0.08    
 White 213 64.9 92 76   305 67.9
 Black 43 13.1 10 8.3   53 11.8
 Other 72 22 19 15.7   91 20.3
BMI, median (IQR) 28.1 (24.3–32.7) 25.9 (22.5–29.2)   27.5 (23.7–31.4)
ASA         0.159    
 I/II 76 34.4 35 43.2   111 36.8
 III/IV 145 65.6 46 56.8   191 63.3
Functional status         0.392    
 Independent 262 79.8 101 83.5   363 80.9
 Dependent 18 5.5 3 2.5   21 4.7
CA-19-9, median (IQR) 24 (15–157) 30 (11–281) 0.863 26.8 (14.5–
172.6)
Albumin, median (IQR) 3.7 (3.1–4.1) 3.8 (3.3–4.2) 0.239 3.7 (3.2–4.1)
Peak bilirubin, median 
(IQR)
0.7 (0.5–1.3) 0.8 (0.4–4.45) 0.472 0.7 (0.5–1.6)
Operation type         <0.001    
 Radical cholecystectomy 170 51.8 9 7.4   98 21.8
 Cholecystectomy only 60 18.3 6 5   66 14.7
 Bile duct resection only 2 0.6 8 6.6   10 2.2
 Hepatectomy +bile duct 
resection
7 2.1 17 14.1   24 5.4
 Other 89 27.1 9 7.4   98 21.8
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At the time of CBD resection, residual disease in the duct was found in 17 out 
of 121 (14.0%) patients. On final pathology, microscopic involvement of the bile 
duct (R1) margin was similar among patients who did (n =4) and did not (n =2) 
undergo CBD resection (P =0.442). Post-operatively, the incidence of complica-
tions was higher among patients undergoing a CBD (n =55, 48.3%) versus no 
CBD (n =109, 37.9%) resection (P =0.020).
Comparison of Risk Factors for Overall Survival
The median follow-up for the study cohort was 37.6 months (IQR: 12.3–82.1). 
Among all patients, median OS was 23.6 months (IQR: 12.0–88.9), while 1-, 2-, 
and 5-year OS were 74.9% (95%CI 69.2–79.6), 49.1% (IQR: 42.6–55.3), and 
31.2% (95%CI 24.6–38.0), respectively. Several patient and disease-specific risk 
factors were associated with a worse OS. Specifically, on univariable analysis, the 
presence of lymph node metastasis, presence of disease at the time of re-resection, 
a greater AJCC T-stage, presence of disease at the surgical margin, advanced tumor 
grade, and the presence of lymphovascular or perineural invasion was associated 
with worse OS. Similarly, patients who underwent a CBD resection had a worse 
median OS (19.2 months, IQR: 9.2–33.9) compared with patients who did not 
undergo a CBD resection (32.4 months, IQR: 15.2–110.3, Fig. 1). However, on 
stratified analyses that took into account CBD resection and lymph node status, 
Table 2 Tumor and Disease-Specific Characteristics by Common Bile Duct Resection
Characteristic
No CBD resection CBD resection
P-value
Total
210 65.80% 109 34.20% 319 100.00%
Tumor size, mm, median 
(IQR)
28 (18–47) 28 (18–47) 0.662 28 (18–47)
AJCC stage         0.002    
 T1 30 14.9 3 3.1   33 11
 T2 89 44.3 39 39.8   128 42.8
 T3 72 35.8 47 48   119 39.8
 T4 10 5 9 9.2   19 6.4
Lymph node metastasis         <0.001    
 Nx 39 18.6 6 5.5   45 14.1
 N0 103 49.1 46 42.2   149 46.7
 N1 68 32.4 57 52.3   125 39.2
Margin status         0.201    
 R0 181 87 89 81.7   270 85.2
 R1 27 13 20 18.4   47 14.8
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only the presence of lymph node metastasis was associated with a worse OS (Fig. 2a 
and b). To further investigate whether CBD resection was independently associ-
ated with OS, multivariable analyses were performed that accounted for compet-
ing clinicopathologic risk factors. After adjusting for potential confounders, an 
advanced AJCC T-stage (T3 vs. T1: HR =3.11, 95%CI 1.22–7.96, P =0.018; T4 
vs. T1: HR =7.24, 95%CI 1.70–30.85, P =0.007) and the presence of disease at the 
surgical margin (HR =2.58, 95%CI 1.26–5.31, P =0.010) were associated with an 
increased risk of death following surgical resection (Table III). Of note, resection 
of the CBD did not impact OS (HR =1.40, 95%CI 0.87–2.27, P=0.170).
Figure 1 Comparison of overall survival by common bile duct resection.
Figure 2 Comparison of overall survival by the presence of lymph node metastasis among patients 
who (a) underwent a common bile duct resection, (b) did not undergo a common bile duct resec-
tion.
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Table 3. Multivariable Analysis of Factors Associated With Overall Survival
Characteristic HR 95%CI P-value
Age 1.01 0.99 1.03 0.171
Sex
 Male Reference      
 Female 1 0.64 1.58 0.994
Residual disease at Re-resection 1.47 0.93 2.33 0.102
AJCC T-stage
 T1 Reference      
 T2 1.49 0.6 3.7 0.384
 T3 3.11 1.22 7.96 0.018
 T4 7.24 1.7 30.85 0.007
Lymph node metastasis
 N0 Reference      
 Nx 2.71 1.44 5.08 0.002
 N1 1.5 0.93 2.43 0.098
Margin status
 R0 Reference      
 R1 2.58 1.26 5.31 0.01
CBD resection
 No CBD resection Reference      
 CBD resection 1.4 0.87 2.27 0.17
Discussion
Prognosis following GBC remains poor with 5-year survival ranging from 10% 
to 90% depending on disease stage 21. While surgery remains the best chance at 
long-term survival, the extent of surgery, as well as the accurate identification of 
patients who would benefit most from surgical resection remains controversial 
1,8,9,22. In particular, whether the CBD should be routinely excised for GBC is 
unclear. While some surgeons routinely recommend the resection of the extra-
hepatic bile duct for GBC, other surgeons have advocated for a more selective 
approach given the possibility of post-CBD resection complications 15,23,24. Most 
studies to date have included, however, only small single center series, with most 
data coming exclusively from East Asian hospitals 9,11,12,14,23,25. The current study 
is important because it utilized the combined experience of 10 major hepatobili-
ary centers throughout the United States. In doing this, we were able to analyze 
a large cohort of patients with GBC to examine how often CBD resection was 
performed in these large tertiary centers, as well as define which factors were 
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associated with CBD resection. Among all patients who underwent surgery, nearly 
one in four patients (26.9%) had a concomitant CBD resection. Interesting, while 
CBD resection was not associated with a higher lymph node yield, it was associ-
ated with more aggressive underlying disease such as advanced tumor stage and 
lymph node metastasis. In turn, although patients who underwent CBD resection 
had a worse OS, the effect was attributable to a greater burden of disease/more 
aggressive disease among patients who underwent a concomitant CBD resection. 
To this end, after adjusting for all other potential risk factors, CBD resection was 
not associated with an increased risk of death. Rather, tumor specific factors—not 
surgical approach—were the drivers of long-term outcome.
Several centers in Asia have advocated for routine resection of the CBD 9,11,12. 
For example, Shimizu et al. proposed routine resection of the extrahepatic bile 
duct 9. The authors argued that gallbladder carcinoma may often extend into the 
subserosa or beyond and can invade the hepatoduodenal ligament. As such, Shu-
mizu and coworkers advocated for routine CBD to facilitate lymphadenectomy, 
avoid bile duct ischemia, and increase the number of lymph nodes harvested 9. 
Other studies have not, however, demonstrated similar potential benefits regard-
ing CBD resection 13,16-18. In a study from the Memorial Sloan Kettering Cancer 
center, D’Angelica and coworkers reported no difference in the number of lymph 
nodes harvested among patients who did and those who did not undergo a CBD 
resection 13. Similarly, in the current study, we failed to find any difference in the 
median number of lymph nodes harvested or the median number of lymph node 
metastasis relative to CBD resection. In aggregate, the data suggest that resection 
of the CBD did not facilitate a more “thorough” lymphadenectomy, as reflected in 
the comparable lymph node counts among patients who did and did not undergo 
CBD resection.
Another theoretical benefit of CBD resection relates to survival. Several groups 
have proposed that radical resections that include the excision of the extra-hepatic 
biliary tree were associated with a survival advantage 11,14,25,26. These surgeons 
point to the removal of potential occult cancer cells in the connective tissue, as 
well as the ability of CBD resection to address the issue of perineural invasion 
11,12. However, other investigators, including Makuuchi’s group from Japan, have 
questioned the survival benefit of CBD resection 23. Citing data showing no im-
provement in long-term survival, and the possible increased risk of complications 
after a bilioenteric anastomosis, the Makuuchi group recommended preservation 
of the extrahepatic bile duct in radical surgery for gallbladder cancer 23. In the cur-
rent study, resection of the CBD common bile duct resection was not associated 
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with an improvement in survival (Fig. 2). Rather patients who underwent CBD 
resection were more likely to have a more aggressive tumor biology (e.g., lymph 
node metastasis and advanced tumor stage) and, in fact, had a worse OS. Of note, 
after controlling for tumor-level factors, CBD was not associated with OS indicat-
ing that biological factors—not surgical approach—dictated long-term outcomes.
While not associated with increased lymph node yield or OS, CBD resection may 
result in an increased risk for postoperative morbidity associated with a bilioen-
teric anastomosis. To this point, using a multi-centric database of French patients, 
Fuks et al. reported no difference in recurrence-free and OS relative to CBD resec-
tion, but did demonstrate that CBD resection was associated with postoperative 
morbidity 15. We similarly noted an increase in the incidence of peri-operative 
complications among patients who underwent CBD resection. As such, the use of 
CBD resection should likely be reserved for that subgroup of patients who require 
CBD resection to extirpate all disease in the biliary tree.
The current study should be interpreted with several limitations. As with all ret-
rospective reports, the current study likely suffered from some selection bias that 
remained unaccounted even on multivariable analyses. In addition, while the use 
of multi-institutional data allowed for a greater sample size and more generaliz-
able results, potential differences in clinical practices among centers could not be 
accounted for. However, given that each of the 10 centers were large, academic, 
referral centers, this variation in practices was likely negligible given the standard-
ized practices at each center.
In conclusion, the current study demonstrates that underlying tumor biology and 
not the extent of surgical resection was the most important risk factor for long-
term outcomes among patients with GBC. The aim for curative surgical resection 
should be to resect regional lymph nodes and to obtain negative surgical margins. 
Given that CBD resection did not yield a higher lymph node count, nor was it 
associated with improved long-term outcomes, a selective approach to the CBD 
should be employed.
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Abstract
Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy 
arising from the liver. ICC makes up about 10% of all cholangiocarcinomas. It 
arises from the peripheral bile ducts within the liver parenchyma, proximal to the 
secondary biliary radicals. Histologically, the majority of ICCs are adenocarcino-
mas. Only a minority of patients (15%) present with resectable disease, with a 
median survival of less than 3 years.
Multidisciplinary management of ICC is complicated by large differences in 
disease course for individual patients both across and within tumor stages. Risk 
models and nomograms have been developed to more accurately predict survival 
of individual patients based on clinical parameters. Predictive risk factors are nec-
essary to improve patient selection for systemic treatments. Molecular differences 
between tumors, such as in the epidermal growth factor gene (EGFR) status, are 
promising, but their clinical applicability should be validated.
For patients with locally advanced disease, several treatment strategies are being 
evaluated. Both hepatic arterial infusion chemotherapy with floxuridine and yt-
trium-90 embolization (Y-90) aim to downstage locally advanced ICC. Selected 
patients have resectable disease after downstaging, other patients might benefit 
because of postponing widespread dissemination and biliary obstruction.
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Incidence and Risk Factors
The incidence of intrahepatic cholangiocarcinoma (ICC) in the Western world is 
approximately 1-2 per 100,000.1-3 ICC is the second most common malignancy 
arising from the liver, accounting for 3% of all cases of gastro-intestinal cancer.4,5 
ICC makes up about 10% of all cholangiocarcinomas. It arises in peripheral bile 
ducts within the liver parenchyma, proximal to the secondary biliary radicals 
(Figure 1).6 It should be distinguished from perihilar cholangiocarcinoma arising 
near the biliary confluence and distal cholangiocarcinoma arising near the head 
of the pancreas. Only a minority (15%) of ICC patients presents with resectable 
disease at the time of diagnosis. Complete surgical resection remains the only 
option for cure with an estimated median survival ranging from 27 to 36 months 
(Figure 2).5,7-10
Figure 1. Types of cholangiocarcinoma (From: Blechacz B, Komuta M, Roskams T, Gores GJ. Clini-
cal diagnosis and staging of cholangiocarcinoma. Nature reviews Gastroenterology & hepatology. 
2011;8(9):512-522.)
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Over three quarters of patients are older than 65 years of age at initial diagnosis3 
and ICC is slightly more common in men.11 ICC is more common in East-Asia; 
in China an incidence 10 per 100,000 persons has been reported, while in Thai-
land the incidence is 71 per 100,000, higher than for hepatocellular carcinoma 
(HCC).1,12
In general, ICC has similar risk factors to hepatocellular carcinoma (HCC). A 
correlation with diseases causing biliary inflammation and fibrosis, such as pri-
mary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC), has been 
noted.13,14 Other risk factors for ICC are congenital malformations of the bile 
duct (ie choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver 
cirrhosis, and smoking.13 In East-Asia hepatic parasite infections, in particular 
Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 
The reasons for the vast difference in incidence between the east and west is not 
fully understood, as it cannot be attributed completely to the spread of the infec-
tious risk-factors.1,12
Figure 2. Overall survival in a large cohort of ICC patients (From Spolverato G, Kim Y, Ejaz A, et al. 
Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocar-
cinoma: A Multi-institutional Analysis of 535 Patients. JAMA Surg. 2015;150(6):538-545.)
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Histology
ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation 
is frequently caused by mutations of the KRAS oncogene, a protein normally 
involved in the cell proliferation, in combination with the deletion of the p53 
tumor suppressor gene.19 A critical signaling protein downstream of KRAS and 
p53 mutations is interleukin 6 (IL-6), which is a serum biomarker for ICC.20-22 
Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, 
have been associated with an aggressive phenotype and metastatic disease at diag-
nosis.23,24
Based on their histological appearance, ICC can be divided into three histological 
growth types: the mass-forming, intraductal infiltrating, and periductal pat-
tern.25,26 The most common of these growth patterns is the mass-forming pat-
tern, of which the clinical symptoms may be similar to HCC as both involve the 
formation of a mass in the liver.27,28 On imaging (ie computed tomography [CT] 
and magnetic resonance imaging [MRI]) these tumors are clearly visible and well-
delineated.26 Mass-forming ICC typically has a diameter of 5 to 10 centimeters 
at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor 
and has a favorable prognosis compared to the other two types.26 On imaging it 
is a 1 to 2 centimeter mass within the bile duct with proximal ductal dilatation. 
The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating 
cholangiocarcinoma is characterized by growth along the bile duct without mass 
formation, which radiologically presents as a small lesion or diffuse bile duct 
thickening.33 This type of tumor is a rare form of ICC and is commonly seen in 
combination with mass-forming ICC.34,35 The different histological appearances 
of cholangiocarcinoma necessitate different surgical strategies, since tumors grow-
ing along the bile duct (intraductal and periductal ICC) often require extrahepatic 
bile duct resection in addition to hepatic resection26,36 
ICC and HCC may occur simultaneously in the same patient or even in the same 
lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive 
behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-
like cells, these tumors are thought to have a monoclonal origin with bidirectional 
phenotype differentiation.38,39 In concordance with this hypothesis, a Korean 
group recently suggested that the acquisition of ICC characteristics is a leading 
cause of atypically aggressive HCC behavior.40 Further research in the fields of 
imaging and molecular analysis are required to improve early diagnosis.38
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Staging
The most commonly used classification system to qualify advancement and resect-
ability of ICC is the American Joint Committee on Cancer (AJCC) TNM staging 
system, currently in its 7th edition, consisting of four stages (Table 1).41 Prior to 
this edition there was no separate staging system for ICC and these tumors were 
classified with HCC.42 The T-stage is determined by the number of liver tumors, 
the presence of vascular invasion, and direct extrahepatic invasion. The T4 stage 
is reserved for tumors with a periductal growth pattern. N1 indicates the presence 
of regional lymph node metastases, and M1 disease distant metastatic disease.42 
Recent research suggests the AJCC staging system performs poorly in differentiat-
ing between various prognoses, with vast inter-patient survival differences within 
TNM stages.43,44 Additional independent prognostic factors have been identified 
to improve staging, including: elevated serum carbohydrate antigen (CA) 19-9 
and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and 
serum alkaline phosphatase (ALP).44
A genomic biomarker profile can also help in differentiating patients with 
ICC.45-47 A genomic study of 149 patients with ICC identified two molecular 
subgroups, an inflammation and a proliferation group, with distinct clinical 
outcomes. The inflammation subclass (40%) showed increased activation of in-
flammation pathways, over-expression of IL-6, IL-10, and IL-17, and constitutive 
activation of immune system transcription factor STAT3.47,48 The proliferation 
subclass (60%) showed increased activation of oncogenic pathways RAS/MAPK 
and MET, specific DNA mutations and risk factors for poor clinical outcome.13,48
In a recent meta-analysis we identified several immunohistochemistry biomarkers 
for patients with ICC.45 An example of a diagnostic and prognostic biomarker 
is fascin, an actin cross-linked protein found in the cell membrane of the biliary 
duct cells.49 The epidermal growth factor receptor (EGFR) also plays an impor-
tant role in prognostics and is a potential treatment target.50,51 Mucin 1, cell 
surface associated (MUC1) and Mucin 4, cell surface associated (MUC4) are two 
membrane proteins that have been shown to be associated with patient progno-
sis.52-54 Lastly, p27, Cyclin-dependent kinase inhibitor 1B, is a protein involved 
in the cell cycle, which also has predictive capabilities in relation to postoperative 
survival.55-57 In addition to these biomarkers, several other biomarkers have been 
shown to have an impact on diagnostics, prognostics, and treatment efficacy; 
HSP27, Akt, HDGF, MUC6, p16, p-4EBP1, S100A4, alpha-SMA, keratin 903, 
and TROP2.45 A composite biomarker profile could improve prognosis and guide 
treatment selection.47
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Diagnosis and Preoperative Workup
The initial diagnosis of ICC is mostly made when the tumor is not eligible for 
resection because of locally advanced or metastatic disease.13,14,58 Typically a very 
large mass has developed in the periphery of the liver with few clinical symp-
toms.19 Most patients present with nonspecific symptoms, such as pain in the 
right upper abdominal quadrant, weight loss and high serum ALP levels. Some 
Table 1. AJCC TNM Classification 7th Edition
T - Stage Definition
Tx No description of the tumor’s extent is possible because of incomplete 
information
T0 There is no evidence of a primary tumor.
T1 There is a single tumor that has grown into deeper layers of the bile duct wall, 
but it is still only in the bile duct. The cancer has not grown into any blood 
vessels.
T2a There is a single tumor that has grown through the wall of the bile duct and into 
a blood vessel.
T2b There are 2 or more tumors, which may (or may not) have grown into blood 
vessels.
T3 The cancer has grown into nearby structures such as the intestine, stomach, 
common bile duct, abdominal wall, diaphragm (the thin muscle that separates 
the chest from the abdomen), or lymph nodes around the portal vein.
T4 The cancer is spreading through the liver by growing along the bile ducts.
N - Stage Definition
Nx Nearby (regional) lymph nodes cannot be assessed.
N0 The cancer has not spread to nearby lymph nodes.
N1 The cancer has spread to nearby lymph nodes.
M- Stage
M0 The cancer has not spread to tissues or organs far away from the bile duct.
M1 The cancer has spread to tissues or organs far away from the bile duct.
Stage Grouping Definition
Stage I T1, N0, M0
Stage II T2, N0, M0
Stage III T3, N0, M0
Stage IVa T4, N0, M0 / Any T, N1, M0
Stage IVb Any T, any N, M1
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patients present with painless jaundice, when the tumor grows towards the biliary 
confluence.14,58 Small ICCs are found in screening programs for early detection 
of HCC.59
Transabdominal ultrasound is often the first imaging modality that detects a 
liver mass with or without dilatation of the biliary tract.60 The number of lesions 
and vascular involvement are determined using a dual-phase multi-detector-CT 
(MDCT). Typical appearance of ICC on CT is a hypodense mass with ir-
regular margins on unenhanced scans, peripheral rim enhancement in the arterial 
contrast-enhancement phase, and progressive contrast uptake in the (portal-)
venous and delayed contrast-enhancement phase.61 Small ICCs can be difficult 
to distinguish from HCC. Biliary drainage (if needed) should be performed after 
imaging, because the presence of stents and drains hamper accurate assessment of 
the extent of the tumor.62
Both magnetic resonance cholangiopancreatography (MRCP) and positron emis-
sion tomography (PET) have a good accuracy for diagnosis and assessment of 
the extent of the tumor. MRCP has a diagnostic accuracy of up to 93% and is 
recommended for visualization of the tumor extension in the ductal system and 
vascular structures.47,63 Clinical utility of PET for diagnosing ICC in the liver 
when CT or MRI imaging has been performed is limited.47 However, preopera-
tive PET scanning may be considered to help rule out occult metastatic disease, 
as PET changes surgical decision making in up to 30% of patients.64-66 Despite 
these imaging modalities, as many as a third of patients with resectable disease 
on imaging have occult metastatic or locally advanced disease during diagnostic 
laparoscopy.67,68 Therefore, better imaging is needed to avoid surgery in these 
patients.14,67,68
Biliary drainage and portal vein embolization
ICC may cause biliary obstruction when the tumor grows towards the liver hilum. 
Biliary drainage may be required in the preoperative setting with resectable disease 
and in the palliative setting. Biliary drainage aims to improve liver function and 
increase appetite.69 Moreover, preoperative biliary drainage may improve liver 
regeneration and decrease the risk of postoperative liver failure .70,71 The main 
drawback of biliary drainage is colonization of the bile duct that often results in 
cholangitis.72 Patients with a future liver remnant of at least 50% should probably 
undergo a resection without preoperative biliary drainage.73,74 Drainage can be 
performed endoscopically (ERCP) or percutaneously (PTCD) Biliary drainage 
can reduce symptoms and improve quality of life in the palliative setting.75,76 
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A resection of more than 75% of the total liver volume in a healthy liver and more 
than 65% of the total liver volume in a compromised liver (eg, due to cirrhosis 
or fibrosis) is an indication for portal vein embolization (PVE).77 PVE results in 
hypertrophy of the future liver remnant by preoperatively embolizing the liver 
that will be resected.77 In a total of 1,791 patients with different hepatic tumors, 
PVE had a technical success of 96.1%.77
Surgical Management
Resection
Surgical treatment is the only potentially curative treatment in patients with 
ICC. ICC is an aggressive cancer, when compared to other primary hepatic neo-
plasms.4,14,58 A large study (n=584) demonstrated that even after curative-intent 
resection the probability of cure is only about 10%.78 Because of the large size 
as well as intraductal and periductal spread, major hepatectomies are required 
to obtain negative resection margins.4 With regards to prognosis, resection is 
only useful when a complete resection (R0) with negative resection margins is 
anticipated. Moreover, the liver remnant should be adequate in size and function, 
with or without prior PVE.8,77,79,80 Extrahepatic disease, including lymph node 
metastases beyond the regional basin (N2), are a contra-indication for curative-
intent surgery.41 Multifocal ICC is considered unresectable by some experts.79-83 
Nevertheless, other experts report favorable long-term outcomes in selected 
patients with typically 2-3 lesions, with a 5-year overall survival (OS) of 20%.84,85 
A 2015 cure model confirms the possibility of cure, albeit at a chance of only 
4%.78 Recent studies have reported favorable outcomes of portal vein reconstruc-
tions.86-88 However, tumor invasion of the main hepatic artery or bilateral hepatic 
artery involvement remain contra-indications for resection in most Western cen-
ters. Hepatic artery reconstruction is associated with a high risk of postoperative 
mortality as well as poor oncologic outcomes.89,90
A complete resection of ICC involves an (extended) hemihepatectomy in most 
(75%) of patients. Many patients (25%) also require a bile duct resection and 
reconstruction. Morbidity rates are often more than 1 in 5, and mortality rates 
vary from 1% to 6%.8,9,91 Intraoperative and postoperative strategies, such as 
low central venous pressure, restricted fluid resuscitation, and enhanced recovery 
pathways, have improved recovery and decreased the risk of complications.87,88,92 
A recent article reviewed perioperative management of patients undergoing 
hepatic resection.93 They noted that surgeons left an operative drain in almost 
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half of patients undergoing liver resection, even though most data suggest that 
routine operative drainage after liver resection (without a biliary anastomosis) is 
unnecessary and should generally be avoided.94-96 
Whereas HCC is commonly treated with orthotopic liver transplantation (OLT), 
ICC as an indication for OLT is still controversial.97 Historical evidence sug-
gests poor outcomes for ICC in single center studies.98-104 Outcomes of OLT for 
combined HCC and ICC were also predominantly unfavorable.98,105 Five-year 
survival estimates in these studies ranged from 10%-18%, which is clearly inferior 
to the benchmark of OLT of about 70%.97  More recent studies indicate that 
strictly selected patients might benefit from OLT, particularly patients with ICC 
smaller than 2 cm.106 
Systemic chemotherapy
Preoperative Chemotherapy
Preoperative chemotherapy (pCT) can be administered for multiple purposes, 
although it is not routinely prescribed due to a lack of evidence.107 Neoadjuvant 
therapy is employed to address occult metastatic disease or facilitate resection. 
We recently evaluated the role of pCT in a cohort of 1,057 patients, of whom 
62 patients received chemotherapy. We found that patients receiving pCT had 
similar survival following curative-intent resection, regardless of more advanced 
disease.107 No regimen is currently proven to have effect during the preoperative 
period. In light of the outcomes of the ABC-02 trial, discussed below, a combina-
tion of gemcitabine and cisplatin was offered most often.108
Adjuvant Chemotherapy
Adjuvant chemotherapy is aimed at decreasing the chance of tumor recurrence.109 
Chemotherapy consists of mainly nucleoside analogues, most commonly gem-
citabine, sometimes in combination with cisplatin.109 Systemic therapy is known 
to have a large impact on patient’s quality of life, and form a large financial 
burden. The efficacy of chemotherapy regimens in ICC is usually poor, with only 
a small subgroup benefitting significantly in both quality of life and length of 
survival.16,109 While a significant portion of US patients receive chemotherapy, 
no randomized trials have been completed.42 A multicenter phase III trial is cur-
rently accruing patients to determine the effectiveness of adjuvant gemcitabine 
and cisplatin in patients with biliary cancer (Table 2).
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Palliative Chemotherapy
A phase III trial, the ABC-02 trial, randomized 410 patients with biliary cancer 
(ie cholangiocarcinoma and gallbladder cancer) and found an improvement in 
overall survival of nearly four months with gemcitabine plus cisplatin compared to 
gemcitabine alone.108 A combined analysis of the ABC-02 trial and the Japanese 
BT22 trial, conducted in a comparable setting, found a hazard ratio (HR) of 0.54 
(95% confidence interval (CI) 0.36-0.81) for the subgroup of 108 patients with 
ICC.110 Gemcitabine plus cisplatin has been the standard palliative regimen for 
locally advanced or metastatic ICC since. Best supportive care is recommended 
for patients with a poor performance status or a life expectancy of less than 6 
months.111-114 
Regional Treatments
Regional treatments rely on the dual blood supply of the liver, where the hepatic 
artery is mostly responsible for the blood supply of tumors, as illustrated by early 
arterial enhancement on imaging.115 116,117 Hepatic arterial infusion (HAI) che-
motherapy using a subcutaneous pump has been investigated for patients with 
ICC at Memorial Sloan Kettering Cancer Center (MSKCC). It involves continu-
ous infusion of floxuridine directly into the hepatic artery. Intra-arterial delivery 
allows for a 200 fold higher drug delivery to the tumor with little systemic toxicity, 
because of the 95% first pass effect of floxuridine in the liver.5 HAI chemotherapy 
has been studied extensively in common malignancies, such as colorectal liver 
metastases.5,118
In a recent study from MSKCC, HAI with floxuridine was combined with sys-
temic chemotherapy in patients with locally advanced (ie unresectable without 
extrahepatic disease) ICC (n=104). 119 Outcomes were compared with locally 
advanced patients receiving systemic chemotherapy alone.5 Median OS was supe-
rior with HAI chemotherapy (30.8 months vs. 18.4 months; p < 0.001). Five-year 
OS was 20% in patients who received HAI chemotherapy compared with 5% 
in the systemic only group. In comparison, 5-year OS was 0% in the ABC-02 
trial.108 Moreover, the partial response rate (RECIST criteria) in the HAI che-
motherapy group was 59%, with conversion to resectability in 8 of 104 patients 
(13%). Future prospective studies should be conducted in order to confirm these 
results. Currently, a phase 2 trial is recruiting patients for HAI chemotherapy in 
the adjuvant setting (NCT01312857).
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Table 2. Currently Active Phase III and Phase IV Studies
Title Collaborators Country / 
Region
Interventions # of 
Patients
Outcome Measures Recruitment 
Start
Completion 
Date
NCT Number
Palliative Setting
Photodynamic Therapy 
(PDT) for Palliation of 
Cholangiocarcinoma
Weill Medical College of 
Cornell University
United 
States
Photodynamic Therapy 55 Efficacy Profile, Safety Profile Feb-12 Dec-16 NCT01755013
Effect of Early Management on 
PAin and DEpression in Patients 
With PancreatoBiliary Cancer, 
EPADE-PB
National Cancer Center, 
Korea
Korea Early Palliative care 
integrated with usual 
oncologic care
288 Reduction in Pain Scale, Reduction in 
Depression Score, Quality of Life, Overall 
Survival
Apr-12 Jun-17 NCT01589328
Active Symptom Control 
Alone or With mFOLFOX 
Chemotherapy for Locally 
Advanced/ Metastatic Biliary 
Tract Cancers
The Christie NHS 
Foundation Trust|Cancer 
Research UK
United 
Kingdom
mFOLFOX 162 Overall Survival, Progression Free Survival, 
Response Rate, Toxicity, Quality of Life, 
Cost-effectiveness
Feb-14 Jan-18 NCT01926236
Early Palliative Care With 
Standard Care or Standard Care 
Alone in Improving Quality of 
Life of Patients With Incurable 
Lung or Non-colorectal 
Gastrointestinal Cancer and 
Their Family Caregivers
Alliance for Clinical Trials 
in Oncology|National 
Cancer Institute (NCI)
United 
States
Early Palliative Care 700 Reduction in Depression, Ilness 
Understanding, Quality of Life, Rate of 
Referral, Lenght of Hospice Stay, Location 
of Death, ICU Visits, Number of Patients 
Treated with Chemotherapy, Overall 
Survival, Perceptions of Cure
Apr-15 - NCT02349412
RFA RCT for Pancreatic or Bile 
Duct Cancer
Weill Medical College of 
Cornell University
United 
States
Radiofrequency 
Ablation using 
EndoHPB Probe vs. 
Stenting only
44 Clinical Success, Mutational Profile of 
DNA
Jun-14 Jun-17 NCT02166190
Chemo Alone or in 
Combination With 
Radiation in Unresectable 
Cholangiocarcinoma
Tata Memorial Hospital India High Dose Radiation 
and Systemic 
Chemotherapy
155 Overall Survival, Progression Free 
Survival, Toxicity, Quality of Life, Surgical 
Resectability Rates
May-15 Jun-22 NCT02773485
Safety and Efficacy of Modified 
Folfirinox Versus Gemcis in Bile 
Duct Tumours
Centre Hospitalier 
Universitaire de Saint 
Etienne|Federation 
Francophone de 
Cancerologie Digestive
France Gemcitabine 
& Cisplatin vs. 
mFOLFIRINOX
316 Progression Free Survival, Overall Survival, 
Response Rate, Toxicity
Nov-15 Jun-18 NCT02591030
Study of SPARC1507 (Sun 
Pharma Advanced Research 
Company Limited Drug)
Sun Pharma Advanced 
Research Company 
Limited
India SPARC1507 198 Progression Free Survival, Overall Survival, 
Response Rate
Apr-16 Nov-19 NCT02597465
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Table 2. Currently Active Phase III and Phase IV Studies
Title Collaborators Country / 
Region
Interventions # of 
Patients
Outcome Measures Recruitment 
Start
Completion 
Date
NCT Number
Palliative Setting
Photodynamic Therapy 
(PDT) for Palliation of 
Cholangiocarcinoma
Weill Medical College of 
Cornell University
United 
States
Photodynamic Therapy 55 Efficacy Profile, Safety Profile Feb-12 Dec-16 NCT01755013
Effect of Early Management on 
PAin and DEpression in Patients 
With PancreatoBiliary Cancer, 
EPADE-PB
National Cancer Center, 
Korea
Korea Early Palliative care 
integrated with usual 
oncologic care
288 Reduction in Pain Scale, Reduction in 
Depression Score, Quality of Life, Overall 
Survival
Apr-12 Jun-17 NCT01589328
Active Symptom Control 
Alone or With mFOLFOX 
Chemotherapy for Locally 
Advanced/ Metastatic Biliary 
Tract Cancers
The Christie NHS 
Foundation Trust|Cancer 
Research UK
United 
Kingdom
mFOLFOX 162 Overall Survival, Progression Free Survival, 
Response Rate, Toxicity, Quality of Life, 
Cost-effectiveness
Feb-14 Jan-18 NCT01926236
Early Palliative Care With 
Standard Care or Standard Care 
Alone in Improving Quality of 
Life of Patients With Incurable 
Lung or Non-colorectal 
Gastrointestinal Cancer and 
Their Family Caregivers
Alliance for Clinical Trials 
in Oncology|National 
Cancer Institute (NCI)
United 
States
Early Palliative Care 700 Reduction in Depression, Ilness 
Understanding, Quality of Life, Rate of 
Referral, Lenght of Hospice Stay, Location 
of Death, ICU Visits, Number of Patients 
Treated with Chemotherapy, Overall 
Survival, Perceptions of Cure
Apr-15 - NCT02349412
RFA RCT for Pancreatic or Bile 
Duct Cancer
Weill Medical College of 
Cornell University
United 
States
Radiofrequency 
Ablation using 
EndoHPB Probe vs. 
Stenting only
44 Clinical Success, Mutational Profile of 
DNA
Jun-14 Jun-17 NCT02166190
Chemo Alone or in 
Combination With 
Radiation in Unresectable 
Cholangiocarcinoma
Tata Memorial Hospital India High Dose Radiation 
and Systemic 
Chemotherapy
155 Overall Survival, Progression Free 
Survival, Toxicity, Quality of Life, Surgical 
Resectability Rates
May-15 Jun-22 NCT02773485
Safety and Efficacy of Modified 
Folfirinox Versus Gemcis in Bile 
Duct Tumours
Centre Hospitalier 
Universitaire de Saint 
Etienne|Federation 
Francophone de 
Cancerologie Digestive
France Gemcitabine 
& Cisplatin vs. 
mFOLFIRINOX
316 Progression Free Survival, Overall Survival, 
Response Rate, Toxicity
Nov-15 Jun-18 NCT02591030
Study of SPARC1507 (Sun 
Pharma Advanced Research 
Company Limited Drug)
Sun Pharma Advanced 
Research Company 
Limited
India SPARC1507 198 Progression Free Survival, Overall Survival, 
Response Rate
Apr-16 Nov-19 NCT02597465
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Table 2. Currently Active Phase III and Phase IV Studies (continued)
Title Collaborators Country / 
Region
Interventions # of 
Patients
Outcome Measures Recruitment 
Start
Completion 
Date
NCT Number
Early Palliative Care in Patients 
With Metastatic Upper 
Gastrointestinal Cancers Treated 
With First-line Chemotherapy
Centre Oscar 
Lambret|Canceropôle Nord 
Ouest
France Early Palliative Care 558 Overall Survival, Quality of Life, 
Reduction in Depression Score, Time 
Until Definitive Deterioration, Advanced 
Directives, Number of Patients Treated 
with Chemotherapy
Aug-16 Aug-20 NCT02853474
Adjuvant Setting
Adjuvant Chemotherapy With 
Gemcitabine and Cisplatin 
Compared to Observation After 
Curative Intent Resection of 
Biliary Tract Cancer, ACTICCA
Universitätsklinikum 
Hamburg-
Eppendorf|Deutsche 
Krebshilfe e.V., Bonn 
(Germany)|medac 
GmbH|Cancer Research 
UK|AGITG Australasian 
Gastro Intestinal 
Trials Group|KWF 
Kanker Bestrijding The 
Netherlands
Europe 
and 
Oceania
Gemcitabine & 
Cisplatin
440 Disease Free Survival, Overall Survival, 
Toxicity, Quality of Life, Function 
Biliodigestive Anastomosis, Infections.
Apr-14 Apr-22 NCT02170090
Oxaliplatin+Gemcitabine 
vs Capecitabine as Adjuvant 
Therapy for Intrahepatic 
Cholangiocarcinoma
Shanghai Zhongshan 
Hospital
China Gemcitabine & 
Cisplatin
286 Recurrence Free Survival, Overall Survival Jul-15 Dec-18 NCT02548195
Abbreviations: FOLFOX, chemotherapy regimen consisting of folinic acid (leucovorin), 5-fluorouracil 
(5-FU), and oxaliplatin; FOLFIRINOX, chemotherapy regimen consisting of folonic acid (leucovorin),
 5-fluorouracil (5-FU), irinotecan, and oxaliplatin.
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Table 2. Currently Active Phase III and Phase IV Studies (continued)
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(5-FU), and oxaliplatin; FOLFIRINOX, chemotherapy regimen consisting of folonic acid (leucovorin),
 5-fluorouracil (5-FU), irinotecan, and oxaliplatin.
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Other hepatic artery–based treatments for locally advanced ICC include transar-
terial chemoembolization (TACE) and radio-embolization with Yttrium-90 (Y-
90).115 TACE affects the blood flow to the tumor in addition to locally releasing 
cytotoxic agents. It causes ischemic tumor necrosis and facilitates intracellular 
transit of chemotherapeutic agents.115,117 In a study of 41 prospectively followed 
patients, one group described a median OS of 11.7 months from first treatment, 
after treatment with irinotecan TACE.120 One patient successfully underwent re-
section following TACE.120 Another prospective study reported a median survival 
of 17.5 months in 24 patients, with 3 patients being adequately down staged to 
undergo resection.121 Despite the encouraging results no phase III trial has been 
performed.115 
Y-90 radio-embolization therapy also aims to improve life expectancy in pa-
tients with unresectable HCC and colorectal liver metastases.115 The technique 
is based on administration of beads filled with the radioactive isotope yttrium 
Y-90 microspheres into the hepatic artery branch responsible for the lobes of the 
liver beset by tumor.122,123 Prior to treatment, embolization of the non-target 
vessels and injection of Technetium-99mm-labeled macro-aggregated albumin is 
performed, in order to exclude extrahepatic accumulation.115,122,123 Several small 
studies indicate that Y-90 is tolerated well in patients with a good performance 
status.124-129 In intrahepatic cholangiocarcinoma patients, Y-90 was associated 
with improved survival, when compared with patients undergoing best supportive 
care only.124-129 Estimates ranged from 9 months post-treatment in a cohort of 
25 Australian patients,128 to 22 months in a cohort of 33 German patients.127 
Randomized trials are required to determine the effectiveness of Y-90 therapy.
Prognostic Models and Nomograms
Several prognostic models have been developed in addition to the AJCC staging. 
More accurate prediction of individual patient outcome may provide better indi-
vidual survival estimates, as well as improve identification of high-risk groups who 
may benefit from adjuvant therapy.11 While the AJCC staging concerns all ICC 
patients, other models pertain only to patients who have undergone a complete 
resection. A Chinese nomogram predicts individual OS after resection of ICC 
(Figure 3).43 Prognostic factors in this model included CEA, CA19-9, vascular 
invasion, presence of lymph node metastases, direct invasion and local metastases, 
number of tumors, and tumor diameter. A similar model was developed with 
a multinational dataset without tumor markers. Risk factors for survival after 
resection were; age, number of tumors, tumor diameter, cirrhosis, lymph node 
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metastases, and macrovascular invasion.130 The Chinese nomogram had superior 
discrimination at external validation.43,44
Figure 3. Validated ICC nomogram predicting overall survival (From Wang Y, Li J, Xia Y, et al. Prog-
nostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 
2013;31(9):1188-1195.)
Other prognostic models were developed for conditional survival, accounting for 
the years that a patient had already survived after surgery.84,131,132 Conditional 
survival was found to be the most important prognostic factor, when predicting 
future survival time.84,131,132 Overall survival in this study decreased over time to 
16% at 8 years, while the three-year conditional survival at 5 years, ie the chance 
of surviving to year 8 after having survived to year 5, was 65%.84
Personalized Treatments
Personalized treatments for ICC patients could improve the overall outcomes, 
mainly by withholding treatments from patients who are unlikely to benefit 
from surgery or chemotherapy. For example, patients with a very poor predicted 
survival after surgery (eg, 3-year OS below 5% based on the Chinese nomogram 
in Figure 3) are unlikely to benefit from surgery. Unfortunately, predictive bio-
markers for response to systemic chemotherapy are not available.45 Future studies 
should further improve prognostic models and identify predictive biomarkers to 
determine the response to chemotherapy.44,133 
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Future Perspectives
ICC is a complex disease, with a dismal prognosis. ICC is typically diagnosed 
with metastatic or locally advanced disease. Surgery may improve both survival 
and quality of life, but comes with a substantial risk postoperative morbidity 
and mortality. The benefit of palliative systemic treatment is real but small. The 
merits of (neo)adjuvant therapy still need to be explored in phase 3 trials. Targeted 
therapies (e.g., targeting IDH 1 or 2 mutations) are promising but require fur-
ther evaluation.134 Hepatic arterial infusion, TACE, and radio-embolization are 
promising locoregional techniques. Appropriate allocation of all locoregional and 
systemic treatments may further improve with better knowledge of histopathol-
ogy and biological behavior. 
Ideally, low-cost diagnostic biomarkers could reliably detect ICC in patients pre-
senting with vague symptoms of the upper abdomen or screened for liver cancer. 
Furthermore, predictive biomarkers are required to determine in advance , which 
patients will benefit from chemotherapy.
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Abstract
Introduction: While preoperative chemotherapy (pCT) is utilized in many intra-
abdominal cancers, the use of pCT among patients with intrahepatic cholangio-
carcinoma (ICC) remains ill defined. As such, the objective of the current study 
was to examine the impact of pCT among patients undergoing curative-intent 
resection for ICC.  
Methods: Patients who underwent hepatectomy for ICC were identified from 
a multi-institutional international cohort.  The association between pCT with 
peri-operative and long-term clinical outcomes was assessed. 
Results: Of the 1,057 patients who were identified and met the inclusion criteria, 
62 patients (5.9%) received pCT. These patients were noticed to have more ad-
vanced disease. Median OS (pCT:46.9 months vs. no pCT:37.4 months; p=0.900) 
and DFS (pCT: 34.1 months vs. no pCT: 29.1 months; p=0.909) were similar 
between the two groups. In a subgroup analysis of propensity-score matched 
patients, there was longer OS (pCT:46.9 months vs. no pCT:29.4 months) and 
DFS (pCT:34.1 months vs. no pCT:14.0 months), however this did not reach 
statistical significance (both p>0.05). 
Conclusion: In conclusion, pCT utilization among patients with ICC is higher 
among patients with more advanced disease. Short-term post-operative outcomes 
were not affected by pCT use and receipt of pCT resulted in equivalent OS and 
DFS following curative-intent resection. 
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Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary 
liver malignancy, accounting for 3% of all cases of gastro-intestinal cancer.1,2 ICC 
makes up about 5% to 10% of all cholangiocarcinomas and originates from bile 
ducts within the liver parenchyma.2,3 Histologically, the majority of advanced 
ICC tumors are adenocarcinoma, which are typically treated with a combination 
of cytotoxic nucleoside analogs and platins.4,5 When feasible, complete surgical 
resection of ICC remains the only possible option for cure with an estimated 
median survival ranging from 27 to 36 months.6-9  However, only a minority 
of patients with ICC present with surgically resectable disease at the time of 
diagnosis. Even with complete surgical resection, recurrence can be as high as 
50% within 24 months of surgical resection.10 In addition, nearly 1 in 5 patients 
undergoing curative-intent resection are left with microscopic disease following 
surgery.11 As such, there has been interest in using preoperative chemotherapy 
(pCT) to improve patient selection, increase the incidence of margin negative 
surgical resection and potentially improve disease-free (DFS) and overall survival 
(OS).
Preoperative chemotherapy is utilized in many intra-abdominal cancers to reduce 
local disease burden and the incidence of micrometastatic disease prior to surgi-
cal resection. In patients with perihilar cholangiocarcinoma (PHC), recent trials 
have shown that pCT may be effective in increasing DFS.12  Furthermore, in 
patients with PHC, pCT can down-size locally advanced tumors in order to help 
facilitate surgical resection.12 Despite this, the use of pCT among patients with 
ICC has not been well-studied.5,12 As such, the objective of the current study was 
to determine the impact of pCT on OS and DFS in a large, multi-institutional 
international cohort of patients who underwent curative-intent resection for ICC. 
Furthermore, we sought to characterize current practice patterns regarding the use 
of pCT among patients undergoing curative-intent resection for ICC.  
Methods
All patients undergoing curative-intent resection for ICC between January 1, 
1990, and July 1, 2016 at one of 12 participating major hepatobiliary institutions 
in the United States, Asia, Oceania and Europe were identified (Johns Hopkins 
University, Baltimore, Maryland; Emory University, Atlanta, Georgia; Stanford 
University Medical Center, Stanford, California; University of Virginia Health 
System, Charlottesville, Virginia; Fundeni Clinical Institute, Bucharest, Roma-
nia; Beaujon Hospital, Clichy, France; Curry Cabral Hospital, Lisbon, Portugal; 
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Eastern Hepatobiliary Surgery Hospital, Shanghai, China; Ottowa General 
Hospital, Ottowa, Canada; Royal Prince Alfred Hospital, Sydney, Australia; San 
Raffaele Hospital, Milan, Italy; Erasmus University Medical Centre Rotterdam, 
Rotterdam, the Netherlands). Sociodemographic and clinicopathologic data were 
collected and include age, sex and race, tumor size, AJCC stage, histologic grade, 
presence of nodal metastases, final resection margin and the presence of vascular 
and/or perineural invasion. 
A minor hepatectomy was defined as a hepatic resection of less than 3 Couinaud 
segments. Suspected lymph node metastases on preoperative scans were con-
sidered suspicious preoperative lymph nodes, while only pathologically proven 
metastases were considered proven metastases. Patients with suspected lymph 
nodes preoperatively, and confirmed lymph node metastases during pathologi-
cal examination of the resection specimen, were considered to have lymph node 
disease preoperatively and postoperatively, respectively. Patients with suspected 
lymph node disease preoperatively, but no evidence in the resection specimen, 
were considered to only have lymph node metastases preoperatively. 
The American Joint Committee on Cancer (AJCC) 7th edition staging was used 
to stratify patients by extent of disease.13 Margin status was categorized as R0 for 
a negative margin, R1 when the margin was microscopically positive and R2 when 
the margin was macroscopically positive. Only patients undergoing a curative 
intent surgery for histologically confirmed ICC were included in the final study 
population; patients who did not undergo resection were excluded. Patients who 
underwent transplantation were also excluded. The respective institutional review 
boards of each participating institution approved this study.
Statistical analysis
Categorical variables were described as whole numbers and percentages while 
continuous variables were reported as medians with interquartile (IQR) range. 
Percentages for each variable were calculated based on available data, excluding 
missing values. Univariable comparison of categorical variables was performed 
using the Pearson chi-square test. Univariable comparison of continuous variables 
was performed using the Mann-Whitney U-test. The primary outcome of the 
study was 5-year OS. OS was calculated as the time from the date of surgery to 
the date of death or date of last available follow-up; OS was estimated using the 
Kaplan-Meier method. DFS was calculated from the date of surgery to the date 
of first-known radiographically or pathologically confirmed metastasis. Logistic 
regression analysis was conducted in order to determine factors associated with 
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receipt of pCT in a multivariable model. Based on this regression model, a pro-
pensity score was calculated to determine the likelihood of receiving pCT. Patients 
were matched based on this propensity score and OS was compared between the 
groups. All analyses were performed using SPSS 22.0 (IBM, New York). All tests 
were 2-sided and p<0.05 defined statistical significance.
Results
Clinical and pathologic description of patient cohort receiving pCT
1,057 patients who underwent curative-intent resection for ICC and met the 
inclusion criteria were identified; 62 patients (5.9%) received pCT (Table 1). 
Among the patients who received pCT, 18 (29.0%) patients were treated with 
intra-arterial chemotherapy, while the remaining 44 patients (71.0%) were treated 
with systemic chemotherapy. Median patient age among patients who received 
pCT was 60 years (IQR 52, 69) and the majority of the patients were male (n=37, 
59.7%). Most patients had an ASA classification of II or III (n=51, 92.7%). 
Based on preoperative imaging and/or biopsy, over one-third of patients had 
suspected or proven lymph node metastases (n=21, 39.6%). We observed that 
patients who received systemic chemotherapy more frequently had suspected or 
confirmed lymph node metastases (n=17, 44.7%), compared to patients who 
received intra-arterial chemotherapy (n=4, 26.7%). However this difference did 
not reach statistical significance (p=0.226). At the time of surgery, approximately 
one-half of patients underwent a major hepatectomy involving more than 3 
Couinaud segments (n=29, 52.7%). The majority of patients underwent a formal 
portal lymphadenectomy (n=39, 70.9%), with a median of 3 lymph nodes (IQR: 
1, 6) examined. On final pathology, the majority of patients had an R0 resection 
(n=42, 73.7%). Lymph node metastasis was noted in 24.2% of patients (n=15). 
Twelve patients (25.5%) who had lymph node metastases on the preoperative 
work-up did not have lymph node metastasis on final pathology. 
Receipt of preoperative chemotherapy
The majority of patients who received pCT (n=50) were treated within the past 10 
years, however the rate of pCT remained stable over the study period (p=0.632). 
Several clinicopathologic features were associated with receipt of pCT (Table 2). 
Preoperatively, patients with suspected or biopsy-proven lymph nodes more likely 
received pCT (39.6% vs. 18.5%, p<0.001).  Patients who received pCT were also 
more likely to have advanced disease compared with patients who did not receive 
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Table 1. Characteristics of the Preoperative Chemotherapy Group (n=62)
Variable n (%) / median (IQR)
Gender
Male 37 (59.7)
Female 25 (40.3)
Age, years 60 (52-69)
Race
Caucasian 49 (79.0)
African-American 8 (12.9)
Other 5 (8.0)
ASA
I 3 (5.5)
II 24 (43.6)
III 27 (49.1)
IV 1 (1.8)
BMI 25.8 (23.5-29.0)
Period of Treatment
1990-2000 3 (5.3)
2001-2005 4 (7.0)
2006-2010 20 (35.1)
2011-2016 30 (52.6)
Preoperative Chemotherapy Type
Intra-Arterial Therapy 18 (29.0)
Systemic Therapy 44 (71.0)
Preoperative Lymph Node Metastases
No 32 (60.4)
Suspicious 12 (22.6)
Proven 9 (17.0)
Type of Resection
Minor Hepatectomy (<3 segments) 6 (10.9)
Right Hepatectomy 9 (16.4)
Left Hepatectomy 8 (14.5)
Extended Right Hepatectomy 18 (32.7)
Extended Left Hepatectomy 11 (20.0)
Central Hepatectomy 3 (5.5)
Lymphadenectomy 39 (70.9)
Lymph Nodes Harvested 3 (1-6)
Lymph Node Metastases 15 (24.2)
Extrahepatic Metastases 8 (12.9)
Margin Status
R0 42 (73.7)
R1 14 (24.6)
R2 1 (1.8)
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Table 2. Comparison of Disease Characteristics Across Treatment Groups
Variable
No Preoperative 
Chemotherapy (n=995)
Preoperative 
Chemotherapy (n=62)
P-value
Preoperative Lymph Node Metastases < 0.001
No 699 (81.2) 32 (60.4)  
Suspicious 121 (14.1) 12 (22.6)  
Proven 38 (4.4) 9 (17.0)  
Type of Resection < 0.001
Minor Hepatectomy (<3 segments) 413 (42.6) 6 (10.9)  
Right Hepatectomy 158 (16.3) 9 (16.4)  
Left Hepatectomy 185 (19.1) 8 (14.5)  
Extended Right Hepatectomy 110 (11.4) 18 (32.7)  
Extended Left Hepatectomy 85 (8.8) 11 (20.0)  
Central Hepatectomy 18 (1.9) 3 (5.5)  
Number of tumors 1 (1-1) 1 (1-1) 0.207
Tumor size (cm) 6.0 (4.2-8.8) 7.1 (5.0-10.2) 0.069
Major vascular Invasion 95 (9.8) 5 (8.9) 0.832
Microvascular Invasion 232 (24.4) 25 (48.1) < 0.001
Perineural invasion 137 (15.6) 15 (30.6) 0.006
Invasion of Adjacent Organs 72 (7.4) 5 (8.9) 0.676
Satellite Lesions 216 (22.2) 17 (29.8) 0.181
Intrahepatic metastases 69 (7.1) 6 (10.7) 0.308
Lymphadenectomy 424 (43.7) 39 (70.9) < 0.001
Lymph Nodes Harvested 2 (0-5) 3 (1-6) 0.074
Lymph Node Metastases 169 (17.0) 15 (24.2) 0.146
Extrahepatic Metastases 32 (3.2) 8 (12.9) < 0.001
Margin Status 0.010
R0 840 (87.1) 42 (73.7)  
R1 120 (12.4) 14 (24.6)  
R2 4 (0.4) 1 (1.8)  
AJCC Stage < 0.001
I 282 (48.0) 7 (24.1)  
II 160 (27.2) 6 (20.7)  
III 22 (3.7) 6 (20.7)  
IVA 112 (19.0) 8 (27.6)  
IVB 12 (2.0) 2 (6.9)  
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pCT. Specifically, patients with microvascular invasion (pCT: n=25, 48.1% vs. no 
pCT: n=232, 24.4%; p<0.001) and perineural invasion (pCT: n=15, 30.6% vs. 
no pCT: n=137, 15.6%; p=0.006) more commonly received pCT. Furthermore, 
based on the AJCC 7th edition staging system, patients who received pCT more 
commonly had stage III or IV disease (pCT: n=16, 55.2% vs. no pCT: n=146, 
24.7; p<0.001). The presence of extrahepatic disease was also associated with 
receipt of pCT (pCT: n=8, 12.9% vs. no pCT: n=32, 3.2; p<0.001). On final 
pathology, patients who received pCT also more often had microscopic R1 (pCT: 
n=14, 24.6% vs. no pCT: n=120, 12.4%; or macroscopic R2 (pCT: n=1, 1.8% vs. 
no pCT: n=4, 0.4%; p=0.010) resections. 
On multivariable analysis, after controlling for all measurable confounders, fac-
tors associated with receipt of pCT included major hepatic resection (OR: 3.88, 
95%CI 1.43-10.49, p=0.008) and the presence of microvascular invasion (OR: 
2.93, 95%CI 1.43-6.02, p=0.003).
Perioperative Morbidity
Overall morbidity among all patients who underwent resection for ICC was 40.2% 
(n=420) with a higher incidence of complications occurring among patients who 
received pCT (pCT: n=36, 59.0% vs. no pCT: n=384, 39.0%; P=0.002); major 
morbidity, however, did not differ between the two groups (p=0.568) (Table 3). 
Median length of stay (pCT: 9 days, IQR 6,15 vs. no pCT: 12 days, IQR 7,17; 
p=0.080) and perioperative mortality within 90 days of surgery (pCT: n=1, 2.2% 
Table 3. Comparison of Postoperative Course and Follow-up Across Treatment Groups
Variable
No Preoperative 
Chemotherapy (n=995)
Preoperative 
Chemotherapy (n=62) P-value
Complication 384 (39.0) 36 (59.0) 0.002
Clavien Dindo Grade 0.568
I-II 239 (58.0) 23 (53.5)
III-V 173 (42.0) 20 (46.5)
Length of Stay (days) 12 (7-17) 9 (6-15) 0.080
Readmission within 30 days 39 (4.8) 8 (15.7) 0.001
Postoperative Mortality 35 (3.9) 1 (2.2) 0.569
Adjuvant Therapy
Adjuvant Intra-arterial therapy 102 (14.1) 7 (14.6) 0.921
Adjuvant Chemotherapy 270 (29.0) 30 (50.8) 0.001
Adjuvant Radiotherapy 56 (6.4) 6 (10.7) 0.203
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vs. no pCT: n=35, 3.9%; p=0.569) also did not differ between the two groups. 
Readmission within 30 days from surgery, however, was more common among 
patients who received pCT (pCT: n=8, 15.7% vs. no pCT: n=39, 4.8%; p=0.001). 
Post-operatively, patients in the pCT group more often received adjuvant chemo-
therapy (50.8% vs. 29.0%, p=0.001). 
Impact of preoperative chemotherapy on overall and disease-free survival
At a median follow-up of 27.6 months, mortality occurred in 522 (49.7%) pa-
tients. Median OS among the entire cohort was 37.4 months (95%CI 32.5-42.3 
months) with 1, 3-, and 5-year OS being 78.9%, 51.4%, and 39.2%, respectively. 
Stratified by receipt of pCT, median OS was similar between the two groups 
(pCT: 46.9 months, 95%CI 28.5-65.2 months vs. no pCT: 37.4 months, 95%CI 
32.3-42.5 months; p=0.900; Figure 1). Disease recurrence occurred in 454 
(43.0%) patients. Median DFS among the entire cohort was 29.6 months (95% 
CI 17.2-42.0 months) with 1-, 3-, and 5-year DFS being 64.7%, 46.6%, and 
44.4%, respectively. Stratified by receipt of pCT, median DFS was also similar 
between the two groups (pCT: 34.1 months, 95%CI 2.5-65.7 months vs. no 
pCT: 29.1 months, 95%CI 16.0-42.2 months; p=0.909; Figure 2). 
Figure 1 Overall Survival Stratified by Preoperative Chemotherapy (p = 0.900) 
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In a subgroup analysis of propensity-score matched patients based on the factors 
associated with receipt of pCT (n=100), there was longer OS in the pCT group 
(pCT: 46.9 months, 95%CI 24.3-69.4 months vs. no pCT: 29.4 months, 95%CI 
14.5-44.4 months), however this did not reach statistical significance (p=0.136; 
Figure 3).  Similarly, there was suggestion of an improved DFS in the pCT group 
(pCT: 34.1 months, 95%CI 0-70.2 months vs. no pCT:14.0 months, 95%CI 
7.0-20.9 months; p=0.551).
Figure 2 Disease Free Survival Stratified by Preoperative Chemotherapy (p = 0.909)
Figure 3 Overall Survival Propensity Score-Matched Patients for Resection and Microvascular In-
vasion (p=0.136)
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Discussion
Preoperative therapy is used in several intra-abdominal cancers to reduce local 
and micrometastatic tumor burden prior to complete surgical resection.  Some 
benefits of pCT include the potential to down-size tumors to increase resectability 
rates among patients who are initially deemed unresectable.  Furthermore, pCT 
can potentially improve completeness of surgical resection, as well as help select 
patients with a better tumor biology, thereby improving OS and DFS.  In the 
current study, we examined a large, multi-institutional international cohort of 
patients receiving pCT for ICC.  As the use of pCT among patients with ICC has 
not been well-studied, this represents to our knowledge the largest study to date 
analyzing the impact of pCT among patients undergoing curative-intent resection 
for ICC.  We noted that patients with more advanced disease were more likely to 
receive pCT.  Of note, the use of pCT did result in higher overall but not major 
perioperative morbidity.  Furthermore, in the propensity score-matched cohort, 
there was a suggestion that pCT improved OS and DFS, however these differences 
did not reach statistical significance perhaps due to a small sample size.
The use of pCT has not been examined among patients with ICC in any prospec-
tive clinical trial to date.  Likely due to the overall low incidence of ICC, patients 
with ICC are often grouped in clinical trials with other patients with biliary tract 
cancers.  As such, the benefit of pCT in patients with ICC is ill-defined and not 
commonly utilized.2,14-16 In fact, in the current multi-institutional international 
cohort, the overall utilization of pCT was only 5.9%.  This is likely due to the 
fact that analyses from available studies have been unable to show a reproduc-
ible benefit with the use of pCT among patients with ICC.2,16 Among patients 
with pancreatic adenocarcinoma, however, pCT has been used in patients with 
locally advanced tumors to define the tumor biology.17 In the current cohort, 
patients with more advanced disease were more likely to receive pCT – suggesting 
that physicians were using pCT, in part, to help define the natural history of the 
disease.  Specifically, patients with more preoperative suspected or biopsy-proven 
lymph node metastasis, as well as those patients with worse pathological tumor 
features more commonly received pCT.  Unfortunately, as the current cohort only 
included patients undergoing curative-intent hepatic resection for ICC, we were 
unable to determine the rate of resectability among patients with locally advanced 
disease.  Of note, on final pathology, the use of pCT did not improve complete 
R0 resection rates.  This is likely multifactorial, but largely be due to the selection 
of pCT use for patients with tumors characterized by worse pathological features. 
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Patients who received pCT had increased minor, but not major perioperative 
morbidity or mortality rates versus patients who did not receive pCT.  This is 
similar to previously published data regarding the safety of pCT among patients 
undergoing resection for intra-abdominal cancer.18,19 Despite having more ad-
vanced disease and undergoing larger hepatic resections, patients who received 
pCT had equivalent peri-operative mortality and LOS.  While long-term OS and 
DFS were comparable among patients who did and did not receive pCT, propen-
sity score-matched analysis suggested a possible benefit of pCT regarding both OS 
and DFS – although the association did not reach statistical significance.  While 
it is difficult to know, the lack of significance, despite the considerable differences 
in the point estimates, was likely due to a type II statistical error given the very 
low utilization of pCT in the current cohort.  Nelson et al. had reported that the 
use of pCT combined with radiation therapy improved survival outcomes among 
patients with extrahepatic cholangiogcarcinoma.20 In a different study, Tamandl 
et al. reported on 10 patients with ICC who were treated with pCT and noted no 
survival benefit.21  While the current study was one of the largest series to examine 
ICC patients to receive pCT (n=62), we similarly failed to find an effect of pCT 
on long-term outcomes. As noted, however, the sample size was still relatively 
small and therefore future prospective studies are needed.
In this study, we included 18 patients who received preoperative intra-arterial che-
motherapy, as opposed to the 44 patients who received systemic chemotherapy. 
Intra-arterial therapy consists of the delivery of high doses of chemotherapy 
directly to the arterial circulation.9 This results in high first pass extraction rates 
and minimizes systemic toxicity, as tumors derive most of their supply from the 
arterial circulation.9,22 The effects of intra-arterial therapy have been described 
in 2 clinical trials and a retrospective analysis, which showed promising results 
in patients with liver-confined disease in a palliative setting.9,23,24 In our cohort, 
the lower percentage of patients with preoperatively confirmed lymph node 
metastases in the intra-arterial chemotherapy group (26.7% vs. 44.7%), suggests 
that intra-arterial therapy was most often used preoperatively in patients with 
suspected borderline resectable disease, as opposed to patients with suspected 
micrometastatic disease. Although our finding is in line with current literature on 
patients with irresectable disease, future studies are needed to confirm the validity 
of this approach prior to a curative resection.
Results of the current study should be interpreted in the context of several limita-
tions. As noted, the number of patients treated with pCT was small as the overall 
utilization was only 5.9%.  Therefore, the lack of statistical significance was likely 
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related to a type II error. Additionally, inherent to all retrospective analyses, there 
may have been a selection bias regarding the diagnosis and treatment of patients. 
The inclusion of multiple centers also did not allow for the standardization of op-
erative approach or protocols related to the use of pCT or adjuvant chemotherapy. 
The multi-center nature of the study adds to the generalizability of the study, 
allowing the finding to be applied across a wide range of patient populations.  
Conclusions
In conclusion, pCT utilization among patients with ICC is higher among patients 
with more advanced disease.  In this large, multi-institutional cohort, the use 
of pCT did not impact short-term peri-operative outcomes such as morbidity 
or LOS.  While OS and DFS following resection were not significantly differ-
ent across treatment groups, propensity matching suggested possible improved 
outcomes in patients treated with pCT.  Further prospective trials are needed, 
however, to better define the role of pCT and to identify the subset of patients 
who might yield the most clinical benefit from the use of pCT.  
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Abstract
Introduction: Extrahepatic biliary malignancies are often diagnosed at an 
advanced stage. We compared patients with unresectable peri-hilar cholangio-
carcinoma (PHCC) and gallbladder cancer (GBC) who underwent a palliative 
procedure versus an aborted laparotomy.
Methods: 777 patients who underwent surgery for PHCC or GBC between 
2000-2014 were identified. Uni- and multivariable analyses were performed to 
identify factors associated with outcome.
Results: Utilization of preoperative imaging increased over time (CT use: 80.1% 
pre-2009 vs. 90% post-2009) (p<0.001). The proportion of patients undergoing 
curative-intent resection also increased (2000-2004:67.0% vs. 2005-2009:74.5% 
vs. 2010-2014:78.8%; p=0.001). The planned surgery was aborted in 106 
(13.7%) patients, and 94 (12.1%) had a palliative procedure. A higher incidence 
of postoperative complications (19.2% vs. 3.8%, p=0.001) including deep surgi-
cal site infections (8.3% vs. 1.1%), bleeding (4.8% vs. 0%), bile leak (6.0% vs. 
0%) and longer length-of-stay (7 vs. 4.5 days) were observed among patients 
who underwent a palliative surgical procedure versus an aborted non-therapeutic, 
non-palliative laparotomy (all p<0.05).  OS was comparable among patients who 
underwent a palliative procedure (8.7 months) versus an aborted laparotomy (7.8 
months) (p=0.23).
Conclusion: Increased use of advanced imaging modalities was accompanied by 
increased curative-intent surgery. Compared with patients in whom surgery was 
aborted, patients who underwent surgical palliation demonstrated an increased 
incidence of postoperative morbidity with comparable survival. 
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Introduction
Extrahepatic biliary malignancies represent up to 3% of all cancers in the United 
States with a dramatic rise in the incidence of these malignancies noted over the 
last several decades.1,2 Despite recent advances in diagnostic tools, peri-operative 
therapy and surgical approach, prognosis following resection of these malignan-
cies remains poor. Given their diffuse and sclerotic nature, extrahepatic biliary 
tumors tend to invade local structures and a subset have an increased propensity 
for distant metastasis. As a consequence, many patients are either diagnosed at 
advanced stages of disease when curative resection is no longer feasible or are 
found to have unresectable or metastatic disease at the time of surgery.2,3 For 
example, in a recent report of patients with hilar cholangiocarcinoma, only 36% 
of patients were amenable to surgery at the time of diagnosis due to metastatic 
or locally advanced disease.4 Under such circumstances, rather than cure, efforts 
are often aimed at palliating symptoms of biliary obstruction including jaundice, 
pruritis, nausea and weight loss. However, procedures for biliary drainage includ-
ing percutaneous transhepatic cholangiography (PTC) and endoscopic retrograde 
cholangiography (ERC) are invasive and complications following their use may 
compromise further management and quality of life.1,2,4 
Currently, there is disagreement about what constitutes the most appropriate 
method for palliation. Non-operative management is typically recommended 
among patients with a life expectancy of less than 6 months who present with 
malignant obstructive jaundice, while the best course of treatment among pa-
tients found to have unresectable disease at the time of surgery is debated.5-8 Data 
evaluating the utilization patterns and outcomes of palliative surgery are scarce, 
with most reports coming from small cohorts at single centers.  As such, these 
reports are limited and may not be generalizable. With an increasing number of 
patients diagnosed with extrahepatic malignancies each year, data on the use of 
palliative surgical procedures may help inform the management of these difficult 
to treat patients. Given this, the aim of the current study was to analyze trends in 
operative approach among patients undergoing non-curative operations for extra-
hepatic biliary malignancies.  Specifically, using a large, multi-institutional cohort 
of patients, we sought to compare short- and long-term outcomes of patients 
with unresectable peri-hilar cholangiocarcinoma (PHCC) and gallbladder cancer 
(GBC) who underwent a palliative procedure versus an aborted non-therapeutic, 
non-palliative exploratory laparotomy.
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Methods
Data Sources and Patient Population
Patients presenting with PHCC or GBC between January 1, 2000 and December 
31, 2014 were identified using the Extrahepatic Biliary Malignancy Consortium 
database from 2000-2014. Collected at and maintained by 10 academic centers 
in the United States (Johns Hopkins University, Baltimore, Maryland; Emory 
University, Atlanta, Georgia; Stanford University, Stanford, California; University 
of Wisconsin, Milwaukee, Wisconsin; Ohio State University, Columbus, Ohio; 
Washington University, St. Louis, Missouri; Vanderbilt University, Nashville, 
Tennessee; New York University, New York, New York; University of Louisville, 
Louisville, Kentucky; Wake Forest University, Winston-Salem, North Carolina), 
the Extrahepatic Biliary Malignancy Consortium database records sociodemo-
graphic and clinicopathologic characteristics for all patients presenting with a 
primary extrahepatic biliary malignancy. Specifically, sociodemographic variables 
including age, sex and race, as well as clinicopathologic characteristics such as the 
American Society of Anesthesiology (ASA) physical classification score, presence 
of preoperative comorbidity, preoperative imaging, preoperative serum CA-19-
9, preoperative peak serum bilirubin and type of cancer were recorded for each 
patient record. Tumor size, tumor grade, margin status as well as the presence of 
nodal disease and / or invasion of adjacent structures was determined using the 
final histopathology report. Additionally, intraoperative characteristics including 
the type and extent of surgery, completion of the procedure as well as the nature 
of the procedure (curative vs. palliative) were also recorded for each patient. Pallia-
tive procedures included both biliary bypass and cholecystectomy, both of which 
have been previously reported as palliative procedures to help improve quality of 
life.9-11 Perioperative morbidity was classified according to the Clavien-Dindo 
classification system while other short-term perioperative outcomes recorded for 
each patient included index hospitalization length-of-stay (LOS), perioperative 
mortality, and 30-day readmission.12 Overall survival (OS) was calculated from 
the date of surgery to the date of death or last follow-up, as appropriate. The 
institutional review board of each participating institutional approved this study.
Statistical Analysis
Continuous variables were described as means with standard deviation or medians 
with interquartile range (IQR) while categorical variables were reported as whole 
numbers and proportions. For ease of interpretation, patients were categorized 
into one of three groups based on year of diagnosis: 2000-2004, 2005-2009 and 
2010-2014.13 Differences in patient, disease and treatment-specific characteristics 
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were compared among these groups using the Pearson’s Chi-squared test or a 
Kruskal-Wallis test, as appropriate. OS was estimated using the Kaplan-Meier 
method and differences in OS were compared between patient groups using the 
Mantel-Haenszel test. Uni- and multivariable Cox proportional hazard regression 
analysis was performed to identify clinicopathologic characteristics predictive 
of a poor postoperative survival. All variables with a corresponding p<0.20 on 
univariable analysis were entered into the multivariable model. Results from mul-
tivariable analysis were presented as hazard ratios (HR) with corresponding 95% 
confidence intervals (95%CI). All analyses were performed using STATA version 
13.0 (StataCorp, College Station, TX) and p<0.05 (two-tailed) was used to define 
statistical signiﬁcance.
Results
Baseline sociodemographic and clinicopathologic characteristics
A total of 777 patients who underwent surgery for hilar cholangiocarcinoma 
(n=328, 42.2%) or gallbladder carcinoma (n=449, 57.8%) between January 1, 
2000 and December 31, 2014 were identified (Table 1). The median age of patients 
was 66.6 years (IQR 57.6-73.1) and a majority of patients were female (n=429, 
55.2%). Nearly two-thirds of patients presented with an ASA score of 3 or 4 
(n=364, 64.2%). The median CA-19-9 among all patients was 63.8 (18.0-281.0) 
U/mL while the median peak and final preoperative bilirubin for all patients was 
1.6 (0.6-8.4) mg/dL and 0.9 (0.5-2.3) mg/dL, respectively. Preoperative clinical 
jaundice was observed in 350 patients (48.4%). Preoperatively, 405 patients had 
no biliary drainage or stent (52.9%), while 191 (25.0%) underwent endoscopic 
drainage, 95 (12.4%) were drained percutaneous and 74 (9.7%) underwent 
both types of drainage.  Neoadjuvant therapy was administered to 43 patients; 
30 (3.9%) patients received preoperative chemotherapy and 13 (1.7%) patients 
received neoadjuvant radiotherapy.
At the time of surgery, a diagnostic laparoscopy was performed in 211 (27.2%) 
patients. Among all patients who underwent surgery, the planned surgery was 
aborted in 106 (13.7%) due to the presence of either locally advanced disease 
(n=22, 20.8%) or the presence of metastatic disease (n=84, 79.3%).  In contrast, 
94 (12.1%) patients who had unresectable disease underwent a palliative surgical 
procedure (cholecystectomy, n=47, 63.5%; bile duct resection, n=14, 18.9%). 
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Trends in patient, disease and operative characteristics over time
To compare trends in disease presentation and treatment over time, patients were 
divided into three categories based on the year of diagnosis. Marked differences were 
noted among these three patient groups. For example, the proportion of patients 
with an ASA score of 3 or 4 undergoing surgery was noted to increase over the 
study time, with 71.9% (n=171) of patients having an ASA score of 3 or 4 between 
2010-2014 compared with 50.0% (n=56) and 63.1% (n=137) of patients between 
2000-2004 and 2005-2009, respectively (p<0.001). Of note, the use of preoperative 
imaging also increased over the study period. Compared with 80.1% (n=153) of 
patients between 2000-2004 who had a preoperative computed tomography (CT) 
scan, over 90% (n=276, 91.1%) of patients underwent a preoperative CT scan 
in the last five years of the study (p<0.001). Similarly, the proportion of patients 
undergoing preoperative magnetic resonance imaging (MRI) increased from 25.1% 
(n=48) between 2000-2004 to 53.5% (n=161) between 2010-2015 (p<0.001). Pa-
tients undergoing surgery in the last five years of the study were also proportionally 
more likely to have received neoadjuvant therapies; specifically, the proportion of 
patients receiving neoadjuvant chemotherapy increased from 1.0% (n=2) between 
2000-2004 to 6.3% (n=19) between 2010-2014 (p=0.009). A similar trend in the 
receipt of neoadjuvant radiation therapy was not observed (p=0.310). Interestingly, 
while the proportion of patients undergoing a curative-intent resection increased 
from 67.0% before 2005 to 78.8% in the last five years of the study, the proportion 
of patients undergoing a palliative procedure decreased from 16.3% between 2000-
2004 to 6.6% between 2010-2014 (p=0.001). Of note, the number of aborted pro-
cedures (in which the surgery was ended due to the presence of unresectable disease 
upon surgical exploration of the abdomen) did not change over time (Figure 1, 2). 
Although the proportion of patients presenting with preoperative jaundice decreased 
from 52.8% between 2000-2004 to 42.0% between 2010-2014 (p=0.017), T-stage 
and the proportion of patients presenting with lymph node metastases and distal 
disease remained the same (all p>0.05).
Trends in diagnosis and treatment of patients with metastatic disease
In our cohort, 123 patients were found to have distant disease.  Disease was lo-
cated in the liver in 33 (27.7%) of these patients, while 53 (44.5%) patients had 
peritoneal carcinomatosis and 11 (9.2%) had both.  The remainder of patients 
(22 (18.5%)), had distant disease elsewhere. Although our dataset is limited, it 
appears that distant disease was not noted on preoperative scans. More specifically, 
none of the patients in the cohort had any visible metastases on preoperative PET-
CT, the image modality of choice for diagnosing distant metastases. Thirty-five 
patients with metastatic disease were diagnosed by laparoscopy. Of those 6 were 
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located in the liver, 22 were cases of peritoneal carcinomatosis, 6 were both liver 
and peritoneal carcinomatosis and 1 was located elsewhere. Four patients then 
went on to have a palliative resection.  The remainder of patients with metastatic 
disease were diagnosed by laparotomy (88 (71.5%)). Of those metastases, 27 were 
located in the liver, 31 were cases of peritoneal carcinomatosis, 5 were both liver 
and peritoneal carcinomatosis, and 21 were located elsewhere. Thirty-five (39.7%) 
patients with distant disease diagnosed by laparotomy went on to have a palliative 
intent resection, while the remaining operations were aborted.
Figure 1. Aborted, palliative and curative-intent operations stratified by year of procedure 
(p=0.001).
Trends in postoperative outcomes over time
Among all patients identified, the total LOS was noted to decrease from an aver-
age of 7 days (IQR 5-11) before 2005 to 6 days (4-10) after 2009 (p<0.001). 
However, a similar trend in postoperative morbidity or mortality was not noted. 
In fact, the overall incidence of postoperative complications, the average number 
of postoperative complications and postoperative mortality was comparable across 
all time periods examined (p>0.05). Of note, patients who underwent a palliative 
procedure had worse postoperative outcomes compared with patients who had 
an aborted non-therapeutic, non-palliative exploratory laparotomy (Table 2). 
Specifically, a higher incidence of major postoperative complications (19.2% vs. 
3.8%, p=0.001), including deep surgical site infections (8.3% vs. 1.1%, p=0.025), 
bleeding (4.8% vs. 0%, p=0.039) and bile leak (6.0% vs. 0%, p=0.020) were ob-
served among patients who underwent a palliative surgical procedure. Similarly, 
the median LOS was higher among patients who underwent a palliative procedure 
(7 days (IQR 5-10) vs. 4.5 days (IQR 2-7); p<0.001).  Readmission rates and 
perioperative mortality, however, were not different between groups (p>0.05).
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Table 2. Comparison between Aborted Resection and Palliative Resection.
Variable N (%)
Aborted 
(n = 106)
Palliative Surgery 
(n = 94)
p-value
Perioperative Mortality 10 (5.1) 4 (3.8) 6 (6.7) 0.349
Complications 76 (38.0) 32 (30.2) 44 (46.9) 0.031
Minor Complication 54 (27.0) 28 (26.4) 26 (27.7) 0.843
Major Complication 22 (11.0) 4 (3.8) 18 (19.2) 0.001
# of Complications 0 (0-1) 0 (0-1) 1 (0-1) 0.010
Clavien Dindo Grade II (I-IIIa) I (I-II) II (I-IIIa) 0.012
Specific Complications  
Superficial Surgical Site Infection 12 (7.0) 5 (5.7) 7 (8.3) 0.495
Deep Surgical Site Infection 8 (4.7) 1 (1.1) 7 (8.3) 0.025
Intra-abdominal Infection 4 (2.3) 2 (2.3) 2 (2.4) 0.962
Bleeding 4 (2.3) 0 4 (4.8) 0.038
Bile Leak 5 (2.9) 0 5 (6.0) 0.020
Anastomotic Leak 1 (0.6) 0 1 (1.2) 0.305
New Post-op Ascites 3 (1.8) 1 (1.15) 2 (2.4) 0.533
Reoperation 5 (2.5) 2 (1.9) 3 (3.23) 0.554
Peak Postop Bilirubin 1.9 (0.8-5.4) 1.8 (0.8-4.9) 2 (0.8-6.2) 0.627
Length-of-Stay (days) 6 (3-8) 4.5 (2-7) 7 (5-10) <0.001
Readmission 55 (29.4) 32 (31.7) 23 (26.7) 0.460
Time to Readmission 17.5 (7-37) 14.5 (7.5-37.5) 24.5 (7-37) 0.481
Location of Readmission  
Participating Center 53 (98.2) 31 (96.9) 22 (100) 0.403
Other 1 (1.9) 1 (3.1) 0  
Trends in OS and factors associated with OS
The median OS among all patients was 17.3 months (IQR 8.2-43.7, figure 3) with 
1-year OS being 64.1% (95%CI 60.4-67.6). Of note, OS increased across the 
time periods examined, varying from 15.5 months (IQR 6.9-41.0) among patients 
undergoing surgery between 2000-2004 to 19.2 months (IQR 10.1-53.1) among 
patients undergoing surgery after 2009 (p=0.069). Similarly, estimates for 1-year 
OS increased from 58.2% (95%CI 50.8-64.9) to 69.9% (95%CI 63.7-75.3) across 
the study period (p<0.001). In contrast, median OS among patients who underwent 
a palliative procedure or a procedure that was aborted was noted to be 8 months 
(IQR 4.0-16.1) and was comparable among patients who underwent a palliative 
procedure (8.7 months) versus patients who had an aborted non-therapeutic, non-
palliative exploratory laparotomy (7.8 months) (p=0.23) (Figure 4). 
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Figure 2. Reason for (a) palliative and (b) aborted, non-therapeutic, non-palliative laparotomy 
stratified by year of procedure.
Cox proportional hazards regression was performed to identify potential risk 
factors for a worse OS.  Increasing patient age (HR 1.01, 95%CI 1.00-1.03, 
p=0.063), a higher peak preoperative bilirubin level (HR 1.02, 95%CI 1.00-1.04, 
p=0.131) and a positive diagnostic laparoscopy (HR 1.54, 95% CI 1.12-2.12, 
p=0.008) were associated with a worse OS (Table 3). After adjusting for these 
competing risk factors risk factors on multivariable analysis, a higher peak preop-
erative bilirubin (HR 1.02, 95%CI 1.00-1.04, p=0.045) and a positive diagnostic 
laparoscopy (HR 1.52. 95%CI 1.09-2.13, p=0.015) were noted to be indepen-
dently associated with a worse overall survival.
Figure 3. Overall Survival.
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Table 3. Univariable and Multivariable Cox Regression Model of Overall Survival after Resections 
with Non-Curative intent.
Variable Name
Univariable Analysis Multivariable Analysis
HR 95%CI P-value HR 95%CI P-value
Age 1.01 1.00-1.03 0.063 1.01 0.99-1.03 0.215
Male Gender 0.91 0.67-1.23 0.542  
Race  
White Ref - -  
Black 1.00 0.56-1.78 0.999  
Other 1.15 0.73-1.82 0.541  
BMI 0.99 0.96-1.02 0.367  
ASA Score 3-4 1.14 0.78-1.66 0.501  
CA 19-9 1.00 1.00-1.00 0.940  
Peak Bilirubin 1.02 1.00-1.04 0.131 1.02 1.00-1.04 0.045
Last Bilirubin 1.01 0.98-1.04 0.453  
Biliary Drainage or Stent  
None Ref - -  
Endoscopic 1.17 0.82-1.67 0.398  
Percutaneous 1.28 0.79-2.08 0.317  
Endoscopic and percutaneous 1.01 0.62-1.65 0.953  
Preoperative Chemotherapy 0.86 0.35-2.10 0.739  
Preoperative Radiation 1.50 0.47-4.71 0.492  
Diagnostic Laparoscopy 1.54 1.12-2.12 0.008 1.52 1.09-2.13 0.015
Palliative Resection 0.84 0.62-1.14 0.274  
Reason for Palliation  
Locally Advanced Disease Ref - -  
Presence of Metastases 1.15 0.85-1.57 0.365      
Figure 4. Overall survival stratified by receipt of palliative procedure vs. aborted, non-therapeutic, 
non-palliative laparotomy (p=0.23).
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Discussion
Extrahepatic biliary malignancies represent a heterogeneous group of malignan-
cies accounting for 3% of all cancers within the United States.1,2 Given their 
aggressive nature and propensity for early metastasis, less than a third of patients 
are amenable to cure.14-18 Given this, palliative surgical resection is often the only 
option to relieve the symptoms of biliary obstruction including jaundice, pruritis, 
nausea and weight loss.19 Data evaluating the patterns of use and prognosis fol-
lowing palliative surgery remain limited with most data collected at single, spe-
cialized centers.5-8 The current study is important in that it represents one of the 
largest studies to assess the patterns of use and trends of non-curative surgery for 
extrahepatic biliary malignancies. Using a multi-centric cohort of 777 patients, 
we noted a decreasing trend in the use of palliative surgery with an increasing 
number of curative-intent resections being performed over the study time period. 
Further, the current study noted an increase in the use of imaging modalities for 
preoperative assessment / planning with the number of patients undergoing a 
preoperative CT or MRI scan increasing with time. Perhaps of greater interest, 
postoperative clinical outcomes were also noted to improve with time as overall 
survival and estimated 1-year OS both were better over time. Specifically, patients 
who underwent surgery before 2004 demonstrated an OS of 15.5 months com-
pared with an OS of 19.2 months among those undergoing surgery after 2009. 
The observed increased trend in the number of curative-intent resections being 
performed is likely multifactorial and may be a consequence of improvements in 
diagnostic imaging and surgical technique in recent years. Studies assessing the 
efficacy of diagnostic imaging for biliary cancers have demonstrated that newer 
imaging modalities such as MRCP and PET scans can achieve an accuracy of 
up to 84.9% and 77.9% in assessing T and N staging, as well as a sensitivity of 
78% in detecting portal vein invasion and a sensitivity ranging from 58-73% in 
detecting hepatic artery invasion.20,21 In the current study, we noted the use of 
CT, MRI and PET for preoperative planning increased from 80.1%, 25.1% and 
4.7% before 2005 to 91.1%, 53.5% and 14.2% in the years following 2009. 
As such, the increased use of MRI and PET scans may have contributed to the 
greater proportion of patients being identified with resectable disease and a greater 
proportion of patients amenable to curative resection. Of note, patients did not, 
however, present with an earlier stage of disease, as T-stage, nodal metastases and 
distant disease status were equal among the three time periods (Table 1). Only 
clinical jaundice declined over time from 52.8% (n=93) between 2000-2004 to 
42.0% (n=123) between 2010-2014 (p=0.017). The increase in curative resections 
in a population in which the stage of the disease is unchanged may also indicate 
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a trend towards a more aggressive surgical approach over time. Furthermore, the 
proportion of aborted non-therapeutic, non-palliative exploratory laparotomy 
procedures was not observed to change over time. This suggests that advancements 
in diagnostic imaging still cannot fully delineate whether all extrahepatic biliary 
tract tumors are resectable based on preoperative cross-sectional imaging, and 
remain inadequate at diagnosing low volume disease such as peritoneal carcino-
matosis.  Due to the aggressive nature of many extrahepatic biliary malignancies, 
it is also possible that disease may spread significantly during the time between 
imaging and operation.  In order to continue the trend toward increased curative 
resections while limiting the number of non-therapeutic laparotomies, we recom-
mend utilizing laparoscopy, whenever possible, to diagnose the extent of disease 
in these patients.  Although our data does show a significant increase in the use of 
laparoscopy over time from 23.6% to 34.3% of cases (p=0.002), the majority of 
patients underwent laparotomies, even in the most recent tercile.
Another interesting finding of the current study was a decreasing LOS among pa-
tients following surgery despite an increasing trend in the proportion of patients 
with a high ASA score (ASA score III or IV) undergoing resection. Specifically, 
LOS was noted to decrease from 7 days before 2005 to 6 days after 2009 while 
the numbers of patients with an ASA score of III or IV increased from 50.0% 
in 2004 to over 71% after 2010. These observed differences are likely due to ad-
vances in surgical technique and improvements in the perioperative management 
of patients. For example, recent studies have reported an increased utilization 
of portal vein reconstruction with favorable outcomes, which in turn allows for 
the resection of more challenging tumors.13,22,23  Additionally, intraoperative 
and postoperative practices such as restricted fluid resuscitation strategies and 
enhanced recovery pathways have facilitated a better perioperative recovery and 
an overall decreased risk for complications.21-23 Further highlighting improve-
ment in peri-operative practices was our finding of a decreased number of patients 
who underwent a palliative procedure over time.  Specifically, the proportion of 
patients undergoing palliative surgery decreased from 16.3% during the first 
five years to 6.6% over the last five years. In contrast, the proportion of patients 
undergoing a non-operative biliary decompression and in particular the propor-
tion of patients undergoing an endoscopic biliary decompression increased over 
time (Table 1). Of note, patients who underwent a palliative surgical procedure 
demonstrated an increased incidence of postoperative complications with major 
complications such as bleeding and bile leaks more often noted following surgery. 
While endoscopic palliation with self-expanding metal stents remains a good 
treatment option for patients with preoperatively identified unresectable disease, 
303
Palliative Surgery for Extrahepatic Biliary Malignancies
our data demonstrated comparable postoperative bilirubin levels among patients 
who underwent surgical biliary decompression suggesting that this approach is 
an effective palliative surgical option.24 Results from the current study, as well as 
previous reports, highlight the potential benefits of biliary decompression among 
patients with unresectable disease.  Surgical palliation did come at a cost, however, 
as these patients had an increased risk of complications and a longer LOS. 
In addition to short-term perioperative clinical outcomes, the current study also 
sought to compare long-term clinical outcomes among patients with biliary can-
cers. The median overall survival for all patients was 17.3 months and was noted 
to be lower among patients undergoing non-curative intent surgery. Perhaps of 
greater interest, median OS among patients who underwent a palliative surgery 
was 8.7 months compared with 7.8 months for patients in whom surgery was 
aborted due to metastatic or locally advanced disease. Consistent with the results 
of the current study, Conner et al. in a review of patients with hilar cholangio-
carcinoma, as well as Ercan and colleagues in a separate study of patients with 
gallbladder cancer, demonstrated comparable long-term survival among patients 
undergoing surgical palliation versus a non-therapeutic laparotomy.25,26  It is also 
important to note that, according to recent literature, median survival in patients 
receiving chemotherapy without surgical resection for locally advanced or meta-
static biliary tract cancers ranges from 8 to 12 months depending upon the type 
of chemotherapy used.  Therefore, palliative resection does not appear to provide 
survival benefit in comparison to medical treatment alone.27, 28  
Results of the current study should be interpreted with the following limitations. 
First, the data used in the current analysis were collected at 10 large, academic 
centers each with their own patient case mix, clinical practices and protocols. As 
such, differences among centers could not be controlled for and may have resulted 
in some residual confounding. However, the use of a large, multi-centric cohort of 
patients facilitated more generalizable results and an adequate sample size to assess 
trends over time. Second, we were unable to account for any selection bias given 
the retrospective nature of the study. For example, patients who underwent a pal-
liative resection may have been more amenable to surgery compared with patients 
who had an aborted non-therapeutic, non-palliative laparotomy. Since this is a 
retrospective study, we were unable to determine all the specific circumstances 
related to the surgeon’s decision to pursue a palliative procedure at the time of 
surgery, or specific information on the type of palliative procedure performed. 
For this reason, we were unable to make data-driven comparisons between those 
undergoing surgical biliary bypass versus endoscopic or percutaneous biliary 
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drainage, which would have helped in making recommendations for the treat-
ment of patients with biliary obstruction.
Conclusion
In conclusion, the current study noted an increase in the number of patients 
undergoing curative intent surgery for gallbladder carcinomas and hilar cholan-
giocarcinomas over time. The observed increase in curative surgery was associated 
with an increased use of advanced imaging modalities preoperatively, which may 
have led to better identification of patients with resectable disease, and therefore 
a decrease in surgical palliation that was observed over time. Compared with pa-
tients in whom surgery was aborted, patients who underwent a surgical palliation 
demonstrated an increased incidence of postoperative morbidity with comparable 
survival. These data should help inform decisions around intraoperative manage-
ment of patients with unresectable PHCC or GBC.
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Abstract
Background Radioembolization with yttrium-90 microspheres (90Y) is a promis-
ing technique for extending intrahepatic cholangiocarcinoma patient survival in 
those patients ineligible for surgical resection.
Methods Patients who underwent 90Y radioembolization were retrospectively 
included from five tertiary care centers. In all hospitals, prospectively maintained 
databases were supplemented with information from electronic patient charts.
Results A total of 89 patients met our inclusion criteria. Of these patients, 69 
were treated with resin microspheres (77.5%), while 19 patients were treated with 
glass microspheres (n = 19; 21.3%), and one patient was treated with both. Toxic-
ity was observed in 55 patients (80%) in the resin group and 11 patients (58%) in 
the glass group. On average, glass seemed to have lower grade toxicity (p = 0.007). 
Complications according to the SIR-definition were noted in 18 patients (26.5%) 
in the resin group and 4 patients (21.1%) in the glass group (p = 0.631). Median 
overall survival (OS) from diagnosis was 29.2 months (95%CI: 18.6-39.8) for 
patients treated with resin microspheres, and 1-, 3- and 5-year OS were 82.8%, 
32.9% and 8.0%. Median OS after treatment with resin microspheres was 9.5 
months (95%CI: 6.1-12.8) and 1- and 3- year OS were 37.1% and 6.8%. These 
estimates were not significantly different in the glass group. Five patients were able 
to undergo curative intent resection after 90Y (5.9%), two of these patients died of 
the complications of their surgery.
Discussion This study shows the potential of 90Y radioembolization, as well as its 
safety and effectiveness.
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Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver 
malignancy in the West, with an incidence of about 2 per 100,000.1-3 Although 
surgical resection is the only curative treatment for proximal bile duct malignan-
cies, only 15% of patients are eligible for operation at the time of presentation.4-8 
In patients who are not eligible for resection, a median survival of 3 to 8 months 
is observed.9,10 It is possible to extend this period up to twelve months with a che-
motherapy regimen of gemcitabine and cisplatin.11 However, almost half of these 
patients develop significant clinical toxicities and adverse events.11-13 In order 
to extend life and increase the quality of life, numerous non-surgical approaches 
are currently being utilized in intrahepatic cholangiocarcinoma, one of the most 
notable being radioembolization with yttrium-90 (90Y ) microspheres.
Radioembolization has been shown to extend life and suppress tumor sequelae in 
large cohorts for unresectable HCC and colorectal liver metastases.14,15 It has been 
pioneered in a number of small series in proximal bile duct malignancies. These 
studies indicate that 90Y radioembolizations are tolerated well in relatively healthy 
patients, as measured by their low Eastern Cooperative Oncology Group (ECOG) 
performance status.9,16-20 In addition, 90Y radioembolization was correlated with 
longer survival, when compared with patients undergoing best supportive care 
only.9,16-20 Further comparisons with other treated groups and eventually prospective 
trials are required to truly evaluate the potential of 90Y radioembolization therapy.
In this study we describe survival after diagnosis, and after 90Y radioembolization. 
Furthermore, we detail and compare the rate and severity of complications after 
90Y radioembolization treatment for two currently used types of microspheres.
Methods
All patients undergoing radioembolization with 90Y microspheres between Janu-
ary 1, 2000 and January 1, 2016 in five tertiary care centers (University Medical 
Center Utrecht, Utrecht, the Netherlands; Johns Hopkins Hospital, Baltimore, 
Maryland; Vanderbilt University Medical Center, Nashville, Tennessee; MD 
Anderson Cancer Center, Houston, Texas; Stanford University Medical Center, 
Stanford, California) were included in this study.
In all hospitals, prospectively maintained databases were supplemented with informa-
tion from electronic patient charts. Sociodemographic and clinicopathologic variables 
were collected for all patients and included age, sex, baseline hepatobiliary disease, 
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lab values, clinical work-up and prior / other treatments including chemotherapy and 
resection. Details on the 90Y radioembolization treatment were collected, including 
the activity calculation method, administered activity, targeted volume and treatment 
sessions. Post-intervention complications were reported following the SIR definition 
and grading system21 and biochemical toxicity was assessed using the Common 
Terminology Criteria for Adverse Events 4.0 based on post-intervention alkaline 
phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and 
bilirubin.22 Follow-up was retrieved from the electronic patient records. The respec-
tive institutional review boards of each participating institution approved this study.
Pretreatment mesenteric angiography and technetium-99m macroaggregated al-
bumin (99mTc-MAA) scanning were performed according to previously published 
guidelines.23 This method was also used to calculate the pulmonary shunt fraction 
(PSF). Devices used were TheraSphere® glass microspheres (BTG, London, United 
Kingdom) and SIR-Spheres® resin microspheres (Sirtex, Lane Cove, New South 
Wales, Australia). The United States Food and Drug Administration (FDA) approved 
TheraSphere® for hepatocellular carcinoma (HCC). This device was used off-label for 
the treatment of the patients included in this study. SIR-Spheres® have been FDA-ap-
proved as a brachytherapy treatment for unresectable liver tumors. For the purpose of 
this study post-intervention outcomes for resin microspheres and glass microspheres 
were compared, with regard to toxicity, and complications. A preliminary analysis 
of long-term outcomes was performed. Dose was calculated using the body surface 
area (BSA) method for resin and using the Medical Internal Radiation Dose (MIRD) 
method for glass. The exception was Stanford University Medical Center, where the 
MIRD method was utilized post 2011 for all patients, including resin. Patients with 
bilobar disease were treated in a sequential lobar fashion. Patients were evaluated at 
regular intervals after treatment. After treatment, best tumor response was assessed 
by post-intervention contrast-enhanced computed tomography (CT) according to 
the Response Evaluation Criteria in Solid Tumors (RECIST).24
Statistical analysis
Continuous variables were described as medians with interquartile range (IQR). 
Categorical variables were described as totals and frequencies. Differences in groups 
were assessed using the χ2 test for categorical and the Mann-Whitney U-test for 
continuous variables. Survival was estimated using the Kaplan-Meier method, and 
differences between survival were examined with the log-rank test. All analyses 
were carried out with SPSS 22 (International Business Machines Corporation, 
NY) and R 3.3.3 (https://cran.r-project.org/), and a P value of <0.05 (two tailed) 
was considered statistically significant.
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Results
A total of 89 patients met our inclusion criteria and were included into this study 
(Table 1). Sixty-nine patients were treated with resin microspheres (77.5%), while 
19 patients were treated with glass microspheres (n = 19; 21.3%). Two patients 
presented with portal vein thrombosis and were therefore treated with glass 
microspheres, as resin microspheres were considered too embolic. One patient 
was treated with both glass and resin microspheres and was disregarded for the 
purpose of comparison. A majority of patients were female (n = 50; 57.2%) and 
most patients had an ECOG/WHO status of 0 or 1 (n = 83; 93.3%). Patients had 
an average BMI of 26.2 (Interquartile range [IQR]: 22.9-30.4). Eight patients 
had a prior medical history of cirrhosis (10.1%). Nine patients had cholangitis 
(10.5%), and 7 patients presented with clinical jaundice (7.9%). In all patients, 
pre-intervention imaging was acquired and in the vast majority of patients this 
consisted of CT with or without further imaging techniques (n = 83; 93.3%). 
Median CA 19-9 was heightened at 107.0 U/mL (IQR: 27.1-683.4), as were 
liver markers AST and ALT. Alkaline Phosphatase, a marker of biliary damage, 
was elevated as well. The average tumor diameter was 6.2 cm (IQR: 4.7-8.0) and 
most patients had multiple tumors (n = 61; 68.5%). Suspicious lymph nodes were 
identified in 32 patients (37.6%), and distant metastases in 22 patients (25.6). 
Vascular involvement was reported in 33 patients (38.8%).
Table 1. Baseline Characteristics
Characteristic
Resin microspheres 
(n = 69)
Glass microspheres
 (n = 19)
Total (n = 89)
Total 69 (100.0) 19 (100.0) 89 (100.0)
Male Gender 31 (44.9) 8 (42.1) 39 (43.8)
ECOG / WHO
0 28 (40.6) 11 (57.9) 39 (43.8)
1 36 (52.2) 7 (36.8) 44 (49.4)
2 4 (5.8) 1 (5.3) 5 (5.6)
3 1 (1.4) 0 (0.0) 1 (1.1)
Body Mass Index 26.2 (22.9-30.2) 29.5 (22.9-31.0) 26.2 (22.9-30.4)
Baseline Hepatobiliary Disease
Biliary Stone 4 (6.0) 1 (5.6) 5 (5.8)
Cholangitis 7 (10.4) 2 (11.1) 9 (10.5)
Hepatitis B 3 (5.1) 0 (0.0) 3 (3.9)
Hepatitis C 4 (6.8) 1 (6.3) 5 (6.6)
Cirrhosis 6 (8.7) 3 (15.8) 9 (10.1)
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At the time of radiological intervention, 12 patients (15.7%) had undergone prior 
resection with curative intent (Table 2). In 40% of cases, these resections consisted 
of a major liver resection >3 Couinaud segments (n = 6; 42.9%). Most patients 
undergoing resection had a negative margin (n = 9; 64.3%); one patient (7.1%) 
had macroscopic disease left at the resection margin and one patient underwent 
margin re-excision during surgery. Prior chemotherapy was given in 66 patients 
(74.2%) and consisted of gemcitabine and cisplatin in most cases. Median frac-
tion of pulmonary shunting was 5.3% (IQR: 3.1-8.7) in patients treated with 
Table 1. Baseline Characteristics (continued)
Characteristic
Resin microspheres 
(n = 69)
Glass microspheres
 (n = 19)
Total (n = 89)
Lab
CA 19-9, kU/L 107.0 (27.1-744.0) 52.0 (18.8-2245.5) 107.0 (27.1-684.4)
Carcinoembryonic antigen, μg/L 3.0 (1.0-15.6) 2.4 (2.0-3.5) 3.0 (1.5-8.5)
Alkaline Phosphatase, U/L 174.0 (129.3-263.5) 125.0 (89.0-151.0) 156.5 (117.8-247.0)
Hemoglobin, g/dL 12.2 (10.7-13.7) 12.4 (10.1-13.4) 12.2 (10.6-13.7)
Platelets x 109/L 210 (129-281) 189 (129-249) 208 (129-265)
ALT, U/L 34.0 (22.0-48.0) 22.0 (20.0-42.0) 33.0 (21.2-47.2)
AST, U/L 38.0 (29.0-50.0) 38.0 (24.0-62.0) 38.0 (27.0-50.0)
Albumin, g/dL 3.9 (3.4-4.1) 3.8 (3.5-4.1) 3.9 (3.5-4.1)
Bilirubin, mg/dL 0.5 (0.4-0.8) 0.6 (0.3-0.9) 0.5 (0.3-0.8)
Clinical Jaundice 6 (8.7) 1 (5.3) 7 (7.9)
Imaging Techniques
CT 68 (98.6) 14 (73.7) 83 (93.3)
MRI 29 (42.0) 7 (36.8) 36 (40.4)
Ultrasound 33 (48.5) 6 (31.6) 39 (44.3)
PET 35 (50.7) 9 (47.4) 45 (50.6)
Tumor Diameter in Imaging, cm 7.0 (4.6-9.2) 6.9 (3.9-10.5) 6.2 (4.7-8.0)
Multiple Tumors 53 (76.8) 8 (42.1) 61 (68.5)
Bilobar Localization 51 (73.9) 11 (61.1) 63 (71.6)
Lobar Atrophy 2 (2.9) 3 (17.6) 5 (5.8)
Vascular Involvement 24 (36.4) 9 (50.0) 33 (38.8)
Suspicious Lymph Nodes 25 (37.9) 7 (38.9) 32 (37.6)
Suspected Distant Metastases 17 (25.4) 5 (27.8) 22 (25.6)
Continuous variables were described as medians with interquartile range (IQR). Categorical variables 
were described as totals and frequencies. ECOG/WHO: Eastern Cooperative Oncology Group/World 
Health Organization performance status. CA 19-9: cancer antigen 19-9. ALT: alanine aminotransfer-
ase. AST: aspartate aminotransferase.
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resin microspheres and 5.6% (3.1-9.1) in patients with glass microspheres. The 
median administered activity was 1.7 GBq (IQR: 1.2-2.3) for resin microspheres 
and 2.4 GBq (IQR: 1.2-3.8) for glass microspheres. The whole liver was targeted 
in 49 (55.1%) of patients. 
Post-intervention Results
The median follow-up of patients treated with resin microspheres was 10.5 
months (IQR: 3.3-22.3), and the median follow-up of patients treated with 
glass microspheres was 14.4 months (IQR:8.2-16.1). Technical success after the 
procedure was noted in all patients (Table 3). No patients died within 90 days 
of their intervention, but two patients treated with glass microspheres developed 
permanent adverse sequelae in the form of radioembolization-induced liver dis-
ease (REILD),25 one of whom eventually passed away. Toxicity was observed in 
the laboratory values of 55 patients (80%) in the resin microspheres group and 
11 patients (58%) in the glass group. On average, glass microspheres treatment 
seemed to cause less overall toxicity, as well as lower grade toxicity (p = 0.007). 
Complications according to the SIR-definition were noted in 18 patients (26.5%) 
in the resin group and 4 patients (21.1%) in the glass group (p = 0.631). The 
average complication grade was C (IQR: B-C), equaling therapy requirement and 
Table 2. Treatment Details
Characteristic
Resin microspheres 
(n = 69)
Glass microspheres
 (n = 19) Total ( n = 89)
Prior Resection 12 (17.4) 2 (10.5) 14 (15.7)
Palliative Drainage 7 (10.1) 2 (14.3) 9 (10.7)
Prior Chemotherapy 54 (78.3) 12 (63.2) 66 (74.2)
Pulmonary Shunt (%) 5.3 (3.1-8.7) 5.6 (3.1-9.1) 5.3 (3.1-8.7)
Activity Delivered, GBq 1.7 (1.2-2.3) 2.4 (1.2-3.8) 1.72 (1.24-2.72)
Treatment Sessions
1 59 (85.5) 14 (77.8) 73 (83.0)
2 9 (13.0) 4 (22.2) 14 (15.9)
3 1 (1.4) 0 (0.0) 1 (1.1)
Tumor Volume
Selected Targeting  
(≤ 2 segments) 3 (4.3) 1 (5.3) 4 (4.5)
Single-Lobe 23 (33.3) 12 (63.2) 36 (40.4)
Whole-Liver 43 (62.3) 6 (31.6) 49 (55.1)
Continuous variables were described as medians with interquartile range (IQR). Categorical variables 
were described as totals and frequencies.
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minor hospitalization (<48 hours) in the resin group, whereas it was D (major 
therapy requirement and hospitalization >48 hours; IQR: C-E) in the glass group. 
According to the RECIST criteria, partial response was noted in 21.4% of patients 
who underwent embolization with glass microspheres, vs. 2.2% of patients who 
were treated with resin spheres (p = 0.021). In the resin microspheres group, 50 
patients (72.5%) experienced recurrence during follow-up. This was the case for 
11 patients (57.9%) in the glass group. Five patients were able to undergo curative 
intent resection after 90Y radioembolization (5.9%), two of whom died of the 
complications of their surgery.
Survival Analysis
Most patients died during follow-up (n = 65; 73.0%). Median overall survival 
(OS) from diagnosis was 29.2 months (95%CI: 18.6-39.8) after resin microsphere 
treatment, and 1-, 3- and 5-year OS were 82.8%, 32.9% and 8.0%. Median 
OS after treatment with resin microspheres was 9.5 months (95%CI: 6.1-12.8) 
and 1- and 3- year OS were 37.1% and 6.8%. Progression free survival (PFS) 
after resin microsphere treatment was 4.4 months (95%CI: 1.9-6.9) and 1-year 
Table 3. Postintervention Outcomes
Characteristic
Resin microspheres 
(n = 69)
Glass microspheres
 (n = 19) P - value
Technical Success 69 (100.0) 19 (100.0)
CTC Adverse Events 0.007
Grade 1 37 (63.8) 6 (35.3)
Grade 2 13 (22.4) 3 (17.6)
Grade 3 5 (8.6) 2 (11.8)
SIR Complication 18 (26.5) 4 (21.1) 0.631
Grade A 2 (12.5) 0 (0.0)
Grade B 7 (43.8) 0 (0.0)
Grade C 7 (43.8) 2 (50.0)
Grade D 0 (0.0) 0 (0.0)
Grade E 0 (0.0) 2 (50.0)
RECIST criteria
Progressive disease 12 (26.1) 5 (35.7) 0.021
Stable disease 33 (71.3) 6 (42.9)
Partial response 1 (2.2) 3 (21.4)
Progression within Follow-up 50 (72.5) 11 (57.9)
Variables were described as totals and frequencies. Differences between groups were assessed using the 
χ2 test.
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freedom from progression was 26.6%. For liver-specific recurrence, median PFS 
was 5.5 months (95%CI 0.9-10.1). Freedom from liver progression at one year 
was observed in 35.0% of patients (Figure 2A & B).
For patients with glass microspheres, median OS after diagnosis was 21.2 months 
(95%CI: 19.6-22.7). This estimate did not differ significantly from the estimate 
of resin microspheres (p = 0.876). The same was the case for median OS after 
treatment (14.8 months; 95%CI: 2.2-27.4; p = 0.811), PFS (median 3.3 months; 
Figure 2A Progression-free survival after 
Yttrium-90 radio-embolization with 
resin-microspheres
Figure 2B Liver-specific progression-free survival 
after Yttrium-90 radio-embolization with resin-
microspheres
Figure 1A Overall survival after diagnosis 
with resin-microspheres
Figure 1B Overall survival after Yttrium-90 radio-
embolization with resin-microspheres
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95%CI: 2.9-3.7; p = 0.601), and liver-specific PFS (median 4.8 months; 95%CI: 
0.15-9.4; p = 0.997).
We separately evaluated outcomes in patients without prior chemotherapy who 
were treated with resin microspheres, in whom median survival from diagnosis 
was 30.8 months (95%CI: 26.8-34.9), and 1- and 3-year OS were 70.0%, and 
28.0% (Figure 3). Overall survival after treatment was 16.2 months (95%CI: 
13.9-18.4). Time to overall progression was 10.8 months (95%CI: 9.8-11.7), 
and time to liver-specific progression was 10.8 months (95%CI: 9.9-11.7). This 
analysis was not performed for patients who underwent glass microsphere 90Y 
radioembolization, as they were too few in number.
Discussion
In this study, a large cohort of ICC patients who underwent 90Y radioemboliza-
tion treatment was investigated. Most patients underwent resin microspheres 
90Y radioembolization, as opposed to glass microspheres treatment, and had a 
relatively low ECOG/WHO status. Few patients underwent primary resection, 
as most tumors were unresectable at diagnosis. At the time of radiological inter-
vention most patients underwent whole liver irradiation. A comparatively low 
number of one in four patients developed a complication according to the SIR 
criteria and no patients died shortly post-treatment, attesting the safety of 90Y 
radioembolization. Less than 10% experienced grade 3 or 4 toxicity, compared to 
up to 70% in currently used chemotherapy regimens.11 A partial response rate of 
20% for glass microspheres and 2% for resin microspheres was achieved. Despite 
these modest response figures, a post-treatment OS of 10 months was observed, 
with a 6% chance of curative intent resection.
Regional treatments rely on the dual blood supply of the liver, where the hepatic 
artery is mostly responsible for the blood supply of tumors.26 27,28 Radioemboliza-
tion was first utilized in colorectal liver metastases and hepatocellular carcinoma.26 
The technique is based on administration of radioactive microspheres into the 
hepatic artery branch supplying the tumor.14,15 Embolization of the non-target 
vessels and injection of technetium-99m (99mTc)-labeled macro-aggregated al-
bumin (MAA) is performed before treatment, in order to exclude extrahepatic 
accumulation.14,15,26 In this study we concluded that radioembolization is toler-
ated well in patients with a good performance status, which is in line with current 
literature.9,16-20 The survival estimates in this study are superior to those of pa-
tients undergoing best supportive care only.9,11,16-20 The post-treatment survival 
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of 9.5 months was relatively low compared to existing literature, with estimates 
ranging from 9 months post-treatment in a cohort of 25 Australian patients,9 to 
22 months in a cohort of 33 German patients.19 Despite being primarily unresect-
able, 5 out of the 89 patients went on to have a curative intent resection. This 
leads us to conclude that 90Y radioembolization can successfully be utilized in 
patients with unresectable ICC to offer a chance to undergo curative resection.
Currently available literature shows a highly significant correlation between dose 
delivered to the tumor and response rate.29-31 The radiation dose that is effectively 
delivered to the tumor tissue and the (unwanted) dose that is absorbed by healthy 
tissue should therefore be calculated when using radioembolization treatment.29-31 
Most clinical trials to date, however, do not calculate these metrics.31 Instead, they 
use the most basic method of determining activity to be administered, in the 
form of the empirical model, based solely on the estimated tumor involvement 
of the liver,32 or the BSA method, which builds on this principle by taking into 
account the size of the tumor and patient.32 Using 99mTc-MAA SPECT images, 
it is possible to carry out provisional dosimetry before the 90Y infusion.29-32 
Although imperfect, this method has been validated for both resin and glass 
microsphere treatments in hepatocellular carcinoma.31,33,34 In the current study, 
dose calculation using the MIRD method was carried out for patients treated 
with glass microspheres and those treated with resin microspheres at Stanford post 
2011. Additional prospective research into a personalized dosimetric approach, 
combined with currently ongoing trials of 90Y-microspheres concurrent with 
chemotherapy, will allow for a more personalized treatment of patients with ICC 
in the future. This approach would ideally lead to optimal efficacy with lower 
toxicity in individual patients.
TheraSphere® (glass) and SIR-Spheres® (resin), the two currently used types of 90Y 
microspheres, demonstrate different biological properties.35,36 These differences 
could theoretically lead to different safety and efficacy outcomes.36 A recent system-
atic review of 38 articles, comparing glass to resin microspheres for the treatment 
of hepatocellular carcinoma, tentatively demonstrated a safety advantage for glass 
microspheres.35 In this study, we observed a trend towards lower toxicity in patients 
with glass microspheres too. Post-intervention RECIST criteria also seemed to 
favor the glass group, in which relatively more patients exhibited partial response. 
Complications according to the SIR definition were not differently distributed. 
Long term outcomes did not differ. These tentative results are difficult to verify in 
a head-to-head comparison, as the low accrual rate of a study specifically aiming at 
ICC patients necessitates a large, and prolonged multi-center cooperation.
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Although 90Y radioembolization studies, including the present, show a relatively 
favorable response, OS and DFS, as well as a relatively low incidence of adverse 
effects, there are several liver-directed techniques aiming to achieve the same goals. 
In a recent study, hepatic arterial infusion (HAI) with floxuridine was combined 
with systemic chemotherapy in 78 patients with locally advanced ICC (n=104). 
This treatment requires a small operation; implanting an arterial pump. Median 
OS of this method was superior to systemic chemotherapy alone (31 months vs. 
18 months).5 Five-year OS was 20% in patients who received HAI chemotherapy. 
Currently, a phase 2 trial is recruiting patients for HAI chemotherapy in the ad-
juvant setting. Another liver-directed technique, transarterial chemo-embolization 
(TACE) affects the blood flow to the tumor in addition to locally releasing cytotoxic 
agents. It causes ischemic tumor necrosis and facilitates intracellular transit of che-
motherapeutic agents.26,28 In a study of 41 prospectively followed patients, one 
group described a median OS of 11.7 months from first treatment after treatment 
with irinotecan TACE in ICC patients.37 One patient successfully underwent resec-
tion following TACE.37 Another prospective study on TACE reported a median 
survival of 18 months in 24 patients, with 3 patients being adequately downstaged 
to undergo resection.38 Again, these results appear similar to those observed in 
our cohort. The costs of TACE, however, are significantly lower than those of 90Y 
radioembolization, with an average treatment costing about $8,000.39 Prospective 
head-to-head studies need to be conducted to compare treatment outcomes.
The results of this study should be viewed in the light of several limitations. First 
and foremost, the retrospective nature of this study precludes definitive conclu-
sions about post-therapy disease progression, because no follow-up schedule was 
predetermined. However, due to the large proportion of patients returning to the 
hospital in which they were treated and due to the high early progression rate, we 
believe we can still draw some tentative conclusions on this issue. Additionally, the 
treatment method, dose calculation method, and device used, differed between 
patients. Although this prevents us from drawing conclusions favoring one method 
over the other, this does add to the generalizability of our results. Finally, for a 
formal treatment benefit analysis, weighing advantages against adverse events, and 
a formal cost-effectiveness analysis, weighing advantages against financial aspects, 
future prospective studies need to be performed.
This study shows the potential of 90Y radioembolization, as well as its safety and 
effectiveness.
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DISCUSSION
Besides etiology and anatomy, the main similarity of biliary tract cancers (BTC) is 
their guarded prognosis. Only for a small number of patients can curative resec-
tion be considered and perioperative outcomes are often complicated by biliary 
leakage and infection.1 In order to provide optimal health care to patients with 
hepatobiliary malignancies, it is of great importance to treat the right patients 
with the right treatment modalities. Where some patients might benefit from 
expansive surgical resection, other patients, either because of their disease status 
or other aspects of their physique, might be more adequately treated by chemo-
therapy or one of the emergent targeted treatment strategies. The personalization 
of treatment provides the best chance of improving postoperative and long-term 
outcomes, and can be divided in three general principles: selecting the correct 
patients for appropriate procedures, determining prognosis after treatment, and 
developing novel treatments as alternatives or as addition to surgery.
Patient Selection
Part I aimed to determine which patients are best selected for the different treat-
ment modalities. More specifically, which patients should be considered eligible 
for surgery and which patients should rather be treated non-surgically. Surgery 
for BTC is highly specialized care and treatment at high volume hospitals has 
been associated with better outcomes.2-5 In Chapter 1, the importance of hospital 
and surgery volume for individual patient outcomes was assessed in the United 
States (U.S.) in the National Inpatient Sample (NIS). A total of 5,075 patients 
underwent liver surgery for primary or secondary malignancies and were included 
in the study. Mortality and failure to rescue (FTR: mortality after a major com-
plication) were noted to be lowest among high volume hospitals and surgeons. 
On multivariable analysis, compared with high volume surgeons, lower volume 
surgeons demonstrated greater odds for FTR. Interestingly, even within high 
volume centers, high volume surgeons reported lower complications and lower 
FTR. This led to the conclusion that, although both hospital volume and surgeon 
volume have a positive effect on postoperative outcome, surgeon volume, rather 
than hospital volume was accountable for most variability in these outcomes. 
Because this study was conducted in a national database lacking necessary details, 
further research should explore the microsystems within hospitals and surgeons 
that potentially drive variations in post-operative outcomes such as mortality and 
FTR.6
A dreaded postoperative complication after surgery for BTC is post-hepatectomy 
liver failure (PHLF). The incidence of postoperative liver failure is currently re-
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ported to be between 0.7% and 34% and mortality following PHLF is reported as 
high as 1 in 3.7-11 Chapter 2 reviewed the different definitions of post-hepatectomy 
liver failure, with a particular focus on detailing predictive patient-specific fac-
tors. Preoperative models utilized for predicting PHLF, include the Child-Pugh-
Turcotte and MELD scores.12-14 Both these scores are also used postoperatively, in 
addition to the often-cited 50-50 criteria and the ISGLS definition.8,15 Although 
all scores were adequate predictors in their derivation study, often with areas under 
the receiver operating characteristic (ROC) curve of over 0.9, scores performed 
considerably worse in validation studies. For example, in one validation of the 
50-50 criteria, only 50% of the patients who experienced postoperative mortality 
had PHLF according to the criteria.16 The conclusion of this literature review was 
that future studies should be aimed at understanding the mechanisms and risk 
factors of PHLF, as no definitive definition and cure have been found.
In order to decrease the chance of postoperative complications, including PHLF, 
in patients who do not benefit from surgery, adequate patient selection is vitally 
important. In previous studies, lymph node metastases have been reported as a 
major determinant of survival after resection.17-19 Presence of lymph node metas-
tases can be determined with reasonable accuracy preoperatively, using radiologi-
cal modalities and Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS/
FNA).20,21 In Chapter 3 a retrospective analysis of PHC patients was conducted, 
in order to try and answer the question whether it is prudent to resect PHC in 
patients with lymph node metastases. Patients who underwent resection for PHC 
with lymph node metastases were compared with patients who did not undergo 
resection because of locally advanced disease at exploratory laparotomy. Resected 
patients had a survival benefit of 7 months, although patients in the comparison 
group were more likely to have more advanced disease. The actual survival benefit, 
therefore, is likely to be smaller. Conclusions inferred from this analysis were 
that the decision to resect should be weighed against considerable postoperative 
morbidity and mortality, especially in the presence of other risk factors for disease 
recurrence.
One of the major determinants of postoperative outcomes is physiologic age.22-24 
In an increasingly aging population, the concept of frailty has been introduced to 
give an indication of physiologic fitness.25,26 Frailty has different definitions, but 
a major recognized component is low muscle mass, or sarcopenia.27 Sarcopenia 
in Chapter 4 & Chapter 5 was defined as low muscle mass, volume or density 
of the psoas muscle at the level of the third lumbar vertebra.28-31 In two large 
cohorts of patients who underwent hepato-pancreato-biliary or colorectal surgery 
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the impact of sarcopenia was reported. On multivariable analysis, independent 
risk factors for 1-year mortality included increasing age, preoperative anemia, and 
preoperative low muscle mass. Using these variables, a 28-point weighed compos-
ite score was able to stratify patients based on their risk for mortality 1 year after 
surgery. For elderly patients a separate 25-point composite score was constructed 
to predict 1-year mortality. This score included comorbidities, malignant disease, 
and sarcopenia measured by density.
Prognosis after Surgery
In Part II, prognosis after surgery was discussed. Prognostic and predictive tools for 
BTC were reviewed, which can be used for both patient information and treatment 
allocation. Chapter 6 provided an overview of the current literature in hepato-
pancreato-biliary model building, discussing current practices and shortcomings 
in validated models. Conclusions of this review were that basic requirements for 
prognostic studies are met in the field of malignant HPB surgery, yet many of 
the most often used models were constructed using dated methods. These models 
need to be updated, using validation and improvement studies. Subsequently, 
models for survival after resection for ICC were validated in a large international 
cohort in Chapter 7.32-38 Although the risk factors included in the models were 
significantly associated with overall and disease-free survival, discrimination 
between good prognosis versus worse prognosis in the new population was dis-
appointing. Only the Wang nomogram had reasonable discrimination.32  Large 
cohorts should be used to derive models, using appropriate statistical methods. 
The validation and updating of models is essential for external validity.39 Further 
research into the optimization of ICC prognostic models, possibly with inclusion 
of specific biomarkers, is warranted.
In Chapter 8 the concept of conditional survival was applied to a large cohort 
of patients with PHC. Conditional survival is based on the notion that accrued 
survival time is the most important prognostic factor for further survival, espe-
cially after a long period has elapsed since operative resection.40-44 This study 
showed that the chance of surviving an additional year could increase to 90% after 
surviving seven years. Additionally, known risk factors of worse outcome, such as 
age, margin status, disease stage, lymph node metastases and perineural invasion, 
became less impactful after time elapsed.18,45,46 This led to the conclusion that use 
of conditional survival can serve as a more valuable estimate in predicting long-
term survival, as follow-up accrues. Therefore, it can help in directing decisions 
pertaining to clinical decision making, surveillance and palliation.41,42
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As in PHC, overall survival after resection of GBC is limited, making the concept 
of survival conditional on the accrued survival time an interesting concept for 
long-term survivors.47 Chapter 9 gave conditional survival estimates for patients 
with GBC. Three hundred and twelve patients who underwent curative resec-
tions for GBC were included, with a median survival of 25 months. Conditional 
survival improved as time after surgery elapsed, resulting in a 90% chance of 
living another year when 7 years had passed. Furthermore, marked differences in 
conditional and actuarial survival were also observed when patients were catego-
rized based on the observed risk factors. Interestingly, while conditional survival 
was consistently higher than actuarial survival among all patient subgroups, the 
effect was most pronounced among patients in those subgroups characterized by 
high risk factors.
Finally, Chapter 10 questions the prognostic impact of routine resection of the 
common bile duct in patients with GBC. Although radical re-resection for GBC 
has been advocated after incidental findings of GBC, the optimal extent of re-
resection remains unknown and the role of routine excision of the common bile 
duct is controversial.48-50 This study aimed to assess the impact of common bile 
duct resection on survival among patients undergoing surgery for GBC. Among 
the 449 included patients, 30% underwent a concomitant CBD resection. After 
adjusting for potential confounders, common bile duct resection did not impact 
overall survival. An increase in lymph node yield was not observed either, although 
common bile duct resection was associated with more aggressive underlying dis-
ease such as advanced tumor stage and lymph node metastases. These outcomes 
correspond with literature from other Western centers.50 The conclusion drawn 
from this data was that the use of common bile duct resection should likely be 
reserved for that subgroup of patients who require it to extirpate all disease in the 
biliary tree.
Novel Treatments
In Part III, non-surgical techniques and their efficacy in the treatment of BTC 
were further explored. A general overview of treatments, prediction and prog-
nostication of ICC was given in Chapter 11. ICC is the second most common 
malignancy arising from the liver, with an incidence of 1-2 per 100,000.51-55 
It develops mostly as a well-differentiated adenocarcinoma and also occurs in 
combination with hepatocellular carcinoma, and might be responsible for worse 
prognosis in some of the patients with that disease.56 The mostly used staging 
system is the American Joint Committee on Cancer TNM staging, although new 
staging systems are being developed.57 Most notably, a prognostic model by Wang 
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et al. performed reasonably in external validation.32 The mainstay of treatment 
remains surgery, even though new techniques are being pioneered. These new 
techniques include hepatic arterial infusion, transarterial chemo-embolization 
and Y-90 radio-embolization.55,58 The conclusion of this review was that advances 
still need to be made in personalized treatment of ICC patients, and future studies 
should further improve prognostic models and identify predictive biomarkers to 
determine the response to chemotherapy.19,59
Chapter 12 discussed the effect of preoperative chemotherapy (pCT) in ICC 
patients. Despite the successful use of preoperative chemotherapy to downstage 
tumors and treat micrometastases prior to operation in other malignancies, the 
use of pCT among patients with ICC has not been well-studied.60,61 Sixty-two 
patients who underwent pCT were identified in a population of 1,057 ICC pa-
tients. In this retrospective analysis, no difference between disease free and overall 
survival was observed, despite the fact that pCT patients had significantly worse 
disease characteristics. After propensity score matching, the group receiving pCT 
had a survival advantage of 17 months, albeit this difference was non-significant. 
Further prospective trials are needed to better define the role of pCT and to iden-
tify the subset of patients who might have the most clinical benefit from the use 
of pCT, although this is made difficult by the low incidence of ICC.
As mentioned previously, many patients with BTC are either diagnosed at ad-
vanced stages of disease when curative resection is no longer feasible or are found 
to have unresectable or metastatic disease at the time of surgery.62,63 Non-operative 
management is typically recommended among patients with a life expectancy of 
less than 6 months who present with malignant obstructive jaundice, while the 
best course of treatment among patients found to have unresectable disease at 
the time of surgery is debated.64-67 Chapter 13 assesses the outcomes and effects 
of palliative surgery in GBC and PHC in a large U.S. cohort, accrued over 15 
years of practice. Of the 777 patients identified, resection was aborted in 106 
patients and 94 patients had a palliative procedure. Median OS among patients 
who underwent a palliative procedure or a procedure that was aborted was noted 
to be 8 months and was comparable between patients in both groups. A higher 
incidence of major complications was noted amongst patients undergoing pallia-
tive resection.
A promising novel technique is Yttrium-90 (Y-90) radio-embolization. This 
technique is based on administration of beads filled with Y-90 microspheres into 
the hepatic artery branch supplying the tumor.68,69 Several small studies indicate 
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that Y-90 is tolerated well in patients with a good performance status.70-75 In 
ICC patients, Y-90 was associated with improved survival, when compared with 
patients undergoing best supportive care only.70-75 Estimates ranged from 9 
months post-treatment in a cohort of 25 Australian patients,74 to 22 months in a 
cohort of 33 German patients.73 Chapter 14 presented an overview of utilization 
of Y-90 for radio-embolization of the liver in patients with cholangiocarcinoma 
in the largest cohort to date, discussing its safety and efficacy. In total, 89 patients 
were analyzed. Median survival after Y-90 treatment was 10 months, survival after 
diagnosis was 29 months. This is longer than the survival of similar patients who 
receive best supportive care. Progression-free survival was 4 months and 6% of 
patients were eligible for curative intent treatment after Y-90 treatment. Although 
these results were promising, randomized trials are required to definitively deter-
mine the effectiveness of Y-90 therapy.
FUTURE PERSPECTIVES
Prognostication and prediction models are still insufficiently capable of delineat-
ing individual patients’ disease course. Although many improvements have been 
made in recent years, truly individualized care for BTC will still require significant 
scientific advances. 
The rise of multi-center consortia such as the ENSCCA, the Extrahepatic Biliary 
Malignancy Consortium, in conjunction with more detailed national databases, 
such as those maintained by the Dutch Institute for Clinical Auditing, will bring 
a generation of databases of adequate size to enable derivation of models.76,77 
Increased awareness amongst peer-reviewers with regard to optimism, overfitting, 
and the merits of (external) validation, will most likely enhance the methods of 
derivation studies.39,78 The guidelines, currently being developed by the Cochrane 
Prognostic Study Group, will further increase reporting and quality.79
In addition to better derived models, the recent increase in use of mobile phones 
and tablets allow computerized models to be used in daily practice.  The main 
advantage of these innovations is that models no longer need to be simplified into 
integer risk scores or paper nomograms. The ease of use in the form of apps and 
web-pages will most likely also promote an increase in the use of prognostic and 
predictive models. Finally, computer interfaces enable the use of more complex 
model-building, e.g. recursive partitioning and artificial neural networking.80
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Even with the use of new possibilities and techniques, the predictive and prog-
nostic ability of models based on a relatively small number of clinical predictors is 
limited. In order to improve the predictive ability of current and new prognostic 
models, new determinants of biological processes in the form of biomarkers will 
be required. Biomarkers such as CEA and CA19-9 have previously been correlated 
with BTC formation and clinical outcomes.81,82 To this end, e.g. Wang et al. have 
proposed that a composite biomarker profile that combines clinical factors (CEA 
and CA19-9) with pathological biomarkers may improve the accuracy of prognos-
tic models and guide treatment in patients with resected ICC.32 This nomogram 
proved to have the best discriminative ability in chapter 11. The potential of this 
approach has been proven with the recent successes of biomarker-based prediction 
in breast cancer and colorectal cancer.83,84 
Predictive and prognostic biomarkers are not readily available.85 A means of better 
differentiating individual tumors is determining a biomarker profile, by means 
of immunohistochemistry.85 A recent meta-analysis identified several biomark-
ers that have prognostic value in patients with BTC.85 An example of a proven 
diagnostic and prognostic biomarker, is fascin, an actin cross-linked protein found 
in the cell membrane of the biliary duct cells.86 The epidermal growth factor 
receptor (EGFR) also plays an important role in prognostics and forms a potential 
treatment target.87,88 Mucin 1, cell surface associated (MUC1) and Mucin 4, cell 
surface associated (MUC4) are two membrane proteins that have been shown to 
have an impact on patient prognosis.89-91 Lastly, p27, Cyclin-dependent kinase 
inhibitor 1B, is a protein involved in the cell cycle which also has predictive 
capabilities.92-94 In addition to these biomarkers, several other biomarkers have 
been shown to have an impact on diagnostics, prognostics and treatment efficacy, 
including HSP27, Akt, HDGF, MUC6, p16, p-4EBP1, S100A4, alpha-SMA, 
keratin 903, and TROP2.85 From a number of these biomarkers a composite 
biomarker profile can be determined for each individual patient, indicating both 
prognosis and treatment efficacy.
Because of a rapidly growing knowledge of BTC biomarkers, treatment efficiency 
can still be vastly improved. A diagnostic biomarker could be a fast, relatively 
low-cost test, to rule out the possibility of BTC in patients presenting with vague 
symptoms of the upper abdomen. A marker predicting medium and long-term 
survival could improve identification of patients eligible for major liver resections. 
Finally, a marker indicating susceptibility for certain chemotherapeutics could 
have a large impact on medical treatment efficacy. A composite of multiple mark-
ers would allow treatment specifically designed for each patient.
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DISCUSSIE
Naast etiologie en anatomie, is de belangrijkste gelijkenis van galwegkankers 
(biliary tract cancers; BTC) hun infauste prognose. Slechts voor een klein aantal 
patiënten kan curatieve resectie overwogen worden en perioperatieve uitkomsten 
worden vaak gecompliceerd door gallekkage en infecties. Om optimale zorg te 
bieden aan patiënten met hepatobiliaire maligniteiten is het van groot belang om 
de juiste patiënten te behandelen met de juiste behandelingsmodaliteiten. Waar 
sommige patiënten baat hebben bij uitgebreide chirurgische resectie, kunnen 
andere patiënten door bijvoorbeeld comorbiditeiten beter behandeld worden 
door chemotherapie of een van de opkomende behandelingsstrategieën. De per-
sonalisatie van behandeling voor BTC biedt de beste kans om postoperatieve en 
lange termijnresultaten te verbeteren en kan worden ingedeeld in drie algemene 
principes: het selecteren van de juiste patiënten voor de juiste procedures, het 
kwantificeren wat de baten van behandeling zijn op het gebied van prognose en 
het ontwikkelen van nieuwe behandelingen als alternatief voor of als aanvulling 
op operatie.
Patiëntselectie
In deel I werd beoogd te bepalen welke patiënten het best geselecteerd kunnen 
worden voor de verschillende behandelingsmodaliteiten. Meer in het bijzonder, 
welke patiënten in aanmerking zouden moeten komen voor een operatie en welke 
patiënten niet-chirurgisch behandeld moeten worden. Chirurgie voor BTC is zeer 
gespecialiseerde zorg en de behandeling in gespecialiseerde centra is geassocieerd 
met betere resultaten. In hoofdstuk 1 is het belang van ziekenhuis- en operatie-
volume voor individuele patiëntresultaten in de leverchirurgie beoordeeld in de 
Verenigde Staten (VS), middels het National In-Patient Sample (NIS). NIS is een 
database waarin een kwart van alle patiënten die een ingreep ondergaan in de VS 
worden opgenomen. Mortaliteit en failure to rescue (FTR: sterfte na een ernstige 
complicatie) bleek het laagst bij ziekenhuizen en chirurgen die grote aantallen 
patiënten behandelden. Bij multivariabele analyse hadden chirurgen met een lager 
operatievolume een grotere kans op FTR. Zelfs in hoog-volumecentra, hadden 
chirurgen met een hoog operatievolume lagere complicaties en lagere FTR. Dit 
leidde tot de conclusie dat het behandelvolume van de chirurg oorzaak is van 
de meeste variabiliteit in de postoperatieve uitkomsten. Omdat deze studie is 
uitgevoerd in een nationale database en hierbij weinig details per casus konden 
worden bepaald, moet verder onderzoek worden gedaan naar de processen bin-
nen ziekenhuizen en de verschillen tussen chirurgen die potentieel variaties in 
postoperatieve uitkomsten veroorzaken.
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Een gevreesde postoperatieve complicatie na operatie voor BTC is postoperatief 
leverfalen (PHLF). De incidentie van PHLF is tussen de 0,7% en 34% en sterfte 
na PHLF treedt in sommige studies op in één op de drie patiënten. In hoofdstuk 
2 zijn de verschillende definities van leverfalen na hepatectomie nader bekeken, 
met in het bijzonder aandacht voor de voorspellende patiënt-specifieke factoren. 
Preoperatieve modellen die worden gebruikt voor het voorspellen van PHLF, zijn 
de Child-Pugh-Turcotte en MELD scores. Beide scores worden ook postoperatief 
gebruikt, met ook de vaak gebruikte 50-50 criteria en de ISGLS definitie. Alle 
scores bleken voldoende voorspellend in de studies waarin ze ontwikkeld werden, 
terwijl dit in validatiestudies aanzienlijk slechter was. Bijvoorbeeld, bij een externe 
validatie van de 50-50 criteria, voldeed slechts de helft van de patiënten die stier-
ven aan de 50-50 criteria. De conclusie van dit hoofdstuk was dat toekomstige 
studies zich meer moeten richten op de mechanismen en risicofactoren die aan 
PHLF ten grondslag liggen.
Om de kans op postoperatieve complicaties zoals PHLF te verminderen bij 
patiënten die geen baat bij chirurgie hebben, is adequate patiëntselectie van 
essentieel belang. In eerdere studies is aangetoond dat lymfekliermetastasen een 
belangrijke determinant zijn van overleving na resectie voor BTC. Aanwezigheid 
van lymfekliermetastasen kan met redelijke nauwkeurigheid preoperatief worden 
bepaald met behulp van radiologische modaliteiten en endoscopische echo-geleide 
dunne naald aspiratie (EUS / FNA). In hoofdstuk 3 is een retrospectieve analyse 
van perihilair cholangiocarcinoom (PHC-)patiënten uitgevoerd om de vraag te 
beantwoorden of het in prognostisch opzicht zin heeft om PHC-patiënten met 
lymfekliermetastasen te opereren. Patiënten die een resectie ondergingen voor 
PHC met lymfekliermetastasen zijn vergeleken met patiënten die geen resectie 
konden ondergaan als gevolg van lokaal gevorderde ziekte. Gereseceerde patiënten 
hadden een overlevingsvoordeel van 7 maanden, hoewel patiënten in de verge-
lijkingsgroep waarschijnlijk meer gevorderde ziekte hadden. Het daadwerkelijke 
overlevingsvoordeel is daarom waarschijnlijk kleiner. Conclusies die uit deze ana-
lyse getrokken kunnen worden is dat de beslissing om een resectie uit te voeren 
afgewogen moet worden tegenover de aanzienlijke postoperatieve morbiditeit en 
mortaliteit. Met name de aanwezigheid van andere risicofactoren voor het ontwik-
kelen van een recidief is van belang.
Een van de belangrijkste determinanten van postoperatieve resultaten is de 
fysiologische leeftijd. In de literatuur is het begrip frailty geïntroduceerd om 
fysiologische leeftijd aan te duiden. Frailty heeft verschillende definities, maar 
een belangrijk onderdeel is lage spiermassa of sarcopenie. Sarcopenie werd in 
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hoofdstuk 4 en hoofdstuk 5 gedefinieerd als lage spiermassa, volume of dicht-
heid van de psoas-spier op het niveau van de derde lumbale wervel. Bij twee grote 
cohorten patiënten die hepato-pancreato-biliaire of colorectale chirurgie onder-
gingen werd de invloed van sarcopenie onderzocht. Bij multivariabele analyse 
waren onafhankelijke risicofactoren voor 1-jaarsmortaliteit: toenemende leeftijd, 
preoperatieve bloedarmoede en preoperatieve lage spiermassa. Met behulp van 
deze variabelen werden twee preoperatieve scores samengesteld.
Prognose na chirurgie
In deel II werd de prognose na de operatie besproken. Prognostische en voorspel-
lende modellen voor BTC werden beoordeeld. In hoofdstuk 6 werd gepoogd 
een overzicht van de huidige literatuur te geven, op het gebied van prognostische 
modellen in de hepato-pancreato-biliaire chirurgie. Tekortkomingen van mo-
dellen die momenteel in gebruik zijn werden besproken. De conclusie uit dit 
literatuuroverzicht was dat de meest gebruikte modellen zijn gebouwd met be-
hulp van gedateerde methoden. Deze modellen moeten bijgewerkt en vernieuwd 
worden, met behulp van validatie- en verbeterstudies. In hoofdstuk 7 werden 
de in hoofdstuk 10 gevonden modellen voor intrahepatisch cholangiocarcinoom 
(ICC) toegepast op een groot internationaal cohort. Hoewel de risicofactoren 
die in de modellen waren opgenomen significant verband hielden met algehele 
en ziektevrije overleving, kon onderscheid tussen een goede en slechte prognose 
onvoldoende gemaakt worden. Alleen het Wang-nomogram had een redelijke 
discriminatie. Meer onderzoek naar de optimalisatie van prognostische ICC-
modellen is noodzakelijk.  Daarbij zou in het bijzonder gezocht moeten worden 
naar prognostische biomarkers.
In hoofdstuk 8 werd het concept van conditional survival (CS) toegepast op een 
groot cohort van patiënten met PHC. CS is gebaseerd op het gegeven dat de tijd 
die iemand reeds overleefd heeft na operatie de belangrijkste voorspeller is voor 
de overleving. Uit deze studie bleek dat de kans op een additioneel jaar overleving 
zou kunnen toenemen tot 90 % na zeven jaar overleefd te hebben. In de aanwezig-
heid van bepaalde risicofactoren bleek dit effect nog meer uitgesproken te zijn. De 
schattingen van CS in dit hoofdstuk kunnen worden gebruikt bij de keuze van 
verdere behandeling van patiënten met bijvoorbeeld een recidief.
Net als bij PHC patiënten, is de overleving na diagnose van galblaascarcinoom 
(GBC) beperkt. In hoofdstuk 9 werd conditional survival voor patiënten ge-
opereerd voor GBC ingeschat. CS verbeterde in de tijd nadat de operatie was 
ondergaan, wat resulteerde in een 90% kans om nog een jaar te overleven nadat 
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7 jaar verstreken is. Net als bij PHC was dit effect het meest uitgesproken bij 
patiënten in subgroepen die gekenmerkt werden door hoge risicofactoren en 
slechte overleving. De gemaakte schattingen van CS kunnen ook hier worden 
gebruikt bij de keuze voor verdere behandeling van patiënten met bijvoorbeeld 
een recidief.
Ten slotte werd in hoofdstuk 10 de prognostische invloed van routinematige ver-
wijdering van de ductus choledochus bij patiënten met GBC besproken. Hoewel 
reeds is aangetoond dat re-resectie bij toevallige vondst van GBC de overleving 
bevordert, blijft de optimale mate van re-resectie onbekend en is de rol van 
routinematige excisie van de ductus choledochus controversieel. Uit de data van 
een groot Amerikaans cohort werd in deze studie de conclusie getrokken dat het 
routinematige excisie van de ductus choledochus alleen dient te geschieden indien 
radicale resectie anders niet mogelijk is.
Nieuwe behandelingen
In deel III werden niet-chirurgische technieken en hun werkzaamheid in BTC 
verder onderzocht. In hoofdstuk 11 is een algemeen overzicht van behandelin-
gen, predictie en prognosticatie van ICC gegeven. Sinds enkele jaren worden 
nieuwe stageringssystemen en modellen ontwikkeld, maar op dit moment is het 
meest gebruikte stageringssysteem de Amerikaanse Joint Committee on Cancer 
TNM-staging. De hoeksteen van de behandeling voor ICC blijft een operatie, 
maar nieuwe technieken worden onderzocht. Deze nieuwe technieken omvatten 
de chemopomp, transarteriële chemo-embolisatie en Y-90 radio-embolisatie. De 
conclusie van dit literatuuroverzicht was dat er nog steeds onderzoek nodig is voor 
gepersonaliseerde behandeling van ICC-patiënten. Toekomstige studies zouden 
zich moeten richten op voorspellende biomarkers voor de respons op behandeling 
en prognose na behandeling.
In hoofdstuk 12 werd het effect van preoperatieve chemotherapie (pCT) bij 
ICC-patiënten onderzocht. Ondanks het succesvolle gebruik van preoperatieve 
chemotherapie om tumoren te verkleinen en micrometastasen te behandelen bij 
andere maligniteiten, is het gebruik van pCT bij patiënten met ICC niet goed 
onderzocht. In deze retrospectieve analyse werd geen verschil tussen ziektevrije- en 
algehele overleving waargenomen, ondanks het feit dat pCT-patiënten aanzienlijk 
slechtere ziektekenmerken hadden. Nadat er gecorrigeerd was voor het verschil 
tussen patiënten, had de groep die pCT kreeg een overlevingsvoordeel van 17 
maanden, hoewel dit verschil niet significant was. Verder prospectief onderzoek is 
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nodig om de rol van pCT beter te definiëren en de patiënten te identificeren die 
het meeste baat hebben bij gebruik van pCT.
Zoals eerder genoemd, worden veel patiënten met BTC gediagnosticeerd wanneer 
curatieve resectie niet meer haalbaar is. In andere gevallen blijkt dat patiënten 
irresectabele of metastatische ziekte hebben op het moment van operatie. Behan-
deling zonder operatie wordt meestal aanbevolen bij patiënten met een levensver-
wachting van minder dan 6 maanden. In hoofdstuk 13 werden de uitkomsten 
en effecten van palliatieve resectie voor GBC en PHC in een groot Amerikaanse 
cohort onderzocht. Mediane overleving onder patiënten die een palliatieve resectie 
ondergingen en onder patiënten bij wie resectie werd afgebroken, was 8 maanden. 
Deze overleving was dus niet hoger na palliatieve resectie. Wel kreeg een hoger 
percentage van patiënten die palliatieve resectie ondergingen een complicatie.
Een veelbelovende nieuwe techniek voor patiënten met een irresectabele kanker, 
is Y-90 radio-embolisatie (Y-90). Deze techniek is gebaseerd op de toediening 
van kralen gevuld met een radioactief yttriumisotoop in de leverslagader die het 
tumorgebied verzorgt. Verschillende kleine studies hebben aangetoond dat Y-90 
goede uitkomsten geeft bij patiënten die verder gezond zijn. Y-90 was in deze 
patiëntengroep geassocieerd met een betere overleving. In hoofdstuk 14 is een 
samenvatting gegeven van de ervaring van vijf grote centra die gebruik maken 
van deze techniek. Een gemiddelde overleving van 10 maanden werd gezien na 
behandeling met Y-90, met een overleving na diagnose van 29 maanden. Dit is 
langer dan de overleving van vergelijkbare patiënten die geen Y-90 behandeling 
ondergaan, maar prospectief onderzoek en klinische trials zijn noodzakelijk om 
definitieve uitspraken te kunnen doen. 
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